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Despite the proposed elimination of tropical diseases 
(WHO 2011, 2012), leprosy will continue to be a public 
health problem for several decades (Scollard 2005, Tal-
hari & Penna 2005). With the increasing decentralisation 
of control activities, primary public health centres will 
be responsible for diagnosing and managing patients to 
achieve programme sustainability (Banerjee et al. 1997, 
Penna & Penna 2007, Penna et al. 2012).
In 1981, the World Health Organization (WHO) rec-
ommended a multidrug therapy (MDT) for leprosy treat-
ment (WHO 1982). The WHO currently recommends 
that leprosy cases be classified as either paucibacillary 
(PB) or multibacillary (MB) based on the number of skin 
lesions. Patients with six or more lesions are classified 
as MB and treated for 12 months with a MDT that com-
prises three drugs: rifampicin, dapsone and clofazimine. 
Patients with fewer than six lesions are classified as PB 
and treated for six months with a two-drug MDT: rifam-
picin and dapsone (WHO 1997a).
Since 1989, Brazilian scientists have been calling for 
a uniform leprosy treatment that would not require dis-
ease classification (Penna et al. 2012). Similarly, tuber-
culosis (TB) can be viewed as a historical example of a 
disease that is more infectious and pathogenic than lep-
rosy that has been treated with a combination of drugs 
since the 1960s. The treatment regimen for all types of 
patients has changed over the years, but currently, all 
pulmonary TB patients, both smear-negative (“PB”) and 
smear-positive (“MB”) cases, are treated for six months. 
There is no doubt that this policy increases patient ad-
herence to treatment and improves the performance of 
health workers in the field (WHO 1997b, 2002).
Analogously, many believe that the regular 12-month 
leprosy MB course can be shortened for a consider-
able proportion of, if not all, MB patients. Shortening 
the treatment in conjunction with increased treatment 
uniformity could help field programmes, particularly in 
situations where leprosy control is integrated into gen-
eral health services. A uniform leprosy treatment regi-
men would simplify treatment in the field and halve the 
treatment duration for MB patients. This change may 
increase the treatment completion rates, given that these 
rates are consistently better for PB patients compared 
to MB patients. Previous results from different control 
programmes (WHO 1994) and research projects (Becx-
Bleumink 1992) have demonstrated that relapse rates 
following MDT were low, approximately 0.2% annually 
among MB cases with the 24-dose regimen (Jesudasan et 
al. 1996, Dasananjali et al. 1997, Li et al. 1997). The low 
relapse rates suggested that there was room to shorten the 
course of MDT to fewer than the 24 supervised monthly 
doses of rifampicin plus self-administered doses of dap-
sone and clofazimine (Vijayakumaran et al. 1996, Li et 
al. 1997). A 12-month treatment course for MB leprosy 
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has been generally recommended by the WHO since 
1998 (WHO 1997a). Although some studies suggest that 
post-MDT relapse rates may be significantly higher in 
the MB patients who have an initial bacterial index (BI) 
≥ 4 (Jamet & Ji 1995), the present leprosy disease group 
includes few patients with those characteristics. Further-
more, the total number of relapses among these patients 
would account for a minimal percentage of cases in a 
control programme (WHO 1997b). 
The objective of this clinical trial is to evaluate 
whether uniform (U)-MDT for leprosy is clinically and 
statistically equivalent in efficacy to the regular regimen 
(R-MDT), to determine patient tolerability of the U-MDT 
regimen among PB patients and to identify the prognos-
tic factors that might influence the U-MDT outcomes.
The current paper presents detailed methodology of 
the clinical trial and the data obtained from patients 
thus far.
SUBJECTS, MATERIALS AND METHODS
Study design - An open-label, randomised clinical 
trial design was used to compare two treatment regimens 
(R-MDT vs. U-MDT) with monthly patient follow-ups 
during the treatment period and for the first six months 
following treatment cessation for the MB patients in the 
U-MDT study group. This procedure was followed by 
yearly post-treatment visits for six years. The study pop-
ulation included newly diagnosed, previously untreated 
PB and MB leprosy patients (LPs) and returning default-
ers and relapse cases, provided that the last treatment 
dose was more than five years prior to enrolment in the 
study. All of the patients were between the ages of six- 
65. Patients were excluded if they were receiving TB or 
steroid treatment, had overt signs of acquired immune 
deficiency syndrome, were not residing permanently in 
the area or were unable to visit the clinic every month 
during the treatment and follow-up periods (Fig. 1).
Study location - A pilot study of 78 patients was con-
ducted at the Federal University of Minas Gerais (UFMG) 
from November 2004-June 2006 to test all of the study 
protocols and clinical report forms (CRF). Following 
adjustments to those protocols, based on the pilot study, 
patients were recruited from March 2007-February 2012 
at two national leprosy reference centres: Dona Libânia 
(Fortaleza, state of Ceará) and Alfredo da Matta (Manaus, 
state of Amazonas). A multidisciplinary team composed 
of 12 physicians (including pathologists and neurologists), 
nine nurses, five physiotherapists and five biochemists 
was responsible for patient recruitment and monitoring. 
Regular patients - A patient receiving regular PB-
MDT or U-MDT treatment is considered a “regular pa-
tient” when he/she completes six months of treatment 
within nine months. A patient receiving regular MB-
MDT treatment is considered a “regular patient” when he/
she completes 12 months of treatment within 18 months.
Irregular patients - Irregular patients are patients 
that complete treatment, but do not do so in the required 
nine or 18 months, as specified above. Instead, irregular 
patients who receive PB/U-MDT and MB-MDT treat-
ment complete their regimens within 12 and 24 months, 
respectively. These patients will be subject to follow-up 
evaluations, but their “irregular patient” status will be 
clearly indicated for data analysis purposes in this study. 
Defaulters - A patient receiving regular PB-MDT 
or U-MDT treatment is considered a “defaulter” if he/
she does not complete six months of treatment within 12 
months. A patient receiving regular MB-MDT treatment 
is considered a “defaulter” if he/she does not complete 
12 months of treatment within 24 months. A patient who 
does not complete treatment within the required period 
will be removed from the study. 
Screening log - All of the patients who were exam-
ined in the reference centres as possible LPs were regis-
tered in the screening log (Fig. 2).
Randomisation - The patients were randomised to 
ensure valid comparisons between the treatment regi-
mens (R-MDT and U-MDT) in each subgroup after be-
ing classified into PB and MB based on their number of 
skin lesions (Fig. 1). A random list of numbers was pre-
pared using the CRF. The randomisation codes on the 
worksheet were covered with the same material that is 
utilised for lottery scratch cards; therefore, the printed 
numbers were not visible. The randomisation numbers 
for the PB patients were revealed at the beginning of 
chemotherapy; for the MB patients, the number was 
revealed on the day the patient arrived for their sixth 
treatment dose. 
Fig. 1: clinical trial for uniform multidrug therapy (U-MDT) for 
leprosy patients in Brazil. BI: bacterial index; MB: multibacillary; 
PB: paucibacillary.
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Patient information - The patient characteristics 
and clinical parameters were recorded and the number 
of lesions and affected nerves were registered. Slit-skin 
smears were also taken to identify those patients with 
high BI and the ML Flow test was used to detect anti-
Mycobacterium leprae phenolic glycolipid-I (PGL-I) 
antibodies (Bührer-Sékula et al. 2003, Oskam et al. 
2003). As a baseline for all new entries and again for 
the patients who were suspected of relapse during the 
follow-up period, punch biopsies were taken for histo-
pathological analyses. The additional test results were 
considered in the final patient classification that was 
used in the analysis. 
Study groups - The U-MDT PB and U-MDT MB 
groups consisted of the patients who received the six-
month U-MDT regimen, as defined by the WHO pro-
tocol, which corresponded to six months of MB-MDT 
treatment with three drugs. 
Control groups - The R-MDT PB and R-MDT MB 
groups consisted of the patients who received the stan-
dard WHO treatment regimens: six months of treatment 
with two drugs for the PB patients and 12 months of 
treatment with three drugs for the MB patients.
Reactions and impaired nerve function - If a patient 
developed reactions or impaired nerve function, he/
she received appropriate treatment and remained in the 
study. All of the reaction and impaired nerve function 
episodes were registered. 
Reaction or relapse - If there was difficulty distin-
guishing between reaction and relapse (5% of all reac-
tions/relapses) then an independent and experienced 
specialist was consulted. 
Laboratory exams - To evaluate the side effects and 
toxicities of the three drugs, in addition to the standard 
clinical examinations, the patients underwent monthly 
laboratory testing during treatment to monitor any hae-
matological or hepatic alterations (full blood tests and 
transaminases).
Treatment - The patients were randomly assigned to 
one of two study sub-groups according to the standard 
PB/MB classification (based on the number of skin le-
sions). The patients returned to the clinic for monthly 
medical evaluations and to receive new monthly blister 
packs, which is consistent with the current standard of 
care in the leprosy control programme in Brazil. When-
ever reactions and impaired nerve function occurred in 
either study group, the affected patients were treated ac-
cording to standard protocol. 
Follow-up during treatment - The patients were 
monitored monthly for adverse reactions, impaired 
nerve function or side effects. In addition, the patients 
were asked to return to the clinic immediately if they 
experienced reactions or impaired nerve function. 
Follow-up after treatment - Slit-skin smears are taken 
at the end of treatment and during follow-up for the pa-
tients who were slit-skin positive at the beginning of treat-
ment. The U-MDT MD study group patients are exam-
ined for reactions and impaired nerve function monthly 
for six months after the end of treatment. The patients are 
actively monitored for reactions, impaired nerve function 
and relapses once yearly for six years post-treatment. In 
addition, the patients were asked to return to the clinic if 
any adverse reactions or side effects occurred (reactions, 
impaired nerve function and relapse). If relapse is sus-
pected, slit-skin smears will be taken and serum tested to 
confirm or support the clinical diagnosis. If a patient is 
diagnosed as a relapse case, they will be treated accord-
ing to standard practice: six additional doses for the PB 
patients and 12 additional doses for the MB patients. The 
event will be recorded and considered the end point of 
follow-up for data analysis purposes.
The U-MDT/CT-BR clinical report form and stan-
dard operating procedures are available as Supplemen-
tary data. 
Ethical considerations - The study was performed 
under international (Helsinki) and Brazilian research 
regulations regarding human beings and was approved 
by three regional research ethical committees from the 
states involved in the study as well as the National Ethi-
cal Research Commission. Written informed consent 
was obtained from all the patients prior to inclusion in 
the study. For patients aged six-17 years, written parental 
consent was required. Data confidentiality was strictly 
guaranteed. The patients were free to leave the study and 
opt for the R-MDT regimen outside the study (Clinical-
Trials.gov identifier: NCT00669643).
Sample - In both treatment groups, the sample size 
was based on the hypothesis of equivalence for the 
disease cure, absent relapses or reactions. Given that 
relapse is the less frequent event, the sample size was 
based on its estimated frequency. We assumed that the 
12-month overall cumulative relapse rate of R-MDT af-
ter nine years of follow-up would not exceed 1%; there-
Fig. 2: screening log for recruitment of patients from March 2007-
February 2012 in Manaus, state of Amazonas, and Fortaleza, state of 
Ceará, Brazil. 
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fore, we set a threshold for the acceptable occurrence of 
relapse following U-MDT equal to 2.6% (1% ± 1.6%). 
To ensure 80% power to detect a statistically significant 
difference in the relapse rates (1% of persons treated 
according to R-MDT vs. 2.6% for persons treated with 
U-MDT), a sample size of 1,181 persons was required 
for each branch of the study. The data analysis will be 
multivariate to control for other prognostic factors, such 
as the patients’ bacterial loads. 
RESULTS
Profile of patient enrolment to date - At the end of 
February 2012, 858 patients were enrolled in this study: 
79% in Fortaleza and 21% in Manaus. Fig. 2 shows the 
screening log for patient recruitment and Table I shows 
the distribution by study centre. Table II shows the base-
line characteristics (age, sex, the number of nerves af-
fected, the BI and the PGL serologic result) for the en-
rolled patients in each classification group. 
DISCUSSION
There are multiple leprosy care paradigms and the 
need for a robust, evidence-based response has motivated 
previous investigation into the viability of uniform treat-
ment for all LPs, independent of their clinical classifica-
tions (Lockwood & Suneetha 2005, van et al. 2010, WHO 
2010, Penna 2011, Penna et al. 2011). This uniform treat-
ment would be a step forward in controlling a disease that 
will affect Brazil for the foreseeable future, perhaps with 
incapacitating consequences (Penna et al. 2009). 
The lengthy treatment course has become one of the 
main obstacles to implementing MDT (Ganapati et al. 
1992), particularly in regions where the existing health in-
frastructure is poor and inaccessible. Leprosy classifica-
tion is a problem for general health workers who have only 
received one or two days of training, particularly where 
leprosy control is fully integrated into health services; the 
number of areas where this situation occurs will increase 
in coming years (Barreto et al. 2011). In cultures where 
only partial skin examination can be conducted, a clas-
sification system that is based on a skin lesion count is 
difficult to implement consistently (WHO 1997b, 2002).
Recently, an open-field, non-controlled treatment 
trial was conducted to determine the efficacy of a six-
month treatment regimen that consisted of three drugs 
(rifampicin at 600 mg/month, dapsone at 100 mg/day 
and clofazimine at 50 mg/day as well as 300 mg/month) 
for all LPs; the trial was coordinated by the National In-
stitute of Epidemiology of the Indian Council of Medical 
Research. From November 2003-May 2007, 2,912 pa-
tients (India, 2,746, China, 166) were enrolled, with 39% 
of patients classified as MB solely on the number of skin 
lesions, 3% of whom had grade 2 disabilities. During the 
follow-up, only 27 patients (0.9%) developed new lesions, 
78% of which were caused by reactions. Six patients had 
clinically confirmed relapse and 2.9% of patients were 
lost during the follow-up period. In the study, 85.9% of 
the patients completed treatment and 19% had inactive 
skin lesions. In general, the PB patients responded bet-
ter than the MB patients (27% vs. 6%, p < 0.001). In the 
post-U-MDT follow-up, at the end of the first (n = 2013) 
and second years (n = 807), the lesions were inactive in 
49% and 46% of patients, respectively [59% (year 1) and 
57% (year 2) in PB, 37% (year 1) and 28% (year 2) in 
MB, p < 0.001] (Kroger et al. 2008). 
TABLE I
Enrolment status by leprosy type according to World Health  
Organization criteria based on number of skin lesions and by  











CDERM 126 552 678 (79)
FUAM 59 121 180 (21)
Total 185 (21.5) 673 (78.4) 858 (100)
CDERM: Dermatology Centre Dona Libânia, Fortaleza, state 
of Ceará; FUAM: Foundation of Tropical Dermatology and 
Venereology Alfredo da Matta, Manaus, state of Amazonas.
TABLE II
Baseline characteristics of patients enrolled  








Patients enrolled 185 (22) 673 (78) 858 (100)
Age group (years)
≤ 14 20 (10.8) 37 (5.5) 57 (6.6)
15-64 163 (88.1) 634 (94.2) 797 (92.9)
65 2 (1.1) 2 (0.3) 4 (0.5)
Sex
Male 62 (33.5) 447 (66.4) 509 (59.4)
Female 123 (66.5) 226 (33.6) 349 (40.6)
Nerve lesions
0 165 (89.2) 389 (57.8) 554 (64.6)
1 6 (3.2) 95 (14.1) 101 (11.8)
2 8 (4.3) 96 (14.3) 104 (12.1)
≥ 3 6 (3.2) 93 (13.8) 99 (11.5)
Slit skin smear (BI)
0 174 (94.6) 192 (28.5) 366 (42.6)
0.1 -2.99 10 (5.4) 158 (23.5) 168 (19.6)
≥ 3 0 324 (48) (37.7)
Not informed - - 1 (0.1)
PGL-I serology
0 155 (83.8) 174 (25.8) 329 (38.4)
1-3 29 (15.7) 327 (48.5) 356 (41.5)
> 4 1 (0.5) 171 (25.3) 172 (20)
Not informed - 1(0.5) 1 (0.1)
BI: bacterial index; PGL-I: phenolic glycolipid-I.
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This non-controlled trial did not include slit-skin 
smears or skin biopsies, which makes the determination 
of relapse unreliable. Additionally, because this trial did 
not include BI, it is not possible to evaluate which group of 
patients required longer treatment (Ji & Grosset 1990).
The main problem when evaluating any new treatment 
regimen for leprosy is the lack of reliable data available for 
the current treatment regimen. The relapse, reactions and 
impaired nerve function rates have never been system-
atically determined (Ji 1985) and reactions and impaired 
nerve function are the major causes of nerve damage that 
leads to impairments and disabilities in LPs (Ji 1998). 
Our study was designed to overcome the need for re-
liable data about the current treatment regimen and to 
statistically compare its efficacy with that of a uniform 
regimen. 
This independent study was coordinated by the Trop-
ical Medicine Centre of the University of Brasília (NMT/
UnB) with the participation of the Institute of Public 
Health and Tropical Pathology of the University of Goiás. 
This study received funding from the Department of Sci-
ence and Technology and National Council for Scientific 
and Technological Development (403293/2005-7). It was 
conceptualised, designed and developed by the NMT/
UnB in partnership with the Royal Tropical Institute of 
Amsterdam and with scientific support from members 
of the International Federation of Anti-leprosy Associa-
tion Medical Commission during all phases, except for 
the pilot study, which was used to test the research forms 
at the Clinical Hospital of the UFMG. The study has an 
independent scientific steering committee that included 
Drs Celina Maria Turchi Martelli, Diana Lockwwod, 
Euzenir Sarno, Ji Bahong†, Maria Leide Wand-del-Rey 
de Oliveira, Paulo Roberto Lima Machado, Vijaykumar 
Pannikar and Sinésio Talhari. Three of these commit-
tee members also form the Database Monitoring and 
Security Committee: Drs Maria Leide Wand-del-Rey 
de Oliveira, Paulo Roberto Lima Machado and Sinésio 
Talhari. Their tasks are the following: (i) assessing the 
field protocol before intake, (ii) assessing the results at 
the end of the monthly follow-up period, (iii) performing 
a mid-term evaluation of the results after six years of 
follow-up and (iv) performing a final evaluation.
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SOP U-MDT 001 
SCREENING LOG 
OBJECTIVE: 
To determine if the person will be able to participate in the study 
 
RESPONSIBLE:  
• Project secretary  
• Physician / Nurse (assistant) 
PRECAUTIONS: 
• Estimate expenses and availability of supplies for this study. 
MATERIAL  
• Patient registry screening log  
• Standard screening log 





1. Include all patients that were enrolled as possible leprosy patients in the patient registry 
screening log.  
2. Fill out spaces 1 to 5 on the form, with information received from the patients 
3. Fill out the patients name on the standard screening log. 
4. Forward the standard screening log to the physician or nurse to complete. 
5. At the end of each work shift, collect all standard screening logs filled out by the nurses 
and physicians.  
6. Complete spaces 6 and 7 on the patient registry screening log with information taken 
from the standard screening log that was filled out for each patient.  
7. File the forms in the appropriate folder labelled U-MDT/SCREENING LOG, located in the 
studys coordination office.  
Physician / Nurse (assistant)  
1. Review the inclusion and exclusion criteria. 
2. Indicate on the standard screening log the reason for non-inclusion of the patient in the 
study. 
NOTE: It is of the utmost importance that the standard screening log is completed so that the 
research coordinators can track the reasons for non-inclusion in the study. 
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SOP U-MDT 002 
HEALTH CENTRE PATIENT CHART  
OBJECTIVE: 
To prepare the health centre patient chart (source document) to include all U-MDT protocol 
forms to be completed during patient visits for the duration of the study. 
 
RESPONSIBLE:   
• Sector worker responsible for opening patient charts 
 
PRECAUTIONS: 
• Estimate expenses and availability of supplies for this study. 
 
MATERIALS: 
• Registration book for the opening of patients charts 
• One brown envelope  
• Ball-point pen 
• Colour sticker for the identification of participants in patient chart 
• Patient visit and follow-up card  
• Forms: 
o Standard patient chart  
o Epidemiological notification form 
o Health centre monthly follow-up card 
 
PROCEDURES: 
1. Note the following data in the registration book of patient charts: 
a. Patients full name 
b. Date of birth 
c. Date chart opened 
d. Complete address with telephone number 
e. Registration number in the health centre (chart number) 
2. Identify the patients envelope with: full name and health centre registration number. 
3. Add the documents completed by the physician into the envelope 
4. Fill out the patients identification and visit follow-up card, writing down the health centre 
registration number, the patients name, and give it to the patient.  
5. Send the patient chart to the Medical Records Service. 
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SOP U-MDT 003 
ADMISSION OF PATIENT TO PROTOCOL 
 
OBJECTIVE: 
To ensure that all procedures for patient inclusion into protocol are followed. 
 
RESPONSIBLE:  
Physician on duty 
 
PRECAUTIONS: 
Verify that all necessary materials are available. 
 
MATERIAL: 
• 1 Clinical Report Form (CRF) -- U-MDT  
• 1 loose copy of the consent form (CF). 
• Black pen. 
• Health Centre Patient Chart  
• White coat  
 
PROCEDURES: 
1. Fill out the Patient Chart according to routine procedure. 
2. Review the inclusion and exclusion criteria to ensure the eligibility of the patient. 
a. Obtain demographic information and age of the patient. 
b. Evaluate the cutaneous lesions and/or systemic symptoms. 
c. Review history of previous treatment or treatment history for leprosy in the past 5 
years. 
d. Check history of intolerance to any of the drugs used. 
e. Check for serious associated diseases e.g. HIV / AIDS, tuberculosis, malaria, 
cutaneous leishmaniasis, visceral leishmaniasis, lymphomas, leukaemia and 
immunosuppression. 
f. Check for the presence of any difficulties in complying with study procedures. 
3. Inform the patient about the study and the benefits and risks of treatment. 
4. If the patient agrees to participate, fill out the patient identification data and his/her legal 
guardian (if applicable), (page 07 CRF) using black pen. 
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5. Fill out the consent form (CF) and write down the names of the patient or any witnesses 
and/or the legal guardian (pages 08 and 09 of CRF) on both copies. 
6. Date and sign the CF in the appropriate spaces. 
7. Give the patient the 2 copies of the CF for him or his legal guardian (if the patient is a 
minor) and the witness (if illiterate) for them to date and sign using black pen. 
8. Give the patient a copy of the CF.  
9. Assign a number to the patient, according to the sequence of enrolment in the study. 
10. Fill out the form for study commencement from the block of forms according to SOP - 
U-MDT 007.  
11. Give instructions regarding the procedures for patient exams. 
12. If the inclusion and exclusion criteria are not completed, or if the CF is not signed, the 
patient will be directed to the nursing department to undergo routine health centre 
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SOP - U-MDT 004 
PATIENT CONSENT FORM (CF) 
OBJECTIVES: 
To guarantee the enrolment of the patient in the study and initial procedures. 




Physician on duty 
 
PRECAUTIONS: 
! Always have copies of the consent form (CF) available in the centre. 
! Make sure the CF forms include all the correct pages. 
! Besides explaining the CF to the patient, give the patient time to read and become 
familiar with the study in order to avoid problems in the future. 
! Do not begin other procedures before certifying the signature of the patient, witness and 
principal investigator.  
! If the patient is illiterate, the signature can be substituted by a right thumb print.  
 
MATERIAL: 
1. One CRF. 
2. One copy of the Consent Form. 
3. Black pen. 
4. Stamp pad (if necessary). 
 
PROCEDURE: 
1. If the patient is illiterate, find a witness to be present at the time of the procedure. The 
first option for a witness should be the person accompanying the patient; the second 
should be another patient at the health centre. 
2. Give a copy of the CF to the patient. 
3. Read the CF, explaining the procedures that will be followed. 
4. Make sure all the questions are answered. 
5. If necessary, let the patient read the CF again. 
6. Give both copies of the CF to patient, witness and principal investigator for signatures in 
the corresponding spaces. 
7. Give one copy of the signed CF to the patient; the other will be filed in the CRF. 
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• General Research Coordinator 
• Local Research Coordinator  
 
MATERIAL:    
• Randomisation table 
• Black pen 
 
PRECAUTIONS: 
The eligibility criteria to enter the study will be determined at the beginning of the study. Patients 
that meet the  inclusion criteria  will be randomised into experimental (U-MDT) and control      
(R-MDT) groups. Prompt action will be important because the experimental group treatment for 
paucibacillary (PB) patients will begin therapy with 3 drugs, and the control group with 2 drugs. 
The multibacillary (MB) patients will only be allocated to the experimental or control group after 
6 months, at which time the experimental group will stop treatment for Hansens disease, while 
the control group will finish the 12 months of therapy.  
 
PROCEDURES:   
The MDT-U co-ordination centre will create a randomisation table with codes for all the patients 
in the study based on a random list of numbers, using the study entrance sequence according 
to CRF number. The space in the worksheet that contains the randomisation code is covered 
with the same material utilised in lottery scratch cards so that the printed numbers are not 
visible. This code will determine the directions for treatment of each patient as follows: when the 
code corresponds to an odd number, the patient will be part of the experimental group 1 or 3 (U-
MDT), according to their classification as PB or MB, respectively. When the code corresponds 
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to an even number, the patient will be part of control group 2 or 4 (R-MDT), according to their 
classification as PB or MB, respectively.  
 
The study will enrol/randomise 392 PB patients and 1730 MB patients eligible from Fortaleza 
and Manaus for the experimental and control groups. 
This spreadsheet will be sent to the local coordinator of each recruiting centre, who will be 
responsible for the allocation of the patients to the study groups. For PB patients, the 
randomisation results will immediately be made known after the inclusion of the patient in the 
study. The randomisation results of each MB case will be kept blind in the spreadsheet until the 
patient completes 6 doses of the MDT regimen, at which point the local coordinator will reveal 
the code.  
The local research coordinators will be responsible for:  
• Coordinating data collection according to the eligibility criteria and the conclusion of the 
six doses of PQT/MB. 
• Keeping the patient randomisation spreadsheet under his/her watch. 
• Coordinating the implementation of the directions for each patients treatment.   
 
The Data Manager of the coordination centre will be responsible for: 
• Coordinating the preparation of the spreadsheet with the randomisation codes; 




Study enrolment: The point at which the patient, after having met the initial eligibility criteria 
during the screening process and freely offering consent to participate in the study, is accepted 
and initiates the leprosy MDT regimen.  
Allocation: The act of randomly designating a patient to either the experimental or the control 
treatment groups. 
Eligibility: Determined during screening based on the inclusion/exclusion criteria for the study. 
The patients who meet the eligibility criteria and agree to participate in the study are enrolled in 
the study, randomised into the experimental or the control treatment groups and begin leprosy 
MDT in accordance with the operational classifications. 
 
NOTE: the inclusion of patients with single lesions will cease when it reaches 20% of the total of 
PB patients in each recruiting centre. These numbers correspond to approximately 50 patients 
with a single lesion at the Dona Libânia Reference Centre and 25 patients with a single lesion at 
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the Alfredo da Matta Foundation. The database coordination is responsible for informing the 
local coordinators that the recruitment of single lesion patients must be discontinued. 
 
 
SPREADSHEET FOR PATIENT RANDOMISATION 
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SOP - U-MDT 006 




To organise the necessary materials for patients participating in U-MDT trial. 
 
RESPONSIBLE: 
Project Secretary  
 
PRECAUTIONS: 
Estimate expenses and availability of supplies for this study. 
 
 MATERIALS:            
• U-MDT CRF  
• Black pen 
 
PROCEDURES: 
1. Check the appointment book of each attending physician for the study patients 
scheduled for the following day. 
2. At the end of each day, set aside the CRFs of the patients scheduled for the following 
day. 
3. At the beginning of each day, take the selected CRFs to the offices of the attending 
physicians. 
4. Provide blank CRFs for the inclusion of new patients in the study, following the 
numerical sequence of inclusion in the study. 
5. Provide blank copies of the informed consent forms, for inclusion of new patients in the 
study. 
6. Ensure that a black pen is available in each medical consulting room for recording the 
information in the patients CRF. 
7. At the end of the attending physicians shift, collect all CRFs, used or not. 
8. File the CRFs in numerical order, in the coordination office 
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SOP - U-MDT 007 
STUDY COMMENCEMENT 
OBJECTIVE: 
 To use the same methodology for all individuals participating in the trial. 
 
MATERIAL 
! White coat  
! Black pen 
! Patients charts  





1. After patients enrolment in study protocol according to SOP 003, begin 
completion of  the CRF according to the order of admission into the study.  
2. Classify the patient as PB or MB, considering only the number of skin lesions 
regardless of the number of nerves affected, as per WHO guidelines. 
3. The following tests and procedures must be done at the beginning of the study 
(treatment can be initiated before results are obtained) 
a. Take the patient history systematically, according to SOP 008. 
b. Conduct a general physical and dermato-neurological examination, 
according to SOP 009 and 010. 
c. Determine de disability grade, according to SOP 011. 
d. Request laboratory and histopathological tests, according to  SOP 012. 
 
Laboratory 
1. Obtain blood samples for the laboratory tests and store serum, according to SOP 013. 
2. Conduct the ML Flow test and attach the test results in the appropriate space, 
according to SOP 016 
 
Histopathology 
1. Obtain a sample of skin lesion fragments, according to SOP 014 
2. Forward the material for histopathological examination, according to SOP 015. 
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1. Check the patients operational classification.  
2. For PB cases, verify the randomisation result for each patient.  
3. Administer the medication under study to the patient.  
4. Register in the Investigational Dose Registration Form:  
a. The number of pills given 
b. Lot number 
c. Expiration date 
 
NOTE: The principal investigator must review all the data registered in visit and study 
commencement forms and sign at the bottom of each page.  
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SOP - U-MDT 008 
PATIENT HISTORY  
 
OBJECTIVE 
To use the same methodology of data collection for all individuals participating in the 
study. 
 




! White coat  
! Black pen 
! Patient Chart  
! CRF  U-MDT 
 
PROCEDURES 
The information below will be collected through interviews with study participants and registered 
on the corresponding forms of the CRF and patient charts: 
1. Identification data: (register on patient chart and the CRF) 
a. Name  
b. Sex: M=male, F=female  
c. Date of birth: dd / mm / yyyy 
d. Profession / occupation 
e. Mothers name 
f. Telephone 
g. Complete Address (w/ neighbourhood)  
 
2. Main symptoms (register on the standard patient chart of the health centre) 
 
3. History of present disease (register on the standard patient chart) 
a. Elapsed time since onset of symptoms 
b. Contact with leprosy patients 
c. Symptoms suggestive of leprosy 
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d. BCG immunisation 
 
4. Systematic review of patient history (register complaints in the patient chart and on page19 of 













5. Previous disease history (register in the patient chart) 
a. Diseases and surgeries 
b. Tobacco use 
c. Alcohol use 
d. Routine use of other medications 
e. Investigate related diseases that could increase the risk of toxicity to the study drugs, 
such as: jaundice, hepatitis, arthritis/gout, convulsion, neuropathy, or diseases 
associated with diminished lifespan, such as diabetes mellitus, kidney failure and 
cancer. 
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SOP -U-MDT 009 
PHYSICAL EXAMINATION 
OBJECTIVE 




• White coat 
• Flashlight, batteries 
• Tongue depressor 
• Stethoscope 
• Monofilament set 
 
PROCEDURES  
1. Register in the patient chart and in the Clinical-dermatological Evaluation Form (page 19 of 
the CRF) only the positive findings, along with the symptoms mentioned in the patient 
history (SOP 008). 
2. The physical examination should be conducted in the following sequence and according to 
patients complaints: 
Head and neck: 
a. Face: presence of infiltration 
Eyebrows (hair loss and/ or madarosis) 
Facial asymmetry   
b. Eyes: mucous membrane of the ocular cavity: pink or pale, jaundiced or anicteric.  
Madarosis of eyelashes  
Ptosis of the eyelid  
c. Nose:  Check if there is nasal septum collapse 
Dryness or crusting of the mucous membrane  
Presence of exudates (mucous, serous, sanguineous)  
d. Oral cavity: describe existing lesions 
Examine teeth and palate  
e. Ears: Presence of secretion 
Presence of infiltration in the ear lobes 
Presence of nodules in the ear lobes 
f. Neck: Thickening of the retroauricular nerve 
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a. Heart rate: count the number of heart beats in a minute with the patient lying on his 
back;  
b. Auscultation: describe the cardiac rhythm as regular/irregular, with or without murmurs; 
c. Blood pressure  
 
Respiratory system 
a. Respiratory rate: carefully observe the movement of the thorax and abdomen, count the 
number of breaths during 30 seconds and multiply by 2; 
b. Respiratory auscultation: this should be done in a quiet environment with the thorax of 
the patient uncovered. The patient should breathe slowly and deeply with the mouth 
opened without making noises. The auscultation should begin on the posterior thorax 
followed by the lateral and anterior faces of the thorax. 
 
Abdomen 
a. Hepatomegaly: present/absent 
b. Splenomegaly: present/absent 
c. Other alterations (describe) 
 
Lymphonodes (in case of peripheral lymphadenomegaly, describe): 
a. Location (cervical, axillary, supraclavicular, inguinal/femoral, other locations),  
b. Consistency: soft or hardened, with or without fluctuation,  
c. Adherence or non-adherence to deep tissues, 
d. Presence or absence of inflammation (pain, heat, redness), 
e. Presence or absence of fistulas (spontaneous or not) with draining of secretion. 
 
Extremities:  
a. Observe and palpate the arm and leg joints, detecting possible signs of inflammation, 
b. Observe limitation of joint movements, 
c. Oedema: present/absent, 
d. Describe other abnormalities that may be present 
 
Genitourinary system:  
a. Normal / abnormal (in case of abnormalities, describe them) 
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Describe in Patient Chart and on page 18 of the CRF, any dermatological alterations 
encountered: 
 
1. Describe the type of lesion, according to the following definitions:  
a. Maculae: circumscribed areas different from the surrounding skin that is not elevated or 
depressed without superficial alterations; 
b. plaques: solid structures, flattened, with easily-detected borders when passing a finger 
over the lesion; these can take variable forms (circular, oval, irregular), frequently 
erythematous; 
c. Papules: solid elevation of the skin, small in size (up to 0.5 cm in diameter), superficial, 
well defined; 
d. Nodules: solid, circumscribed lesions, elevated or not, above 0,5 cm in diameter, soft or 
firm consistency; when located in the hypodermis, they are more noticeable through 
palpation than inspection; 
e. Infiltration: alteration in thickness and increase in the consistency of skin, with small 
evidence of ridges, imprecise limits and, eventually, erythema; 
f. Anaesthetic area: area of skin without evident lesions, but with clear alteration of 
thermal, dolorous and/or tactile sensibility. 
 
2. Describe alterations in lesion coloration, according to the following definitions: 
a. Hypochromic: lighter than surrounding skin 
b. Erythematous: of pinkish or reddish colouration 
c. Hyperchromic: darker than surrounding skin 
d. Normochromic: similar to regular skin 
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3. Register the total of existing cutaneous lesions: 
a. One to ten: register the exact number of lesions 
b. Over 10: record code 11. 
c. Presence of diffuse infiltration, without individual lesions: record code 88.  
 
4. Describe alterations in sensitivity in areas of lesions, according to the following definitions 
and abiding by the protocol below (item 5): 
a. Altered: an abnormal response is observed every time the test is performed.  
b. Dubious: different responses are observed when the test is performed.  
c. Normal: correct response is observed every time the test is performed.  
 
5. Test of sensitivity of lesions: 
Changes in sensitivity of cutaneous lesions are caused by the impaired functioning of the 
cutaneous nerve branches. Usually there is a reduction of sensibility (hypoesthesia), and 
sometimes a complete absence of sensibility (anaesthesia). In the initial phase there may be an 
increase of sensibility (hyperesthesia).  
 
5.1. The thermal sensibility test can be done using cold and hot water, or cotton wool soaked in 
ether. 
Test using hot and cold water:  
Necessary material: 2 test tubes, one with cold water, the other with water heated to 45°C.  
Procedures:  
a. Explain to the patient how the test will be done. 
b. Touch the healthy skin and the suspected area with the cold and hot test tubes, 
alternately. 
c. Ask the patient to identify if the tube is cold or hot. 
d. Touch the skin only with the bottom of the tube as touching it with the side of the 
tube will provide a larger contact area that could give a false result. 
e. Take into consideration answers such as colder and warmer. 
f. Compare the results and make a conclusion about the alteration of sensibility. 
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Test with the ether-soaked cotton  
Necessary material: one cotton ball soaked in ether; another dry. 
Procedures:  
a. Explain to the patient how the test will be done 
b. Touch the healthy skin and the suspected area with the dry or the ether-soaked 
cotton ball, alternately. 
c. Ask the patient to mention when he feels a cold sensation. 
d. Compare the results and make a conclusion about any alteration of sensibility. 
 
5.2. Test for tactile sensibility 
Necessary material: Thin strand of cotton wool 
Procedures: 
a. Explain to the patient how the test will be done and make sure they understand it 
correctly. 
b. Touch the healthy skin and the suspected area alternately with the strand of cotton wool. 
c. Ask the patient to let you know when he feels contact. 
d. Compare the results and make a conclusion as to alterations of sensibility. 
e. Remember that the tactile sensibility test can be normal even when the thermal and pain 
sensibility have already presented alterations. 
 
6. Register the number of impaired nerves, whether thickened, painful and/or with altered neural 
function on p. 18 of the CRF, in the area of corresponding innervation, according to the protocol 
below (item 7). 
 
7. Examination of Peripheral Nerves:  
The main impaired nerves in leprosy are the ulnar, median, radial and radial cutaneous 
branch in the upper limbs, the fibular and tibial in the lower limbs, the auricular and 
supraorbital in the head. These main nerves should be systematically palpated before and 
during treatment, and also during the follow-up visits after treatment. Compare the palpated 
nerve on one side with the nerve on the opposite side, observing the texture, thickness, 
presence of nodules and adherence. Observe the face of the patient during examination to 
detect any signs of pain.  
Independent study to establish the efficacy of the six dose uniform MDT regimen  




a. Ulnar nerve should be palpated at the level of the elbow at the trochlear notch, with 
the elbow flexed and the hand of the patient resting on the arm of the examiner. 
b. Median Nerve  rarely palpable, because it passes deeply beneath the skin at wrist 
level. Determine if the patient feels pain or a shocking sensation when tapped.  
c. Radial Nerve  the elbow should be flexed with the forearm of the patient supported 
by the hand of the examiner. The palpation should be done the upper arm, 
approximately two finger-widths behind the entrance of the deltoid.  
d. Fibular Nerve  palpated at the level of the lower leg, approximately two finger-
widths behind and below the head of the fibula, with the patient seated, knees flexed 
and feet planted on the floor. 
e. Posterior Tibial Nerve  palpated at the level of the ankle, behind and below the 
medial malleolus nerve, with the patient seated, knees flexed and feet planted on the 
floor or being held by the examiner.   
f. Auricular Nerve  turn the head of the patient towards the shoulder opposite the 
side that will be examined and palpate the nerve located above the 
sternocleidomastoid muscle.  
 
Regarding thickness, register findings according to the following scale: 
$ 0= normal; 1= thickened; 2= nerve abscess 
 
Regarding pain, the intensity reported by the patient will be used, according to the 
following scale: 
$ 0= no pain; 1= weak pain; 2= strong pain  
 
8. Determine and register the operational classification by the number of skin lesions, without 
regard to the number of nerves affected, as per the WHO classification (enter this information 
on page 18 of the CRF).   
a. Paucibacillary (PB): cases with as many as 5 cutaneous lesions  
b. Multibacillary (MB): cases with 6 or more cutaneous lesions  
 
9. Determine and record the clinical classification as described below (enter on page 18 of 
CRF): 
a. Indeterminate Leprosy(1) 
One or few cutaneous lesions, normally presenting a skin lesion lighter than the normal 
skin, not elevated, with undefined borders, altered thermal sensibility, normal or slightly 
altered pain sensibility and tactile sensibility intact. There is no thickening of the nerve 
trunks. 
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b. Tuberculoid Leprosy(2) 
Skin lesion or plaques with papules or tubercles at the edges with hair loss, hypohidrosis 
or anhidrosis and clear loss of sensibility. Small number of lesions with asymmetric 
distribution. The nerve trunks are affected. 
 
c. Lepromatous Leprosy(3) 
Hypochromic or erythematous lesions, infiltrated, with irregular edges, papules, plaque 
infiltration, nodules (leproma), diffuse infiltrations in the face that can progress to 
madarosis of the eyelashes and eyebrows, deepening of the natural skin creases, 
altering the individuals appearance, often referred to as leonine face. The lesions are 
symmetrically distributed. The nerve trunks are affected. 
 
d. Borderline Tuberculoid Leprosy(4) 
More numerous skin lesions, more extensive and clinically similar to those of tuberculoid 
leprosy, tending to be symmetric.   Numerous nerve trunks affected, plaque lesions with 
irregular borders that tend to form satellite lesions. 
 
e. Borderline Borderline Leprosy(5) 
Numerous skin lesions with poorly defined external edges and normally at the centre 
(foveolar or having a Swiss cheese appearance), plaque lesions, sometimes 
resembling the tuberculoid type; papular or tuberous lesions and infiltration similar to 
those observed in the lepromatous cases. There is a tendency towards symmetric 
distribution and considerable involvement of nerve trunks.  
 
f. Borderline Lepromatous Leprosy(6) 
Numerous skin lesions of differing types, such as infiltration, plaques (some foveolar), 
poorly defined external borders and nodules. There is a tendency towards symmetric 
distribution and thickening of many nerve trunks.  
 
IMPORTANT NOTE 
After receiving the exams results, the patients physician, along with the study coordinators, 
both local and general, shall determine the final operational classification of the patient, which 
will be entered on page 18 of the CRF.  
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SOP - U-MDT 011 
 
SIMPLIFIED NEUROLOGICAL FUNCTION 
AND COMPLICATIONS EXAM 
 
OBJECTIVE 
To use the same methodology for determining the disability grade of all individuals 
participating in the study. 
 MATERIAL 
! White coat   
! Black pen 
! Coloured pen set -- green, blue, purple, red, orange and black 
! Flashlight 
! Monofilament set 
! Snellen eye chart 
! Metric ruler  
 
 PROCEDURES 
The information below will be collected by interviewing and examining the study participant: It 
should be recorded on the Simplified Neurological Function and Complications Exam Form at 
the beginning of the study, at the sixth month mark for patients of groups 3 and 4, at the end of 
the treatment for all groups and following each leprosy reaction. (Procedure timetable  page 13 
of the CRF)  
 
Nose 
a. Ask if the patient has a stuffy nose, increased secretion or persistent malodour. 
b. Lightly press the tip of the nose and, using a flashlight, check the inside of the nostrils to 
determine if there is crusting due to drying, blisters and erosion spots in the mucosa, or 
perforation of the septum cartilage. 
c. Register findings in the Simplified Neurological Function and Complications Exam 
Form, using the code: Yes (Y) or No (N) 
 
Eyes 
a. Ask the patient if he/she has burning, aching, redness or itching of the eyes. 
b. Observe if patient blinks spontaneously. 
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c. Evaluate the eyelid muscle tone: 
i.  Ask the patient to close his eyes slowly and, using the examiners little finger, lift 
the upper eyelid, observing and feeling its resistance and its return to the original 
position once the eyelid is released:   
• Diminished resistance indicates paresis 
ii. Ask the patient to close his eyes forcefully and observe for symmetric wrinkling of 
the eyelids: 
• Asymmetric wrinkling indicates paresis 
• Presence of a gap between the eyelids with the eyes closed indicates 
lagophthalmos: 
iii. With the patient closing the eyes softly and then forcefully, observe and measure 
(in mm) the gap. 
d. Observe:  
i. Conjunctiva: hyperaemia, secretion, scars, nodules, ulcers. 
ii. Cornea: transparency, homogeneity or reflection, scars, foreign bodies, 
vascularisation, white spots.  
iii. Trichiasis  ingrown eyelashes.  
iv. Ectropion  eversion of the eyelid. 
v. Cataract  through the pupil, observe if the lens is whitened. 
e. Visual acuity 
i. Evaluation using eye chart 
ii. The line 0.8 on the table should be located at eye level for the patient 
iii. Set it 5 or 6 metres from the patient 
iv. Explain the procedure to the patient 
v. Evaluate each eye separately 
vi. Use a black pencil to point to each optotype of the chart starting with the largest: 
• Register the line that the patient correctly identifies ⅔ of the optotypes 
• If the patient cannot read the biggest one (0.05 or 0.1), hold up a varying 
number of fingers and have him/her count them, starting at a distance of 6 
metres and moving closer step by step:  
• Take into account the distance in which the patient correctly counts the 
number of fingers 2 or 3 times. 
• If he is not able to count correctly at a distance of 1 metre, check if the 
patient can perceive hand movements at that distance. If not, check if 
he/she is able to perceive light. 
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$ Register disability on the Simplified Neurological Function and Complications Exam Form, 
using: Yes (Y) or No (N) 
 
Upper limbs 
a. Observe:  
i. Skin: hair loss, dryness, alterations of colour, conditions of the nails, oedema, calluses, 
scars, fissures, infiltration, macerations, traumatic or dermatologic lesions, conditions 
of the spaces between the fingers. 
ii. Muscles: muscle volume of the thenar and hypothenar regions, the first and 
subsequent interosseus spaces and in the forearm. 
iii. Fingers: observe the form and alignment of the metacarpals with the phalanx, the 
presence of deformities, bone absorption, retraction and the position of the fingers. 
b. Nerve palpation 
i. Ask the patient about presence of pain before beginning palpation 
ii. Palpation of the main nerves must be done systematically, always comparing the 
palpated nerve on one side with the nerve on the opposite side, observing its 
thickness, texture, presence of nodules and if it has any type of adherence to 
surrounding tissues. 
iii. Observe the patients face during the palpation to detect any expression of pain.  
iv. Ulnar Nerve  should be palpated at the level of the elbow at the trochlear notch, 
with the elbow flexed and the hand of the patient resting on the forearm of the 
examiner. 
v. Median Nerve  rarely palpable, because at wrist level, it passes deeply beneath the 
surface of the skin.  Determine if the patient feels pain or a shocking sensation when 
tapped. 
vi. Radial Nerve  the elbow should be flexed with the forearm of the patient supported 
by the hand of the examiner, and the palpation should be done on the upper arm 
using two finger widths behind the entrance of the deltoid. 
$ Register in the Simplified Evaluation of the Neural Function Form, using the scale: normal 
(N), thickened (T), painful (P). 
$ Evaluation of Muscle Strength: 
i. Ulnar nerve: ask the patient to extend the little finger (abduction) and maintain this 
position while the examiner tries to push it inward. 
ii. Median nerve: ask the patient to keep the hand in a horizontal position and to raise the 
thumb and point it up (abduction), maintaining this position while the examiner tries to 
push it down. 
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iii. Radial nerve: ask the patient to close the hand, flex the wrist backwards (extension) 
and hold this position while the examiner tries to push the hand down. When it is not 
possible to extend back, the hand is classified as having dropped. 
$ Enter the results of this evaluation on the Simplified Neurological Function and 








$ Inspection and sensitivity evaluation 
Test using the monofilament kit 
i. The monofilament is applied to the patients skin perpendicularly which 
makes it bend. This bend point should not touch the skin of the patient so as 
to avoid an extra stimulus. Maintain this pressure for 1-1.5 seconds. Avoid 
sudden as well as very slow movements.  
ii. If the filament slips when it touches the skin, disregard the patients response 
and repeat the test at the same point. 
iii. Ask the patient to answer yes when he/she can feel the monofilament, or 
point to the spot that is being touched.  
iv. If there is any doubt, repeat the test at each point twice, to be sure of the 
result. 
v. In case of positive and negative answers at the same point, consider it a 
correct response if the patient is right on at least 1 of 3 attempts. 
vi. Begin the test using the green monofilament (0.05g) at all the indicated points 
on the form. 
vii. For each point tested, the green monofilament (0.05g) and the blue one 
(0.2g) should be applied 3 times in a row to ensure that the patient feels it. 
The remaining monofilaments in general, should only be applied once. 
viii. At the points where the patient cannot feel the green monofilament, do the 
evaluation using the blue one and then the other monofilaments in order. 
STRENGTH LEVEL DESCRIPTION 
strong 5 Can execute the full range of movement with maximum resistance 
4 Can execute full movement with partial resistance 
3 Can execute full movement with no resistance reduced 
2 Can execute partial movement 
1 Muscle contraction without movement 
paralysis 
0 Paralysis, no movement 
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$ Enter the answer on the Evaluation Form, colouring each point with the appropriate pen 
colour, or key code corresponding to each filament.  
• Test 6 points on the hand, three in the area of ulnar innervation and three 











$ Observe and record on the Simplified Neurological Function and Complications Exam 
Form:  
i. Mobile claw (M)  reduction of active mobility of the joints and maintenance of the 
range of passive movement, even if this does not reach 100%.  
ii. Fixed claw (S)  when there is a loss of 25% or more of the passive mobility of the 
joint.  
iii. Ulnar claw: affects the 4th and 5th digits 
iv. Median claw: affects 2nd and 3rd digits.  




$ Palpation of the nerves 
• Fibular nerve should be palpated two finger-widths behind and below the head of the 
fibula, with the patient seated with knees flexed and feet firmly on the floor. Damage to 
this nerve results in drop foot or an everted foot. 
MONOFILAMENT INTERPRETATION CODE 
Green (0.05g)  Normal sensibility in hands and feet. Green dot 
Blue (0.2g) 
Reduced sensibility in the hand, with difficulty in 




Reduced protective sensibility for the hand, but 
enough to prevent damage. Difficulty discriminating 
between form and temperature.  
Purple 
dot 
Dark red (4.0g) 
Loss of protective sensitivity for the hand and most 
parts of foot. Vulnerable to tissue damage. Loss of 
differentiation between hot and cold. 
Red dot 
Orange (10.0g) Loss of protective sensitivity for the foot, however may still feel deep pressure and pain. 
Red X  
 
Magenta (300g) Sensitivity to deep pressure, may still feel pain.  Red circle 
None Loss of Sensibility to deep pressure, normally cannot feel pain.  Black dot 
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• Tibial posterior nerve  should be palpated at ankle level, behind and below the medial 
malleolus, with the patient seated, knees flexed and feet on the floor or held by the 
examiners hand.  
• Register on the Simplified Neurological Function and Complications Exam Form, using 
the scale: normal (N), thickened (T), painful (P). 
$ Evaluation of Strength : 
• To test the fibular nerve: 
• ask the patient to lift the hallux (dorsiflexion) and keep it in this position, 
while the examiner tries to push it down;  
• ask the patient to lift the entire foot (dorsiflexion) and keep it in this position, 
while the examiner tries to push it down;  
• Write down on the Simplified Neurological Function and Complications Exam Form, 









$ Inspection and sensitivity evaluation 
Test using the monofilament set 
$ The monofilament is applied to the patients skin perpendicularly which makes it 
bend. This bend point should not touch the skin of the patient so as to avoid an 
extra stimulus. Maintain this pressure for 1-1.5 seconds. Avoid sudden as well as 
very slow movements. 
$ If the filament slips when it touches the skin, disregard the patients response and 
repeat the test at the same point 
$ Ask the patient to answer yes when he/she can feel the monofilament, or point to 
the spot that is being touched.  
$ If there is any doubt, repeat the test at each point twice, to be sure of the result. 
STRENGTH LEVEL DESCRIPTION 
strong 5 Can execute the full range of movement with maximum resistance 
4 Can execute full movement with partial resistance 
3 Can execute full movement with no resistance reduced 
2 Can execute partial movement 
1 Muscle contraction without movement 
paralysed 
0 Paralysis, no movement 
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$ In case of positive and negative answers at the same point, consider it a correct 
response if the patient is right on at least 1 of 3 attempts. 
$ Begin the test using the green monofilament (0.05g) at all the indicated points on 
the form. 
$ For each point tested, the green monofilament (0.05g) and the blue one (0.2g) 
should be applied 3 times in a row to ensure that the patient feels it. The remaining 
monofilaments in general, should only be applied once. 
$ At the points where the patient cannot feel the green monofilament, do the 
evaluation using the blue one and then the other monofilaments in order. 
$ Enter the answer on the Evaluation Form, colouring each point with the 
appropriate pen colour, or key code corresponding to each filament.  
$ In the foot, test 9 points, seven in the area of innervation from the posterior tibial, 
one in the region of the saphenous nerve (heel) and one at the plantar arch.   
 
Observe and register on the Simplified Evaluation of Neural Function and Complications Form:  
• Mobile claw (M)  reduction of active mobility of the joints and maintenance of the range 
of passive movement, even if this does not reach 100%. 
• Fixed claw (S)  when there is a loss of 25% or more of the passive mobility of the joint. 
• Tibial posterior claw: affects all toes 




MONOFILAMENT INTERPRETATION LEGEND 
Green (0.05g) Normal sensibility in hands and feet. Green dot 
Blue (0.2g) Reduced sensibility in the hand, with difficulty in relation to the lighter weight. Within normal range for the foot. Blue dot 
Purple (2.0g) 
Reduced protective sensibility for the hand, but enough to 
prevent damage. Difficulty discriminating between form and 
temperature.  
Purple dot 
Dark red (4.0g) 
Loss of protective sensitivity for the hand and most parts of 
foot. Vulnerable to tissue damage. Loss of differentiation 
between hot and cold. 
Red dot 
Orange (10.0g) Loss of protective sensitivity for the foot, however may still feel deep pressure and pain. 
Red X  
 
Magenta (300g) Sensitivity to deep pressure, may still feel pain.  Red circle 
None Loss of Sensibility to deep pressure, normally cannot feel pain.  Black dot 
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$ Fill out the disability grade according to the WHO, using the classification below:  
GRADE CHARACTERISTICS 
0 No problems with eyes, hands and feet due to leprosy 
1 Loss or reduction of the sensibility in the eyes 
Loss or reduction of the sensibility in hands and/or feet (Does not feel the 2g 
monofilament / purple) 
2 Eyes: lagophthalmos and/or ectropion; trichiasis; central corneal opacity; visual acuity 
less than 0.1 or cannot count fingers from a distance of 6m. 
Hands: atrophy/hypotrophy and/or traumatic lesions; claws; digit absorption; dropped 
hand 
Feet: atrophy/hypotrophy and/or traumatic lesions; claws; digit absorption; dropped 
foot, ankle contracture 
 
$ Report the highest level of disability found. 
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SOP - U-MDT 012 
LABORATORY EXAM REQUESTS 
 
OBJECTIVE 
• To guarantee the collection of necessary materials for the protocol as well as for the 
storage of blood/tissue samples.   
 
Request and record the results of the following tests at the beginning of the study: 







• C- Reactive Protein 
• Bacilloscopy (Search for AFB) in ear lobes, elbow (R and L), and cutaneous lesions 
• ML-Flow 
• Histopathology, using the standard form (appendix I of SOP-U-MDT  012) 
 
Request and record the results of the following tests at each monthly visit: 
• complete haemogram 
• SGOT 
• SGPT 
• C- Reactive Protein  
 
Request and record the results of the following tests at each reactional episode: 
• C- Reactive Protein  
 
Request and record the results of the following tests if relapse is suspected: 
• Bacilloscopy, elbow (R and L), and cutaneous lesions 
• ML-flow 
• Histopathology 
• C- Reactive Protein 
 
Independent study to establish the efficacy of the six dose uniform MDT regimen  







SOP - UMDT 013 
 
DRAWING AND STORAGE OF BLOOD 
 
OBJECTIVE: 




• Tourniquet  
• Hydrophilic cotton 
• 70% alcohol  
• Blood testing tubes 
• without blood thinners 
• with EDTA 
• needle for vacuum drawing 
• Anti-septic bandages 
• Slide   
 
PRECAUTIONS: 
 In all procedures, observe the Standard Protocol of Laboratorial Best Practice.  
 
PROCEDURE: 
1. Check the patients information at the time of exam request, remembering to check that 
the date of birth has been registered.  
2. Identify the tubes with the patients initials and date of birth.  
3. Draw and process the samples according to lab routines, following the Standard 
Protocol of Best Practice for safely handling biological samples.  
4. Store the samples, filling out the Sample Distribution form (Appendix I of SOP-UMDT 
013) 
a. Number of patients chart; 
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b. Number of the patients CRF in the study (AM0001/CE0001, AM0002/CE0002, etc);  
c. Time  identifies the month of the treatment or month of follow-up after the treatment 
has ended; the first visit corresponds to point ZERO (0), that is, before the beginning of 
the treatment.  
 
The following table relates the time with the treatment doses: 
 
TIME DOSE 
M0 Before 1st dose 
M1 2nd dose visit 
M2 3rd dose visit 
M3 4th dose visit 
M4 5th dose visit 
M5 6th dose visit 
M6 7th dose visit 
M7 8th dose visit 
M8 9th dose visit 
M9 10th dose visit 
M10 11th dose visit 
M11 12th dose visit 
M12 1st year visit post-ttmt 
M13 2nd year visit post-ttmt 
M14 3rd year visit post-ttmt 
M15 4th year visit post-ttmt 
M16 5th year visit post-ttmt 
 
d. Name of the patient; 
e. Date of birth (this information is of the UTMOST importance for the correct 
identification of patients with the same name; do not forget to enter it) 
f. Date of sample collection; 
g. Signature of the professional who took the sample; 
 
2. According to the Standard Protocol of Best Practice for safely handling biological 
samples, divide the sample in three tubes, one from each box (A. B, C). Note that the 
code on the bottom of the three tubes must be the same of the column of tube 
identification (N tube) in the control spreadsheet of sample distribution.  
3. The numbering of the boxes must follow a direct numerical order: 
• Alfredo da Matta Foundation: AM 001 A (white caps) AM 001 B (red caps) e AM 
001 C (transparent blue caps). 
• Dona Libânia Dermatology Centre: CE 001 A (yellow caps) CE 001 B (green caps) 
e CE 001 C (blue caps). 
4. Close the tubes with the corresponding colours, according to the instructions above. 
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5. Place the tubes in the boxes AM001A/CEM001A, AM001B/CEM001B e AM001C/ 
CEM001C, following the sample control plan and the layout of samples in an ELISA 
plate (see scheme below).  
 
SAMPLE DISTRIBUTION IN BOXES 
 
 1 2 3 4 5 6 7 8 9 10 11 12  
A A 1 A 2 A 3 A 4 A 5 A 6 A 7 A 8 A 9 A 10 A 11 A 12  
B B 1 B 2 B3 B4 B 5 B 6 B 7 B 8 B 9 B 10 B 11 B 12  
C C1 C 2 C 3 C 4 C 5 C 6 C 7 C 8 C 9 C 10 C 11 C 12  
D D 1 D 2 D 3 D 4 D 5 D 6 D 7 D 8 D 9 D 10 D 11 D 12  
E E 1 E 2 E 3 E 4 E 5 E 6 E 7 E 8 E 9 E 10 E 11 E 12  
F F 1 F 2 F 3 F 4 F 5 F 6 F 7 F 8 F 9 F 10 F 11 F 12  
G G 1 G 2 G 3 G 4 G 5 G 6 G 7 G 8 G 9 G 10 G 11 G 12  
H H 1 H 2 H 3 H 4 H 5 H 6 H 7 H 8 H 9 H 10 H 11 H 12  
 
IMPORTANT: the codes of the tubes (N tube) follow this scheme, whereby rows are identified 
by letters (A, B, C, D, E, F, G and H) and columns are identified by numbers (1, 2, 3, 4, 5, 6, 
7, 8, 9, 10, 11 and 12). 
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• One vial containing 10% buffered formaldehyde (40% aldehyde-100 ml; 1 tablet of 
phosphate pH 7.0, distilled water900 ml), approximately 20ml for a 5mm biopsy; 
• A 3mm, 4mm, and 5mm skin biopsy punch (3mm for the face and 4mm or 5mm for 
other areas), sterile and disposable; 
• Topical anaesthesia (lidocaine without vasoconstrictors);  
• Gauze and anti-septic material for cleaning (alcohol); 
• Small, curved tip scissors; 
• Small anatomic tweezers; 
• 3ml syringe with 27 x 8 needle for insulin syringes; 
• Suture hook; 
• Suture thread -- nylon 4.0 and 6.0 for face; 
• Kelly tweezers; 
• Gauze and bandages. 
 
PROCEDURES: 
1- Select for testing the lesions that are most representative, attempting to collect material 
from the borders that demonstrate signs of activity (erythema, infiltration or oedema). 
2- Clean the area. 
3- Apply the anaesthesia to the lesions and other chosen sites. 
4- Remove the biopsy with a punch at the edge of the lesion.  
5- Avoid compressing the tissue. If necessary, use sterile hypodermic needles to facilitate 
the procedure. 
6- Place the sample immediately in the 10% buffered formaldehyde. 
7- Stitch the site from which the biopsy was taken. 
8- Cover with bandages. 
9- Schedule the removal of the stitches, according to the health centres protocols. 
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10- Fill out the Histopathology Request Form. 
11- Send the biopsy to the histopathology lab within 8 hours of the collection, providing 
the following mandatory information: 
a) Type of material sent; 
b) Site of removal (it should be clearly indicated on the anatomical chart), giving details 
regarding the description of the lesion from where the sample was taken; 
c) Description of the lesions; 
d) Patients clinical classification; 
e) Age, sex, duration of lesions, result of bacilloscopy (if taken).  
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SOP - U-MDT 015 
 HISTOPATHOLOGY EXAM 
OBJECTIVE: 
 To use the same methodology for all individuals participating in the study. 
 
METHODOLOGY: 
• The specimen should be cut in half when collected with a 5.0mm punch, after removal. 
The other sized punches should be included whole. 
• The specimens should be left in formaldehyde for twelve hours and then inserted into 
the tissue processor for preservation in paraffin. 
• After placed in histological paraffin, the specimens should be sectioned using a rotating 
microtome; each section should be five micrometres in thickness. 
• Each slide should have at least 5-6 cuts. 
• One slide is to be stained with haematoxylin and eosin and another by the Fite-Faraco or 
Wade-Klingmuller methods. 
• For each batch of slides, it is necessary to use one positive slit skin smear control slide. 
 
STAINING TECHNIQUES 
I Wade Staining  
Reagents  
Ziehl-Nielsen dye   
  Phenol 8 ml
  Absolute Ethanol 20 ml
  Basic fuchsin (powder) 2 g
  Distilled water 200 ml 
Methylene blue dye  
  Distilled water 99 ml
  Methylene blue 0,5 g
  Glacial acetic acid 0,5 ml 
Differentiator    
  70% ethanol 99 ml
  Pure chloridic acid 1 ml
De-paraffin solution  
  Terebenthene 60 ml
  Vaseline 30 ml
 
Wade method for slide staining techniques 
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1. Remove the cuts from low-heat with the slide and put them in the steriliser for 5 minutes.  
2. Remove the paraffin from the cuts with the terebenthene - Vaseline solution  2 rounds 
of 15 minutes in the steriliser. 
3. Pass through 3 cubes with absolute ethanol.  
4. Wash under running water (10 minutes).  
5. Dry with filter paper. 
6. Cover the slide with fuchsin filtered for 25 minutes. 
7. Wash quickly under running water.  
8. Remove the excess dye with acid-alcohol solution for approximately 3 seconds.  
9. Wash under running water for one minute.  
10. Stain with the blue methylene solution for 1 minute.  
11. Wash under running water. 
12. Dry in the steriliser or at room temperature. 
13. Assemble the slide with Canada balsam.  
Result: 
• Bacilli presenting violet coloration. 
• Background of the cut in pale blue.  
 
II - Staining with Haematoxylin-Eosin 
Reagents 
Harris Haematoxylin  
 Haematoxylin 5 g
 95% ethanol 50 ml
 Aluminium potassium sulphate 100 g
 Distilled water 1000 ml
 Mercury oxide 2,5 g
Preparation: 
1. Dissolve the haematoxylin in the ethanol and the aluminium potassium 
sulphate in distilled water, with the aid of heat.  
2. Mix the two solutions and boil as quickly as possible.  
3. Remove from heat and add the mercury oxide slowly and carefully, reheat 
until it boils and count one minute.  
4. Remove from heat and immerse in a basin with ice water immediately.  
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Eosin   
 Eosin 2,5 g
 Distilled water 50 ml
 95% alcohol 200 ml
 80% alcohol 750 ml
 Acetic acid 5 ml
Preparation: 
a. Dissolve the eosin in the distilled water and add the 95% alcohol.  
b. Add the 750 ml of 80% alcohol and 5ml of acetic acid.  
 
Haematoxylin-Eosin slide staining techniques.   
1. Remove paraffin from the histological slices in a stove for 10 minutes.  
2. Put in xylene immersion (2 immersions of 5 minutes each). 
3. Hydrate in alcohol immersions with decreasing concentration. Begin with 2 flasks of 
absolute alcohol, 5 minutes each, and then in 1 flask of alcohol 96º for five minutes.  
4. Wash under running water. 
5. Stain with the haematoxylin solution for 10 minutes. 
6. Wash under running water without letting the material separate from the slide. 
7. Stain with eosin for two minutes.  
8. Wash under running water.  
9. Run again through the set of alcohol flasks with decreasing concentration. Begin with 2 
flasks of absolute alcohol, 5 minutes each, and then in 1 flask of alcohol 96º for five 
minutes. 
10. Dry at room temperature. 
11. Run through xylene (2 immersions of 3 minutes each) 
12. Assemble the slide with Canada balsam. 
 
 
DESCRIPTION OF HISTOPATHOLOGY FINDINGS (MICROSCOPIC READING) 
 
• The description of the histopathological exam must be done in standardised form 
(Appendix I of SOP-UMDT 015) 
• Use microscopic magnification of 10, 25, 40 and 100X   
• Evaluate the quality of the specimen.  
• Determine if there are epidermal alterations or not 
• Determine the presence of dermal infiltrates 
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• What are the cell types of the infiltrate 
• Location of the infiltrate 
• Define if nerve sheathes were visualised in the samples examined  
• Determine if pill-erector muscle was visualised in the samples examined  
• Determine if there is collagen or intercellular oedema 
• Indicate if vasodilatation and/or congested blood vessels were observed 
• Indicate presence of necrosis 
• Note if cutaneous annexes are present 
• Presence or absence of subcutaneous annexes.  
• Morphological characteristics of the bacilli identified (whole, fragmented, 
granular, bacillary remains) 
• Indicate the bacteriological index for each granuloma (0  6+) 
CLASSIFICATION CRITERIA: 
(I) INDETERMINATE LEPROSY 
• Discrete, non-specific infiltrates with small cells, mononuclear, perineural 
and perivascular, containing lymphocytes, non-differentiated histocytes 
and fibroblasts. Exam report only indicates compatibility and is affirmative 
if acid-fast bacilli are identified. 
 
(TT) TUBERCULOID LEPROSY 
• Granulomas of epithelioid cells, with numerous lymphocytes in the 
periphery and surrounding giant cells. The infiltrates can affect the base 
layer of the epidermis. Slit skin smears will almost always be negative. 
The final result is suggestive of leprosy when there is presence of bacilli 
within the nerve sheaths.  The bacteriological index of the granulomas will 
be 0-1. 
 
(BT) BORDERLINE TUBERCULOID LEPROSY 
• Granulomas of epithelioid cells, with Langerhans-type giant cells 
predominating, permeated by lymphocytes and histocytes. There is 
variable infiltration of the sub-epidermal zone. Usually, the nerve 
sheathes are inflamed. Bacilloscopy can be negative or positive with a 
limited number of bacilli.  If negative, the exam report should note 
compatibility with a positive diagnosis. A positive bacteriological index of 
the granulomas will be in the range of 0-2. 
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(BB) BORDERLINE BORDERLINE LEPROSY  
• Granuloma of epithelioid cells, without giant cells and few and diffuse 
lymphocytes. The granulomas do not affect the epidermis; nerves are 
usually thickened and identifiable. Bacilli are always present in varying 
amounts. The bacteriological index of the granulomas will be 3-4. 
 
(BL) BORDERLINE LEPROMATOUS LEPROSY 
• Inflamed infiltration from macrophagic granulomas, with numerous 
lymphocytes densely grouped over some parts of the granuloma but not 
over the whole granuloma; some accumulation of epithelioid cells 
between the macrophages, with or without lymphocytes or with a 
combination of a moderate number of lymphocytes and non-differentiated 
cells from the granuloma. The nerves in general present with perineural 
covering from some cell infiltrates that can invade the nerve. Layer of 
sub-epidermal collagen is intact.  Bacilli are always present and the 
bacteriological index of the granulomas will be 4-5. 
 
(LL) LEPROMATOUS LEPROSY 
• Inflamed infiltration macrophagic granuloma without epithelioid cells and 
few lymphocytes. Dense infiltrates, compact, separated from the 
epidermis by a collagen strip (Unna band). Bacilli are always present and 
the bacteriological index of the granulomas will be 5-6. 
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SOP - U-MDT 016 
BACILLOSCOPY 
OBJECTIVE: 
 To use the same methodology for all individuals participating in the study. 
MATERIAL: 
• Exam request; 
• Glass slide (new) with frosted end; 
• Spirit lamp; 
• Alcohol; 
• Cotton; 
• Marking pencil or regular pencil; 
• Matches; 
• No. 3 scalpel handle and no. 15 scalpel blade; 
• Container for storage and transportation of samples; 
• Antiseptic bandages; 
• Gloves; 
• Tweezers to produce ischemia at the site of incision (can be done by pinching the skin 
firmly between your thumb and forefinger). 
• Container for disposal of used material. 
 
PRECAUTIONS: 
• Ensure that all necessary materials are available. 
• All materials should be disposable.  
• For each set of slides, it is necessary to use one AFB positive control slide  
PROCEDURES: 
1. Sites for sample collection: 
a) In patients with visible cutaneous lesions, the sample should be collected from the right 






Fig. 1  Example of smear position on slide  patient with multiple lesions 




                          1ª               2ª               3ª              4ª 
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b) In patients with a single lesion, the sample should be collected from the left and right ear 






Fig. 2 -- Example of smear position on slide  patient with single lesion 
 
c) In patients with no visible active lesions, collect samples from the R and L ear lobes, and 






Fig. 3 -- Example of smear position on slide  patient with no visible cutaneous lesions 
 
 
2. Sample collection: 
a) Make the patient comfortable; explain the procedure that will be carried out. If the patient 
is a minor, explain the procedure to their parent/guardian; 
b) Identify sampling sites by following points indicated on the exam request; 
c) Hold the slide by the edges to avoid touching the spots where the sample will be 
distributed; 
d) Identify the slide with the patients initials and registration number; 
e) Select the site for sample collection and clean it; 
f) Pinch the skin, and maintain pressure to remove blood from surrounding area 
(ischemia), keep the pressure until the end of the sample removal; 
g) Make a cut in the skin of approximately 5mm long by 3mm deep. If it starts to bleed, dry 
it with a cotton wad. Position the scalpel blade at a 90 degree angle to the cut, scrape 
the edge and the bottom of the incision to obtain enough visible material for the smear; 
h) Release the pressure and smear the material on the glass slide making circular 
movements from the centre to the edge in an area of approximately 5-7mm in diameter; 
ATTENTION: maintain a consistent amount of material in the area of smear, to guarantee its 
uniformity.   




                          1ª               2ª               3ª              4ª 
 




                          1ª               2ª               3ª              4ª 
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i) Clean the scalpel blade with a cotton ball soaked in alcohol and then sterilise it by 
passing it through the flame of an alcohol lamp. This sterilisation should be done 
between sample collections from one site to another for the same patient, to avoid 
carrying AFB-positive lymph from one collection site to another that may not be positive; 
j) The first smear should be placed at the edge closest to the patient identification 
information on the slide and the second next to the first keeping a space of about 0.5cm 
between samples and, 
k) Follow the order of the requested points from exam request.  
                                                                        
 
3. Fixation: 
       The slides containing the samples should be air dried for about 5 -10 minutes until they are 
completely dry, to guarantee a proper fixation. This is done using the spirit lamp or Bunsen 
burner, passing the slide quickly 2-3 times through the flame, with the smears facing upwards 
and never in direct contact with the flame. Be careful not apply too much heat, because that can 
alter the morphologic-staining characteristics of the bacilli present in the smear. 
 
4. Staining of the smear: (ZIEHL NEELSEN) 
a) Place the slide on a staining rack; 
b) Cover the slide with ZIEHL-NEELSEN carbol fuchsin until the smears are totally covered. 
c) Immediately after applying the fuchsin, heat the slide gently by holding a lit alcohol lamp 
underneath it, until vapour begins to rise from the fuchsin. Make sure the stain does not boil.    
d) Stop heating and set timer for 5 min. 
e) Remove the slide from the rack and wash it under a running tap. 
f) Cover the slide with decolourising reagent (1% acid-alcohol) until it becomes pinkish in colour. 
h) Wash the slide again under running tap. 
i) Place the slide in the rack, cover it with methylene blue stain until the smears are totally 
covered for 1 min. Rinse it with water and leave it to dry in the drying rack in an inclined position 
at room temperature.  
 
5. Slit skin smear microscopy reading: 
        It is very important to move the microscope correctly over the smear. During the reading, 
never go back to the same place already examined, so as to avoid an incorrect final result. In 
selecting the fields to examine, avoid the ones containing many red blood cells and focus on 
those areas with many macrophages. Count the bacilli in each microscope field, including 
isolated bacilli, some in small groups which can be viewed individually, and globi of bacilli. The 
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number of bacilli in a globi cannot be counted, although it can be estimated. A large one 
contains about 100 bacilli, a medium size one has approximately 60 bacilli, and a small one 
around 30 bacilli. In reality, almost all the smears with clusters have numerous isolated bacilli 
that can be adequately counted.  Limit each smear with a marking pencil, drawing around each 
existing smear on the slide, or drawing a line between the smears, so that it will be less 
confusing. 
 
5.1. Microscopic movement over the slide: (delimit the smear using blue marking pencil).                         
                                 _             
             _ - _ -_  - _ -   -                
       _  -  _    -    \ -     -   -                          Count 20 fields (horizontal)                                -
-_-  _--- _   -/   _-  _- --                        Count 5 fields  (vertical) 
       -_  ´ _   \    _  _  - -_--- 
      -  _  _ _    _ \    _- - _--- 
         _ -  - _ _ - - _--  
               -_ ---  _ -  _ - 
                                                               
 
 
5.2. Morphology of the bacilli under optic microscope: 
            In a POSITIVE smear for Mycobacterium leprae, the bacilli are either isolated or in 
clusters.   
 
5.2.1  In the case of ISOLATED bacilli, observe and describe: 
 
- INTACT Bacilli: Bacilli that after staining, are completely red, without any colouration 
gaps in the cell wall.  
- FRAGMENTED Bacilli: Bacilli that present small gaps in their cell wall due to 
interruption of the synthesis of its components. After staining, only parts of the body of the bacilli 
that have cell wall will be red. 
- GRANULATED Bacilli: These are bacilli that present significant gaps in their cell wall. 
Sometimes after staining, only a few small dots will be red. 
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5.2.2  If GROUPS of bacilli are present, observe and describe: 
 
- CLUSTERS of bacilli: Bacilli that are very close to each other forming small and long 
rods. The light from the microscope passes through the spaces between them. 
- Bacilli in GLOBI: These are structures made with a colourless substance that forms 
between the bacilli, keeping them connected in an organized form. The light emitted by the 
microscope does not pass through them because there is no free space between the bacilli. 
For counting, the globules can be: 
- SMALL: Around 30 bacilli. 
- MEDIUM: Around 60 bacilli. 
- LARGE: Around 100 or more bacilli.  
 
5.2.3. Calculation of the Bacteriological Index (BI): 
     To calculate the Bacilloscopic or Bacteriological Index (BI), use the logarithm scale 
proposed by RIDLEY in1964. 
 
5.2.4. Logarithmic Scale of RIDLEY: 
( 0 )  - Absence of bacilli in 100 examined microscopic fields. 
( 1 ) -  Presence of 1 to 10 bacilli, in 100 microscopic fields examined. 
( 2 ) -  Presence of 1 to 10 bacilli, in 10 microscopic fields examined. 
( 3 ) -  Presence of 1 to 10 bacilli, on average, in each microscopic field examined. 
( 4 ) -  Presence of 10 to 100 bacilli, on average, in each microscopic field examined. 
( 5 ) - Presence of 100 to 1000 bacilli, on average, in each microscopic field examined. 
( 6 ) - Presence of more than 1000 bacilli, on average, in each microscopic field examined. 
 
5.2.5. Calculation of the average BI of the Patient: 
The Average Bacteriological Index should be calculated by adding the indexes found for each 
collection site, divided by the total number of collection sites. 
EX:   Right ear lobe        =  4  
         Left ear lobe          =  3               BI  =       17/4    =  4.2 
         Left elbow             =  4                               
         Lesion                   =  6  
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6. Quality Control: 
After reading the skin smear slides, store them in appropriate laboratory containers. These 
slides are important because study supervisors will examine the samples later and evaluate the 
quality of the skin smear exams. The sample of slides should be selected from the laboratory 
registry, based on the BI. Approximately 20 to 30% of the smears should be negative, 50 to 
60% should have a BI of 1, 2 or 3 and no more than 20% should have a BI of 4, 5 or 6. At the 
time of re-examination, the results should be given to the supervisor after the two outcomes are 
compared and correlated. The results of the supervisors readings should be returned, along 
with the slides. The differences found should be identified and corrected. 
 
7. Preparation of the reagents used during the Staining Procedure: 
 
7.1 ZIEHL- NEELSEN staining (used at the Centre of Dermatology Dona Libânia) 
a)  Decolourising solution (1% acid-alcohol): 
        Ethyl Alcohol P.A.........................................99ml 
        Hydrochloric Acid concentrated P.A............ 1ml 
• Add 50ml of ethyl alcohol P.A to a graduated cylinder.  
• Add the concentrated hydrochloric acid (1ml) to the alcohol, drop by drop; complete the 
volume to the 100 ml mark on the cylinder with ethyl alcohol.  
• Keep the solution in appropriate container at room temperature. 
 
b)  Methylene blue (ZIEHL- NEELSEN contrast): 
        Methylene blue powder............................................................10g 
        Distilled water......................................................................1000ml 
        Absolute ethanol. 50ml 
• Dissolve the methylene blue powder with ethanol in a small bowl.  
• Add distilled water, until the final volume reaches 1000ml.  
• Transfer to the appropriate vial, let it rest for 24 hours.  
• Filter before use. 
 
c) - ZIEHL-NEELSEN Carbol Fuchsin: 
        Basic Fuchsin powder..............................................10g 
        Ethyl Alcohol P.A......................................................100ml 
        Phenol .....................................................................55ml 
        Distilled water............................................1000ml  
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• Dissolve the basic fuchsin with ethyl alcohol P.A or pure ethanol. 
• Add the phenol and homogenise. 
• Transfer to a graduated cylinder and add distilled water until the final volume reaches 
1000ml. 
• Wait 24 hours, filter and transfer to an amber vial, keeping it sheltered from light at all 
times. 
• Mix and filter before use. 
 
7.2 KINYOUN staining (used at Alfredo da Matta Foundation) 
a)  Preparation of Kinyoun Carbol Fuchsin: 
Basic fuchsin powder .. 4g 
Ethyl alcohol P.A .. 20ml 
Phenol crystals8g 
Distilled water..100ml 
• Dissolve the fuchsin with ethyl alcohol PA in a small bowl; 
• Transfer to the appropriate vial (beaker); 
• Dissolve the phenol crystals (low heat, 56ºC) and mix it to the fuchsin solution; 
• Heat the distilled water and slowly add it to the vial containing the fuchsin and phenol, 
with circular movements; 
• After reaching the final volume, heat the vial with the dye on low heat (do not let it boil); 
• Store in vial containing glass beads and sheltered from light for 24 hours; 
• Mix and filter before use. 
 
b)  Staining through the Kinyoun method (cold staining): 
• Wait for the smear to completely dry at room temperature; 
• Fix the smears through heat. This is done using the ethanol flame or Bunsen burner, 
passing the slide quickly 2-3 times through the flame, with the smear side facing 
upwards and never in direct contact with the flame; 
• Immerse the slide in the appropriate support (vial) containing the KINYOUN fuchsin for 
five minutes (5min); 
• Remove the slide from the rack, washing quickly with running water; 
• Drip the decolourising solution (acid-ethanol, 1%) on the smears until they reach a 
pinkish colour; 
• Wash the slide again with running water; 
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• Immerse the slide in the appropriate support (vial), containing the methylene blue dye 
(the same as Ziehl-Neelsen) for five minutes (5min); 




8. Disposal of materials 
The disposal of material is a very important topic. The slides or any other potentially 
contaminated material must be eliminated in special containers. 
 
Slides  
The scalpel blades used to collect material must be handled with care and disposed in special 
boxes for the disposal of sharp materials that are already in use by the health service. When 




All potentially contaminated material must be handled with care and disposed in appropriate 
containers in use at the health centre.  
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SOP U-MDT 017 
 
ML FLOW TEST 
 
Objective:  
       Detect the presence of IgM antibodies specific to Mycobacterium leprae in the blood 
sample. 
Material necessary:  
 
• alcohol swab 
• needle  
• capillary tube 
• adhesive bandage 
• ML Flow test kit 
• container for the disposal of used material  
Material collection 
1- Prepare, in a tray, the material to collect a blood sample: alcohol swab, needle, capillary 
tube and adhesive bandage. 
2- Remove the ML Flow test kit from its protective wrapping and place it flat on a surface with 
the round receptacle for the sample and the rectangular window of the test kit facing 
upwards. 
3- Observation: the rectangular window located at the centre of the test device, contains 2 
strips: one containing the antigen (T), located closer to the sample receptacle and, a control 
strip (C).  
4- Open the alcohol pad wrapping.  
5- Explain to the patient the procedure that will be done. 
6- Clean the tip of the left index finger with the alcohol pad (if left handed, then do this on the 
right index finger). 
7- Prick the skin using the needle, and immediately place it in the sharp materials waste 
container.  
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8- Touch the blood with the end of the capillary tube and collect about 5 micro-litres of blood 
(corresponds to 0.5 cm). Use this blood directly to immediately perform the ML Flow test.  
9- Clean the pricked finger with the alcohol pad, place the adhesive bandage and ask the 
patient to apply pressure to it for a minute to stop the bleeding. 
 
EXECUTION OF THE ML FLOW TEST  
 
1- Place 5 µl of blood in the round receptacle and add 4 drops (or 125 µl) of the running buffer 
solution to the same location.  
2- Set the timer for 5 minutes. 
3- Close the vial with the buffering solution and store it at room temperature for later use. 
4- Read the result after 5 min. 
5- Observation: Results read more than 20 min after the addition of blood and sample fluid are 
not valid. 
6- To open the test device, fold the test cartridge backwards. 
7- With a tissue paper dry the excess liquid by pressing on the top of the paper filter, where the 
blood drop was placed. 
8- Immediately write down the patients initials and the date of birth and also his/her code on 
the back of the test.  
9- Allow the test to dry.  
10- The test must be taped to the sheet containing the patients results.  
TEST READING 
 
1- After the addition of the buffering solution to the receptacle where the blood sample was 
placed, a colour reaction will be visible moving through the test and control strips. This 
shows that the test is working. 
2- The control strip should always show colour. 
3- The colour in the control band guarantees the integrity of the detection reagent, but is not a 
control of the quality of the sample. 
4- If the control band does not show any colour, the test is not working. 
5- A negative result is indicated by the absence of a line in the detection strip and its presence 
in the control strip.  
6- A positive result is indicated by the presence of a strong line both in the detection and 
control strips. 
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7- The pigmentation of the antigen band indicates the presence of IgM antibodies specific for 
Mycobacterium leprae. 
 











The intensity of the positive result varies from 1+ to 4+.  See picture below.  
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DISPOSAL OF WASTE MATERIALS 
The disposal of materials is a very important topic. The needles, capillary tubes and any other 
potentially infected material must be disposed of in special containers.  
 
NEEDLES  CAPILLARY TUBES   
The needles and capillary tubes used for cutaneous smears and for the lateral flow, must be 
handled carefully and disposed of in special boxes for the disposal of sharp materials that 
are in use at the health centre. When the boxes are full, send them to the recommended 
location, according to the routine of the health centre.  
 
ALCOHOL SWABS - TEST CARTRIDGE - GLOVES 
All material potentially contaminated must be handled with care and disposed in the 
appropriate containers in use at the health centre.  
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SOP U-MDT 018 
 









• 1 litre cylinder;  
• 500ml cylinder; 
• Pipettes; 
• Distilled water; 
• Concentrated chloridic acid  HCl 
• Normal urine  urine of a donor who is not on any medication that contains dapsone or 
sulfone. 
• Dapsone  4,4 Diaminodiphenyl Sulfone  (D -2505 Sigma)   
 
HCl solution at approximately 1mol/l  expires after one year. 
1. Follow the routine for preparing solutions, adding 100ml of chloridic acid to 1000ml of 
distilled water.  
2. Transfer to capped flask and label properly (name of the solution, date, signature of the 
responsible) 
 
Preparing the NEGATIVE control  solution A  expires after one week. 
1. Mix 90ml of normal urine with 10ml of HCl 1mol/l solution. 
2. Transfer to capped flask and label properly (name of the solution, date, signature of the 
responsible); 
 
Preparing the dapsone stock solution  solution B  expiration date undetermined. 
1. Mix 1g of dapsone in 100ml of HCl 1mol/l. 
2. Transfer to capped flask and label properly (name of the solution, date, signature of the 
responsible). 
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Preparing the diluted dapsone solution  solution C  expires after one year. 
1. Mix 1ml of the dapsone stock solution  solution B  in 49ml of distilled water. 
2. Transfer to capped flask and label properly (name of the solution, date, signature of the 
responsible). 
 
Preparing the POSITIVE control  solution D  expires after one week. 
 This solution contains approximately 5ml/l of dapsone in acid urine.  
1. Mix 1ml of the diluted dapsone solution  solution C  in 39ml of the control.  
2. Transfer to capped flask and label properly (name of the solution, date, signature of the 
responsible). 
 
STORAGE AND EXPIRATION 
 
Test strips: 
The strip covered with filter paper must be kept in plastic with silica desiccants and stored at 
4ºC. Well-stored testing strips can be used for years, although it is important to undertake 
control quality reviews to ensure that they are still valid. Tests for use during a period of one 
week, when not stored at 4ºC, must be kept in complete darkness.  
 
Controls: 
Controls must be stored at 4ºC. 
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1. Flask for collecting urine 
2. Test paper 




Person Responsible  study coordinator 
10% of each weeks patients will be tested. The person responsible for randomisation must list, 
each Friday, all the patients scheduled to receive the supervised dose during the following 
week. The chart numbers for these patients should be placed in an opaque receptacle, and a 
simple random drawing should be done, pulling from the recipient as many numbers as are 
determined by the following table:  
 
Total of patients scheduled to receive 
medication during the week 
Number of patients wholl take the test 
01 to 10 patients choose 01 number by lot 
11 to 20 patients choose 02 numbers by lot 
21 to 30 patients choose 03 numbers by lot 
31 to 40 patients  choose 04 numbers by lot 
41 to 50 patients choose 05 numbers by lot 
51 to 60 patients choose 06 numbers by lot 
61 to 70 patients choose 07 numbers by lot 
71 to 80 patients  choose 08 numbers by lot 
81 to 90 patients choose 09 numbers by lot 
91 to 100 patients  choose 10 numbers by lot 
After the drawing, underline in red the names of the patients who will take the test. 
 
COLLECTION: 
Responsible persons: nursing department 
1. When the patient arrives, before administering the dose, explain that they have been 
randomly selected to take the test.  
2. Provide a collecting flask and ask the patient to provide a urine sample. 
3. Send the material to the lab.  
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QUALITY CONTROL OF THE TEST STRIPS: 
Responsible: laboratory personnel 
 
The quality control of the strips will be done on Monday, in the lab. After performing the control, 
the lab will provide only the sufficient amount of strips for the nursing section to perform the 
tests of one week. The laboratory will also be responsible for providing the HCl 1mol/l solution, 
being careful to label with HCl 1mol/l solution and informing that it is a toxic and corrosive 
solution.  
 
1. Prepare the material for the test: negative control (A)  positive control (D)  1N solution of 
HCl  pipettes  SAMPLE.  
2. Remove two strips from wrapping and place them on a counter.  
3. On one of them, add a drop of negative control (A) and on the other, one drop of positive 
control.  
4. Add slowly to the sample 3 to 4 drops of the HCl solution, in the middle of the sample.  
5. Observe that a colour will move from the middle to the edges of the test.  
6. Read the test results immediately after the complete cleansing, using the HCl solution, of 
the test area. 
 
EXECUTION OF THE TEST:  
Responsible: nursing department 
1. Remove a test strip from its wrapping and place it on a counter.  
2. Add a drop of the SAMPLE to the test strip. 
3. Add slowly to the sample 3 to 4 drops of the HCl solution, in the middle of the sample.  
4. Observe that a colour will move from the middle to the edges of the test.  
 
READING 
1. Read the test results immediately after the complete cleaning of the test area, using the HCl 
solution. 
$ Observation:  The results should be read immediately. If the reading of the results is 
done after more than 5 min from the addition of the HCl, they are not valid 
2. Immediately write down the results of the test in the appropriated form.  
INTERPRETATION OF THE TEST RESULTS: 
 
- A negative result is indicated by the absence of a central stain as observed in the 
negative control. 
- A positive result is indicated by the presence of a central stain equal to or larger 
in size than the one observed for the positive control.  
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Sulfonuria test results:  
Negative test on the left and 





DISPOSAL OF MATERIAL 
 
The disposal of material is a very important issue. The test paper, the pipettes, the sample vials 




Independent study to establish the efficacy of the six dose uniform MDT regimen  









 To use the same methodology for all individuals participating in the study. 
 
MATERIAL 
! White coat  
! Black pen 
! Health Centre Patient Chart  
! CRF  U-MDT 
 
PROCEDURES 
The following tests and procedures should be executed during the monthly visits (PB  6 
months; MB  12 months) 
 
Physician 
1. Fill out the CRF according to the patient registration information in the study. 
2. Clinical-dermatological evaluation: verify the following aspects of cutaneous lesions: 
colour, sensibility and infiltration, entering findings in the CRF according to the evolution 
observed: if there was regression, improvement, worsening, or no changes observed. In 
case of multiple lesions, consider the evolution of the majority of lesions.  
3. Verify the presence of side effects and register them on the monthly evaluation form, 
analysing their severity according to SOP 022.  
4. Neurological exam: proceed to palpating the nerve trunks and register in: Peripheral 
Nerve Examination Form. 
5. Determine if there are symptoms of reactional episodes and evaluate the degree of 
seriousness for each one of them. Record them on the Form for Follow-up of Reactional 
Episodes. 
6. Begin treatment of the reactional episodes, if necessary, according to SOP 021. 
7. During scheduled visits, classify the disability grade and enter it on the CRF form.  
8. Verify the use of other medications and enter this on the Simultaneous Medication 
Registration Form. On this form, you should not include medication used for treatment of 
reactional episodes.  
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9. Observe the existence of any side effects for other medications and register them in 
Log of Side Effects in the CRF, including the side effects of anti-reactional drugs.  
10. Request the laboratorial exams according to SOP-012 
 
Laboratory 
1. Obtain blood sample for clinical-laboratorial tests.  
2. Record the results for C Reactive Protein, complete haemogram and transaminases 
(SGOT/ SGTP). 
3. Register the sulfonuria results.  
4. Store the blood/serum sample, according to SOP-UMDT 013. 
 
Nursing 
1. Administer the study medication to the patient. Enter the following information on the 
Investigational Dose Registration Form:  
a. the number of pills given  
b. the lot number 
c. the expiration date 
 
2. Observe the regularity of dose administration, according to what has been established in the 
study protocol: 
a. PB patients  must receive six doses in 9 months, maximum. 
b. MB patients 
i. U-MDT group: must receive six doses in 9 months, maximum.  
ii. R-MDT group: must receive twelve doses in 18 months, maximum. 
 
OBSERVATION: 
A maximum of one unsupervised dose of MDT will be permitted, in the condition that it is 
impossible for the patient to come to the recruiting centre that month.  
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SOP U-MDT 021 
LEPROSY REACTIONS  
 
OBJECTIVE 
Use the same procedures and definitions for the collection of information related to 
leprosy reactions occurring in the participants of this study. 
 
PRECAUTIONS 
Episodes of leprosy-related reactions are acute inflammatory events, resulting from the 
activation of an auto-immune response to M.leprae.  
They can be Reverse Reaction (type 1 reaction); Erythema Nodosum Leprosum (type 
2 reaction); Neuritis (isolated or associated with type 1 or type 2 reactions). 
 
 MATERIAL 
! White coat  
! Black pen 
! Health Centre Patient Chart  
! CRF  U-MDT 
! Monofilament set 
 
PROCEDURES 
1. Check the skin, nerves and eyes, to identify signs of a leprosy reaction. 
2. Examine and ask the patient:  
a) Overall symptoms: 
! Check for fever, malaise, nausea, anorexia and other systemic symptoms.  
! Inquire about the presence of headaches, arthralgia, swelling of lymphnodes 
and cervical / axillary ganglia, enlargement and pain in the testicles.   
b) Skin 
! It is important to examine all the skin of the patient  
! Check for pain and oedema in the skin lesions. 
! Determine if inflammation is present in the lesions. 
! Examine the hands and feet to determine presence of oedema, muscular 
atrophy and/or reduced function of sweat glands. 
! Check for the presence of painful nodules in subcutaneous.  
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 c) Nerves 
! Ask the patient if there is any reduction of sensibility or strength in hands and 
feet. 
! Ask about difficulties in performing daily tasks. 
! Ask about pain, burning and/or tingling sensation in the nerves.  
! Palpate the nerves to evaluate for hypersensitivity or pain. 
! Test for loss of sensitivity in hands and feet, using the set of monofilaments.  
! Test the muscle strength of hands and feet. 
d) Eyes 
! Ask the patient if there is pain in the eyes, photophobia or recent loss of 
eyesight (worsening of visual acuity). 
! Look for signs of inflammation: hyperaemia or irregularity in the form of the 
pupils. 
! Test the muscle strength of the eyelids. 
3. Compare the results of this clinical examination with those of the previous examination. 
4. Record the results of the clinical examination in the patients chart. Describe in the 




1. Reversal Reaction (Type 1 Reaction)  
The most common clinical characteristic of this type of reaction is the inflammation of 
pre-existing cutaneous lesions that become more erythematous, even vinous, and new 
lesions may appear. If the oedema is greatly accentuated, the lesions can peel and 
even ulcerate. The sensibility of the lesions is generally exacerbated, and patients may 
complain of intense pain even for small injuries. They might recur and last for months 
or even years. Systemic symptoms such as fever, malaise, anorexia, can accompany 
the more serious reactions, but this is less frequent than in type 2 reactions. Swelling 
of the hands, feet and face may be present.  Neuritis is the most important 
manifestation of the type 1 reaction, occurring by itself or in association with 
cutaneous lesions.  
 
2. Erythema Nodosum Leprosum (Type 2 Reaction)   
The lesions of erythema nodosum leprosum (ENL) are the most common 
manifestation and sometimes the only one for type 2 reactions. They are characterized 
by erythematous nodules, 2 to 5mm in diameter, tender to the touch or even painful in 
the absence of external stimuli. They can be few or many more frequently localized in 
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legs and arms and less frequently in trunk and, in several cases they can disseminate. 
They can be superficial or quite deep, which in this case makes them more palpable 
than visible, and can sometimes ulcerate. In general, they occur in outbreaks with 
intermittent spells of fever, and tend to recur in the same parts of the body. If they dont 
totally disappear, a chronic, painful panniculitis can develop that sometimes lasts for 
months or years.  Some patients have reactions with blisters, erythematous plaques 
and ulcerations  a reaction of the polymorphous erythema type.   
Neuritis is a common manifestation, but is less intense than in the type 1 reaction.  
Iritis and episcleritis are also common, and can be the only manifestation of the 
reaction, as well as being present at the time of diagnosis.  Symptoms of the upper 
respiratory apparatus, and others, such as epistaxis, can worsen and even ulcerate.  
Orchitis can be acute, with oedema and pain in the testicles, which can rapidly 
atrophy, or even occur without symptoms, with little pain and oedema, but lead to 
gradual loss of function.  Pain and oedema in lymphnodes can accompany or 
occasionally be predominant in type 2 reactions.  Rarely, necrosis may occur.  
Oedema and pain in the feet and hands can happen more frequently than in type 1 
reactions, or occurs in the joints, simulating arthritis.  The term of reaction hands 
and feet is used when there is diffuse and acute inflammation of all soft tissue of the 
hands and feet, such as tenosynovitis, myositis, arthritis e osteitis, which can leave 
retractile dysfunction.  General symptoms like fever, exhaustion, malaise, headache, 
anorexia, insomnia and depression are more commonly seen than in type 1 reactions.   
Hepatomegaly and splenomegaly can be present. 
 
3. Neuritis 
The condition of neuritis manifests itself through spontaneous neural pain or when 
nerve trunks are palpated, and can be associated with sensation, motor or sudden 
autonomic deficit. The nerve diameter may or may not be thickened.  
While palpating the nerves, its important to watch the face of the patient for 
expressions of pain. Always compare a palpated nerve from one side to the other side, 
observing thickness, texture and the presence of nodules.  
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Classification of neural pain and presence of NEURITIS. 
Level Neural pain Neuritis*
0 Absent No 
1 Light  when distracted the patient does not manifest pain at 
palpation. 
No 
2 Moderate  even when distracted, the patient manifests pain at 
palpation. 
Yes 
3 Severe  the patient pulls away the member in a defensive 
movement. 
Yes 
* Consider neuritis only when the status found is described as moderate or severe (2 
or 3).  
 
4. Silent neuropathy 
The state of silent neuropathy occurs when the patient presents sensibility and/or 
recent motor deficit (< 6 months of duration), in an area innervated by one or more 
nerve trunks, with no sign of reverse reaction or erythema nodosum and with no pain 
or neural hypersensitivity.   
 
5. Sensibility deficit 
Test six spots in each hand and nine spots in each foot, according to what has been 
described in SOP 011 (Simplified Neurological Exam).  
The following conditions, when compared with previous records, represent a case of 
neuritis, with or without pain at nerve palpation.  
1) Worsening of at least three levels of monofilament in any spot OR; 
2) Worsening of two levels of monofilament in one spot AND at least one level in 
another spot OR; 
3) Worsening of one level of monofilament in three or more spots corresponding to 
the trajectory of the same nerve.  
 
6. Motor deficit  
Test six muscles in each side of the patients body: one muscle that affects the eyelid, 
three muscles of the hand and two muscles in the foot, according to what has been 
described at the Simplified Neurological Evaluation SOP.  
Consider motor deficit to be present if the response to the test for any muscle is less 
than four, in the gradual scale of muscular strength.  
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The decrease of strength in a muscle of more than two levels, when compared to 
previous exams, represents the onset of neuritis, with or without pain at nerve 
palpation.   
 
7. Neural thickness 
Consider the following scale to define neural thickness: 
0  absent 
1  doubtful  
2  defined.  
Only the defined scale (2) should be included as neural thickness.  
 
$ Register on the CRF, on the Diagnosis and Follow-up of Reactions form, according to 
the codes below. Remember that one or more options are acceptable. 
1- Reverse Reaction 19- Neuritis + Reverse reaction 
2- ENL 20- Neuritis + ENL 
3- Necrosing ENL 21- Neuritis + Mix Reaction 
4- Polymorphic Erythema 22- Neuritis + necrosing ENL 
5- Arthritis  23- Neuritis + Polymorphic Erythema 
6- Lymphadenopathy 24- Neuritis + Arthritis 
7- Orchitis 25- Neuritis + lymphadenopathy 
8- Iritis / Iridocyclitis 26- Neuritis + Orchitis 
9- Reaction hand and foot 27- Neuritis + Iritis / Iridocyclitis 
10- ENL + necrosing ENL 28- Neuritis + reaction hand and foot 
11- ENL + Polymorphic Erythema 29- Neuritis + ENL + necrosing ENL 
12- ENL + Orchitis 30- Neuritis + ENL + polymorphic erythema 
13- ENL + Arthritis 31- Neuritis + ENL + Orchitis 
14- ENL + Lymphadenopathy 32- Neuritis + ENL + Arthritis 
15- ENL + Iritis / Iridocyclitis 33- Neuritis + ENL + Lymphadenopathy 
16- ENL + reaction hand and foot 34- Neuritis + ENL + Iritis / Iridocyclitis 
17- Mixed reaction / Type 1 + Type 2 35- Neuritis + ENL + Reaction hand and foot 
18- Neuritis  
 
• Involvement:  
1  Cutaneous 
2  Neural 
3  Cutaneous + neural 
4  Cutaneous + systemic 
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5  Neural + systemic 
6  Cutaneous + neural + systemic 
 
 
•   Precipitating factors of the reactions: 
1) Intervening infections 
2) Pregnancy 
3) Surgery 
4) Physical and/or psychological stress 
5) Medication 
6) Vaccinations 
7) Unidentified  
8) Others  specify which.  
 
 
• Treatment used:  
1) Corticosteroid  
2) Thalidomide  
3) Clofazimine    
4) Pentoxifylline  
5) Corticosteroid +  Thalidomide 
6) Corticosteroid + Clofazimine 
7) Corticosteroid + Pentoxifylline 
8) Thalidomide + Clofazimine 
9) Thalidomide + Pentoxifylline 
10) Corticosteroid + Thalidomide + Clofazimine 
11) Corticosteroid + Thalidomide + Pentoxifylline 
12) Corticosteroid + Pentoxifylline + Clofazimine 
13) Corticosteroid + Pentoxifylline + Clofazimine + Thalidomide 
14) Other  specify which.  
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POP MDTU 022 
 
SIDE EFFECTS OF MDT 
 
OBJECTIVE: 
To detect the occurrence of signs or symptoms that may be related to the use of any medication 
in the course of Multi-Drug Therapy. Determine the measures to be taken in case side effects 
should occur, according to their type and the drug responsible.  
 
MATERIAL 
• White coat 
• Black pen 
• Health Centre Patient Chart  
• CRF  U-MDT 
 
PROCEDURES 
• During each monthly visit, inquire the patient as to the presence of symptoms and 
observe signs that may be related to adverse effects of the medication used in MDT. 
• On the monthly visit form, only the side effects that may be related to medication used in 
MDT should be recorded.   
• Adverse effects related to other medications in use, including anti-reaction medications, 
must be written on the Registration of Side Effects form (page 126 of the CRF). 
• Critical side effects that indicate the need for suspension of MDT must be registered on 
the Description of Critical Side Effects (page 127 of the CRF). 
• Classify the side effects, according to their severity, using the tables below. In these 
tables, DLA means daily life activities.  
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Mild or localised 
Intense or 
disseminated, without 
interfering in DLA 
 
Interfering in DLA 
Xerosis Asymptomatic Symptomatic without interfering in DLA 
Symptomatic, 
interfering in DLA 
Cutaneous  
pigmentation Mild or localised 
Intense or spread Not applicable 
 
Cutaneous Rash / 
erythrodermia 
 
macular or papular 
eruption, or erythema, 
with no associated 
symptoms 
macular or papular 
eruption, or erythema, 
with itching or other 
symptoms, and 
localised peeling 
affecting less than 
50% of body surface 
 
Severe or spread 
erythema or macular, 
papular or vesicular 
eruption; peeling 
affecting 50% or more 
of body surface. 
Photodermatitis Erythema without 
pain 




Sign or symptom Mild Moderate Severe 
 
Abdominal pain Mild discomfort; does 
not interfere in 
behaviour.  
Pain or use of 
medication interferes 
in behaviour, but does 
not interfere in DLA. 
Pain or use of 
medication interferes 







making the regular use 
of laxatives necessary. 
Symptoms interfere in 
DLA.  
 
Nausea Loss of appetite; does not interfere in 
eating habits.  
Altered intake of food, 




Inadequate intake of 
calories and liquids.  
Vomit 01 episode in 24 hours.  
2  5 episodes in 24 
hours 





Increase of less than 
4 daily defecations 
more than usual.  
 
Increase of 4-6 daily 
defecations more than 
usual. 
Increase of 7 or more 
daily defecations, more 
than usual, interfering 
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Loss of appetite 
without interfering 
with eating habits.  
Altered intake of food, 




Important weight loss 




















medical intervention.  
Radiological, 
endoscopic or surgical 
intervention is 
recommended.  
* Hepatitis e Cholecystitis should be registered in the Critical Side Effects form (page127 do CRF). 
 
Haematological 
Sign or symptom Mild Moderate Severe 
 
Red cell count 
Slight cellular 
reduction or 
reduction ≤ 25% of 
normal according to 
age.  
Moderate cellular 
reduction or reduction 
> 25% - ≤ 50% of 
normal according to 
age.  
Severe cellular 
reduction or reduction 
> 50% - ≤ 75% of 
normal according to 
age.  






Evidence of red cell 
destruction and 
reduction of ≥ 2 gm of 
haemoglobin, 
transfusion is not 
indicated.  







Purplish or cyanotic 
lips.  
Cyanotic extremities, 
light dyspnoea.  








Discreet bleeding, no 
need for intervention. 
 
Symptomatic bleeding, 
with indication for 
medical intervention.  
Intense bleeding, 
requesting admittance 
to a hospital and/or 
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Sign or Symptom Mild Moderate Severe 
Weight loss 5 to < 10% of initial weight.  
10 to < 20% of initial 
weight.  
≥ 20% of initial weight. 
 
Dyspnoea 
Shortness of breath, 
the patient is able to 
climb a flight of stairs 
without needing to 
stop.  
The patient cannot 
climb one flight of 
stairs or walk 100m 
without needing to 
stop.  
 
Makes it impossible to 




Doesnt interfere in 
DLA 
Makes it difficult to 
perform some DLA.  
 
Interferes in DLA.  




Mild muscular pain, 
does not interfere in 
behaviour.  
Moderate muscular 
pain; pain or the use of 
medication interferes 
in behaviour, but not in 
DLA.  
 
Severe muscular pain; 
pain or use of 
medication interferes 









does not interfere in 
behaviour.  
Moderate headache; 
pain or use of pain-
killers interferes in 
behaviour, but not in 
DLA.  
 
Severe headache; pain 
or use of pain-killers 









alteration, interfering in 




alteration, interfering in 
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CONDUCT TO BE APPLIED IN CASE OF SIDE EFFECTS: 
 
1. Nausea and vomiting 
• Investigate if those effects occurred after taking the supervised dose or after the 
self-administered doses of MDT.  
• Investigate cause (gastro-intestinal intolerance, viral or drug-induced hepatitis, 
etc), through the patient history information, physical exam and requests for 
complementary exams.     
• In case it relates to the self-administered dose, orient the patient to take it after a 
meal.  
• In the case of repeated vomiting, suspend treatment, removing the patient from the 
study  fill out the study withdrawal form, according to SOP 024.  
 
2. Cutaneous effects or dryness  
• Prescribe the daily application of mineral oil or urea cream after showering, and 
orient the patient to avoid exposure to direct sunlight.  
 
3. Jaundice 
• Investigate if the existence of this side effect relates to the administration of the 
supervised dose or to self-administered doses.  
• Evaluate previous history for alcoholism, hepatitis and other hepatic diseases; 
• Request complementary exams for differential diagnoses; 
• If there is an alteration of indicators of liver function, with values greater than twice 
the normal value, suspend treatment and remove the patient from the study  fill 
out the study withdrawal form, according to SOP 024. 
 
4. Haemolytic anaemia 
• Remember that most patients tend to improve as the treatment goes on; 
• Give the patient folic acid: 5 to 10mg/day 
• In severe cases: 
- suspend treatment; 
- refer the patient to a haematologist for evaluation and treatment. 
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• Mild: suspend dapsone and observe. Usually it disappears gradually after 
suspending medication.  
• Severe: refer for hospital admittance and intravenous administration of methylene 
blue, 1 to 2mg/kg of body weight, in 1% solution, during 5 minutes. If the cyanosis 
does not disappear in one hour, repeat the medication, in the same proportions, never 
exceeding 7mg/kg of body weight. Methylene blue should not be used for G6PD 
(glicose6 phosphate dehydrogenase) deficient. 
• Other measures to be taken: diminish the absorption of dapsone through emetics 
and gastric lavage, haemodialysis, peritoneal dialysis or exsanguinous-transfusion, 
use of manitol and urea to increase the excretion of dapsone.  
 
6. Pseudoflu syndrome 
• Immediately suspend rifampicin and evaluate the severity of the case; 
• In mild cases, administer anti-histamine, anti-thermal and keep the patient under 
observation for at least 6 hours; 
• In moderate and severe cases, administer corticosteroids (hydrocortisone 
500mg/250ml of saline  30 drops/minute IV), and then oral corticosteroids 
(prednisone) with progressive reduction of dosage until complete removal.  
 
7. Mild Pharmacodermy to Stevens-Johnson Syndrome, exfoliative dermatitis 
or erythrodermia caused by dapsone.  
• Suspend, definitively, treatment with dapsone. 
• Depending on the severity of the pharmacodermy, refer for hospital admittance. 
• In case of suspected hypersensitivity syndrome related to dapsone, request 
complete blood scan, hepatic and renal functions, refer for hospital admittance.  
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POP MDTU 023 
RELAPSE 
OBJECTIVE 
 To detect the presence of signs or symptoms that may indicate leprosy relapse.  
     
MATERIAL 
• White coat  
• Black pen 
• Patient Chart 
• CRF  U-MDT 
 
PRECAUTIONS 
Always verify the possibility that the manifestations are caused by a leprosy reaction. 
Confirmation of relapse will only be done after discussing the case with the studys general 
coordinators.  
 
CRITERIA FOR SUSPECTING RELAPSE  
Paucibacillary Patients PB:  
1. Appearance or ongoing presence of Reversal Reaction (RR), with cutaneous effects 
and/or neuritis, three years after release from treatment with MDT (RFT).  
2. Slow or gradual appearance of new lesions (skin and nerves) and/or worsening of 
residual lesions, three years after discharge. Cases that had improved cutaneous 
condition, but saw reactivation of lesions following gradual reduction of corticosteroids 
should also be included. 
3. Absence of significant improvement of lesions 1 to 2 weeks after beginning treatment 
with prednisone 1mg/kg/day.  
4. Patients that fall outside the criteria above, but who present clinical signs of relapse, 
including tuberculoid cases 
5. Even beyond the three-year period, the physician should consider the possibility of 
relapse any time the clinical signs are strongly suspicious. 
 
Multibacillary Patients MB:  
1. Continuation or worsening of reactions (type 1 or type 2) five years after release from 
MDT treatment;  
2. Appearance of new lesions (skin and nerves) and/or exacerbation of residual lesions 
after RFT that do not respond to treatment with corticosteroids and/or thalidomide;  
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3. Bacilloscopic exam with intact bacilli present; 
4. Increase of 2+ of BI (at any site) when compared to the BI taken at RFT, when available; 
5. Clinical-histopathological correlation: AFB intact even with negative bacilloscopy. 
6. Even beyond the five-year period, the physician should consider the possibility of 
relapse any time the clinical signs are strongly suspicious. 
 
PROCEDURES 
The following tests and procedures should be done when active leprosy relapse is 
suspected, and registered in the Relapse Registration Form (page 132 of the CRF).  
1. Collect information regarding previous treatment:   
• Initial clinical classification 
• Date the previous treatment ended 
• Occurence of reactions during and after treatment 
• Initial bacilloscopy, with BI present.  
• Initial ML Flow, with intensity present.  
2. Ask when the current symptoms began; 
3. Take the patients history and perform a full physical exam, following SOPs 008 and 009.  
4. Perform the dermatological-neurological exam, according to SOP 010.  
• Describe the type, alterations of colour, total number and sensibility alterations of 
the lesions, entering the results on the patient chart. 
• Register the number of affected nerves--thickened, painful and/or presenting 
altered neural function, in the area of corresponding innervation. 
5. Determine and record the operational classification, according to the number of skin 
lesions, regardless of the number of nerves afflicted, as per WHO classification.  
• Paucibacillary (PB): cases with up to 5 cutaneous lesions.  
• Multibacillary (MB): cases with 6 or more cutaneous lesions.   
6. Determine e register the clinical classification as described in SOP 010.  
7. Evaluate the Disability Grade, according to SOP 011. 
8. Request the following tests: bacilloscopy, biopsy and ML Flow, according to SOP 012. . 
9. Compare the results of the clinical examination with those of the previous exams.  
 
TESTS TO CONFIRM RELAPSE 
To confirm the suspicion of relapse, beyond a detailed clinical examination and the results of 
conventional laboratory exams, such as bacilloscopy, biopsy and ML-flow, the following tests 
must be performed: 
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1. ELISA (Enzyme Linked Immunosorbent Assay) technique  for detection of IgM antibodies 
against PGL-1:  
• It will be done with the same blood sample used to perform the ML-flow test.  
• Inform the studys general coordination of the existence of the sample so that the 
conduction of the exam can be scheduled.   
2. Study of resistance to medication: 
• Before doing the biopsy, verify the availability of the reference laboratory for receiving 
the material below (Laboratory for Mycobacterial-Applied Molecular Biology (Room 31 / 
33)  Mycobacterial Department  Oswaldo Cruz Foundation (FIOCRUZ). Av. Brasil, 
4365. Manguinhos - RJ. CEP 21045-900).  Once the shipping of the material has been 
agreed by the Laboratory, then: 
a. Take a skin fragment through biopsy with 4 or 5mm punch.  
b. Store the skin fragment in a sterile glass flask containing 70% ethanol. 
c. Seal off the cap of the flask with adhesive tape, and identify it with the patients 
information.  
d. Send it to the reference lab.  
3. Inoculation in mouse footpad 
• Before doing the biopsy, check:  
o The patients bacteriological index. Only perform this test for patients with BI ≥ 3. 
o Availability of the reference laboratory (Microbiology Laboratory -  Lauro de Souza 
Lima Institute, rodovia Comandante João Ribeiro de Barros km 226, caixa postal 3021, 
CEP 17034-971) to receive the material. Once the shipping of the material has been 
agreed by the Laboratory, then:   
b. Take a skin fragment through biopsy with 4 or 5mm punch.  
c. Store the skin fragment in a dry, sterile glass flask with rubber cap.  
d. Seal off the cap of the flask with adhesive tape and identify it with the patients 
information. 
e. Put the flask inside a surgical glove, tying its opening with a knot.  
f. Place the glove inside a styrofoam box containing packs of recyclable ice (DO 
NOT USE DRY ICE); the box can be small, but must be made of strong material, 
so as not to break or crack during shipping; seal it with adhesive tape, identify it 
as containing perishable material and send it as quickly as possible to the 
reference laboratory. 
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POP MDTU 024 
PATIENT WITHDRAWAL FROM STUDY  
OBJECTIVE 
 To detect the occurrence of situations in which the research participant must be officially 
removed from the study.  
     
RESPONSIBLE 
 Local Coordinator, after obtaining authorisation from general coordinator. 
 
Definition of removal 
Patient whose clinical progress will not be registered on the CRF from the date of removal 
onward. Observe that every recruited patient will be analyzed until the period stipulated.  
 
PROCEDURES 
1. To withdraw the patient complete the following data in the CRF: 
a. Wether the patient completed the full course of treatment or not, enter the date of the 
last dose taken.  
b. If the course of MDT was not completed, inform why: 
1. Patient requested to be removed from the study  
The voluntary patient who, for whatever personal reason, decides and requests to be 
withdrawn from the study, even if means that he/she has received all doses but does 
not wish to participate in the follow-up period, will be removed from the study. 
2.  Unable to reach the patient during the treatment period. Specify if the address 
was not located, if the patient moved to a new residence or to another State.  
3.  Violation of Protocol  incorrect inclusion criteria used during recruitment.   
Any voluntary patient will be removed from the study who, during the time of the 
study, develops any of the conditions listed in the exclusion criteria. 
4. Violation of Protocol  treatment irregularity.  
Any voluntary patient will be removed from the study who has participated irregularly 
in the study and will not finish treatment within the period defined in the research 
protocol. The patient will be removed at the time it becomes impossible for them to 
finish treatment, under the following definitions: 
PB Patients: U-MDT e R-MDT groups the point at which the sum of defaulted doses 
reaches four months.  
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MB Patients: U-MDT group  the point at which the sum of defaulted doses reaches 
four months. R-MDT group  the point at which the sum of defaulted doses reaches 
seven months.  
5. Side effects. 
Any patient will be removed from the study who presents severe side effects to the 
MDT drugs, that justify the suspension of the drug in question. The withdrawal from 
the study will take effect from the date the physician removes or replaces any 
component of MDT.  
6. Intervening disease. 
Any patient who, during the period of treatment, presents any intervening disease 
that justifies the interruption of the drugs used at the MDT.  
 
2.  To register an active search on follow-up after the completion of MDT,  include the 
following information: 
1. Patient was lost to the study during the follow-up period, after the completion of 
MDT.  
Patients who cannot be found during the follow-up period, even after repeated 
attempts at recovery, will not be removed from the study, as long as: 
! For each patient with a telephone, at least three calls will be made to 
request their presence at the Health Centre; 
! For those patients who do not have a telephone, at least three letters will 
be mailed requesting their presence at the Health Centre;   
! For each patient who does not answer the phone call and/or letters, at 
least three active search visits will be made to his/her residence.     
2. Death 
All patients who pass away during the study, no matter the cause of death, will have 
their death certificate attached to the chart and duly noted on their CRFs.   
3. Others 
Other situations that are not listed in this protocol, but for which the removal of the 
patient from the study is recommended, must be communicated and discussed with 
the studys coordinators so that the withdrawal procedures for each case are 
determined in consultation with the Data and Safety Monitoring Board (DSMB).    
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APPENDIX I of SOP UMDT 012 
 




Age: _____________                  Date of Birth: ___/ ____ / _____               Sex: _______               
 
Date of request: _____/_____/_______      Chart no.:  _____________           CRF:_________ 
 
HISTOPATHOLOGICAL EXAM REQUEST 
Site of biopsy:  ___________________________________________________________ 
Description of lesion: 
_____________________________________________________________________________ 
Duration of lesion: ___ months.    Alteration of sensibility:  (   )Thermal  (   )Pain   (   )Tactile    
No. of lesions: ___________      BI: ____________  
Diagnostic hypothesis: _______________________________________________________________ 
Differential Diagnosis: 
_____________________________________________________________________________ 
      
__________________________________ 
                                                                                                                  Requesting Physician 
 









Independent study to evaluate the efficacy of the 
Six-dose uniform MDT regimen (U-MDT) 













Dr. Gerson Penna, MD, PhD 
Dr. Samira Bührer-Sékula, PhD 
 
 
Researchers at the Dona Libânia National Dermatological 
Reference Centre  
 
Dr. Maria Araci Pontes 
Dr. Heitor de Sá Gonçalves 
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Dona Libânia National Dermatological Reference Centre Fortaleza (CE) 
INFORMED CONSENT FORM  
 
The study must be explained orally to children in a simple way allowing them to understand, as much as 
possible, what will happen in the study. 
 
(1) Explanation of the Consent Form: 
 
Title of the study:Independent study to establish the efficacy of the six-dose uniform MDT 
regimen (U-MDT) for leprosy patients. 
Principal investigators: 
Principal investigator: Dr. Gerson Oliveira Penna, Tropical Medicine Unit, University of Brasilia  
Principal investigator at the Dona Libânia National Dermatological Reference Centre: Dr. Maria Araci 
Pontes 
 
(2) Information regarding participation in the study: 
  
Institutions: Tropical Medicine Unit, University of Brasilia 
           Dona Libânia National Dermatological Reference Centre 
             
You have been invited to participate in a medical research study. It is important for you to understand 
the general principles that will be applied to all participants of this study: (1) Your participation is 
voluntary. (2) You may decide to withdraw from the study before initiating treatment, or at any 
subsequent time.  You will not be penalised or lose your right to treatment if you decide not to 
participate. (3) After reading this explanation, feel free to ask any questions you have to understand the 
study completely.   
 
You are presenting symptoms that might be LEPROSY (HANSENS DISEASE), a curable disease that 
is treated with various types of medicines given at the same time. When leprosy is not treated, it can 
cause physical deformities. The study you are invited to be part of voluntarily is a clinical study that will 
attempt to better understand this disease, especially in relation to the length of time needed for 
treatment, because for some forms of the disease, the current treatment period is still very long.  
 
Some researchers think that the length of treatment can be reduced without compromising patient cure. 
Read the information carefully before giving your consent. By signing this consent form you are agreeing 
to participate in the clinical research called:Independent study to establish the efficacy of the six 
dose uniform MDT regimen (U-MDT) for leprosy patients. 
 
The objective of this study is to verify if one treatment regimen can be used for all leprosy patients, 
reducing the treatment to 6 months for those patients who at the present time are being treated for 12 
months.  
 
(3) Procedures to be followed: 
 
If you agree to participate in this study, after signing the consent form, we will fill out your medical form, 
do a physical examination and run some laboratory tests so that we can determine the type of leprosy 
you have: (1) leprosy with few lesions (paucibacillary) or (2) leprosy with a greater number of lesions 
(multibacillary). 
 
If you are classified as paucibacillary, you will participate in a random selection that will determine your 
participation in one of the 2 groups below:  
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Group 1  you will use the one regimen treatment consisting of six-dose of three medications and 
annual follow-up for 5 years after the completion of treatment (U-MDT), 
Or 
Group 2  you will use the same regimen as presently used, consisting of six-dose of two medications 
and annual follow-up for 5 years after the completion of treatment (R-MDT). 
  
If you are classified as multibacillary, you will participate in a random selection that will determine your 
participation in one of the 2 groups below: 
  
Group 3  you will receive six-dose of three medications and monthly follow-up for 6 months and annual 
follow-up for 5 years after the completion of treatment (U-MDT), 
Or  
Group 4 - you will receive twelve doses of three medications and annual follow-up for 5 years after the 
completion of treatment (R-MDT). 
 
The medication will be taken every day at home and once a month at the Health Centre. The oral 
medications used daily have been used for the treatment of leprosy for over 25 years.  
 
We will also collect blood and take a small piece of your skin (biopsy) for examination. A picture of your 
lesion will be taken as well, at the beginning of the treatment, for comparison in the case of relapse. 
These tests are important for your participation in this study. 
  
A sample of your blood will be collected and stored and will only be used if authorised by the lead 
investigator of the study.  
All the samples will be labelled with the patient number and their initials so that confidentiality is 
guaranteed. If any new test or component is discovered that would benefit the participant, the 
researcher will access the lead investigators filethe only place where patient data will be stored-- the 
patient will be contacted and informed about this benefit.   
 
During the duration of your treatment, you will be examined monthly to monitor the treatment. After that, 
you will be examined once a year for five years, and after that your participation in the study will end.  
 
If during the study you present any leprosy reactions or any other health problem, you should come to 
the Health Centre and inform the research team. 
If you present symptoms of leprosy again, your physician may start a new treatment, following the 
recommendations of the Ministry of Health.  
 
(4) Medications being researched  
 
You will not be the first person to use the medications prescribed in this study, they have been in use for 
the successful treatment of leprosy for the last 20 years. Initially, they were used for periods of 5 years, 
then the treatment was reduced to 2 years and now they are used for 1 year. This study seeks to obtain 
information about the ideal treatment duration and determine if it is possible to treat all patients with only 
one treatment regimen for 6 months, instead of the current 12 months. We are going to evaluate the 
efficacy of shorter treatment by studying the possibility of relapse.  
 
(5) Duration of your participation: 6 or 12 months of treatment and 5 years of follow-up. 
 
(6) Risks, side effects and discomforts.  
 
It is important for you to know that the risks involved with the treatment of leprosy are minimal. When not 
treated, it can cause physical deformities. Death as a result of leprosy is very rare.  
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The medications presently used in the standardised treatment of this disease (rifampicin, dapsone and 
clofazimine) are the same that will be used in this study.  Occasional side effects can include nausea, 
redness in urine, and one of the drugs can temporarily change skin colour. All these side effects will 
disappear once the treatment is over. It is important to take the medication everyday to obtain good 
results. 
  
After the completion of the treatment, you should return to be examined at the Health Centre once a 
year for the next five years. It is important that you return for these visits so that we can be sure that the 
treatment duration is adequate. Independent of the course of treatment used, a small percentage of 
patients could relapse, and in this case, the patient will need to be treated again with the same multi-
drug therapy as per Ministry of Health guidelines.  
 
Only qualified health workers will administer treatment and examine the patients who voluntarily enrol in 
this study. They will observe you carefully to prevent any reaction and are prepared to treat you 
promptly, if necessary. 
 
By participating in this study you will be contributing to the advancement of scientific knowledge about 
leprosy and as such you have certain responsibilities: follow closely the instructions given by your 
physician; come to the Health Centre on the dates scheduled; inform your doctor about any changes 
(good or bad) you notice during this study. 
 
(7) Benefits.  
 
The reduction of the treatment from 12 to 6 months for some patients and the possibility of having only 
one course for treatment for this disease will be of great benefit for all patients. Nevertheless, we cannot 
guarantee that this will be true for all patients.  
 
In addition, you will be collaborating in a study that could benefit other people who may fall sick with the 
same disease. 
  
The medical attention you receive is the principle benefit to you; there will be no monetary compensation 
for your participation in this study. At the same time, you will not incur any costs as a result of your 
participation. Given that you will often have to come to the Centre, you will receive bus vouchers to 
cover transportation costs for your visits.  
 
(8) Identity confidentiality for the participants in this study.  
 
The records of your participation in this study are confidential. However, these records will be available 
to the representatives of the institutions participating in the study, the Research Ethics Committees and 
health authorities. Your name will never be used in any study report. 
  
(9) Your participation can be cancelled without your permission. 
 
Your participation in this study can be interrupted if the state of your health begins to represent a risk to 
you in the opinion of the doctors responsible for this study. 
  
(10) New significant findings.  
 
Any important information that may become known during your participation in this study and that can 
affect your health will be given to you.  
 
(11) Number of volunteers participating in this study.  
 
A total of 2,122 patients will take part in this study, ranging from 5 to 65 years of age. 
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Patients with known allergies (hypersensitivity) to the drugs used in this study and patients with 
associated diseases will not be able to participate in this study. 
 
(12) Reimbursement and Compensation.   
 
If it is proven that you have suffered any injury as a result of your participation in this study, you will be 
entitled to medical treatment and reimbursement according to item V.6 of Resolution 196/96 of the 
National Health Council of the Ministry of Health that covers all medical research involving human 
subjects. This resolution establishes that: Research subjects, when injured in any way by any protocol 
done by the research study, stated or not in the consent form, and as a result of his participation, will be 
entitled to complete medical assistance and legal compensation. 
 
(13) People and places to obtain answers to questions and further information related to the study. 
 
Please contact one of the persons listed below in case you have questions related to this study or if you 
have any problem:  
Dr. Maria Araci de Andrade Pontes - telephones: 3101-5452 / 9981- 8124;  
Dr. Heitor de Sá Gonçalves - telephones: 3101-5452 / 9988- 0777;  
Address: Centro de Dermatologia D. Libânia 
Rua Pedro I, 1033 - Centro  
Fortaleza - Ceará 
 
If any symptoms of the disease return, please come immediately to the Dona Libânia National 
Dermatological Reference Centre.   
 
You can and should ask any questions you might find necessary before agreeing to participate in this 
study and at any moment during the treatment. Your doctor can give you all the information about your 
health, your rights, and possible complications and benefits related to your participation in this study. If 
you did not understand any part of this document or the explanation that was given to you, ask the 
physician before signing the consent form. 
 
IF YOU DID NOT UNDERSTAND ANY PART OF THIS DOCUMENT OR THE EXPLANATION THAT 
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RESEARCH SUBJECT OR LEGAL GUARDIANS (if subject is a minor < 15 yrs.) 
 IDENTIFICATION DATA  
 
1. PATIENT NAME: 
.............................................................................................................................. 
Sex:  M (   )  F (   )  Date of birth:  ........./........../........    Age: ................. 
Address .................................................................................. N° ......................   
District ....................................................................  City ................................. 
Postal code .......................................Telephone: (.....).............................................   
 
2. LEGAL GUARDIAN 
Name.................................................................................................................... 
Relation to the patient (relative, tutor, legal representative, etc)...................................... 
Identity number ..................................   Sex:  M (   )     F (   ) 
Date of birth:........./........../......... 
Address ..............................................................................  N° ...........................  
Apt................................... 
District /Bairro.......................................................................... 
City ....................................... Postal code ........................Tel: (....)......................  
 
 
3. ADDITIONAL INFORMATION 
Medical chart number in the Health Centre................................................................ 
Main symptom..................................................................................................... 
BCG scars:         !  No scar,    !  1 scar,   !  2 scars 
History of current disease (HDA) 
How long have the symptoms been present:   ..................months 
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FREE AND INFORMED CONSENT FORM  
 
I,_______________________________, of sound mind, am 18 years of age or older and volunteer  
                  (name of the volunteer) 
to participate in the study entitled Independent study to establish the efficacy of the six dose 
uniform MDT regimen (U-MDT) for leprosy patients. 
. 
 The implications of my voluntary participation, including the nature, duration and objective of this 
study, the methods and means of its conduction, as well as any problems and risks that might occur, 
were explained to me. I had the opportunity to clarify any doubts about the study and obtain 
explanations for those doubts. I voluntarily agree to participate in this study. I also understand that I can 
at any time withdraw my participation without punishment and retaining all my rights. My refusal to 
participate will not result in loss of any benefits I am otherwise entitled to. I will receive a copy of this 
statement and the consent form. 
 
I ___________________________ authorise the use of the blood and skin samples collected in this  
            (Name of the volunteer)  
study for use in future studies. 
                                                                                                     .  
 
__________________________                   ______________________________ 
            Volunteer name    Signature or thumb print 
 
   ____________________________ 
                          Date and time of signature 
 
For illiterate volunteers: 
I was present during the explanation of the study, and can confirm that the volunteer was given the 
opportunity to ask questions and has given his/her signature above.  
 
______________________   _____________________________ 
     Witness name                       Signature 
 
________________________ 
Date and time of signature 
 
Researcher declaration: 
The objective of the study was explained to the volunteer.  To the best of my knowledge, he/she 
understood the objectives, procedures, risks and benefits of this study. 
  
_________________________                   ___________________________ 
         Name of the researcher                           Signature of the researcher 
 
____________________________ 
Date and time of signature 
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VOLUNTARY CONSENT FORM AND EXPLANATION FOR MINORS 
 
 
I,_________________________________________, of sound mind, am 18 years of age or older and  
                     (name of legal guardian)  
capable of giving consent for _________________________________  and through this document,  
                                                                      (name of minor) 
I agree for him/her to volunteer as a participant of the study, Independent study to establish the 
efficacy of the six-dose uniform MDT regimen (U-MDT) for leprosy patients. 
 
The implications of his/her voluntary participation, including the nature, duration and objective of 
this study, the methods and means of its conduction, as well as any problems and risks that might 
occur, were explained to me. I had the opportunity to clarify any doubts about the study and obtain 
explanations to those doubts. I also understand that I can, at any time, withdraw my consent for the child 
under my responsibility to participate in this study, without any punishment to the child and retaining all 
his/her rights. I will receive a copy of this statement and the consent form. 
 
  
I ___________________________ authorise the use of the blood and skin samples collected from  
            (Name of the volunteer)  
the minor under my responsibility in this study for use in future studies. 
 
 
__________________________                   ______________________________ 
       Name of legal guardian                         Signature or thumb print 
 
____________________________ 
Date and time of signature 
 
For illiterate legal guardians: 
I was present during the explanation of the study, and can confirm that the volunteer was given the 
opportunity to ask questions and has given his/her signature above. 
 
______________________   _____________________________ 
     Witness name                       Signature 
 
________________________ 




The objective of the study was explained to the volunteer.  As best as I can tell, he/she understood the 
objectives, procedures, risks and benefits of this study. 
  
_________________________                   ___________________________ 
         Name of the researcher                           Signature of the researcher 
 
____________________________ 
Date and time of signature 
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                                        PROCEDURE TIMETABLE 
 












In case of 
Leprosy 
Reactions 
Clinical-dermatological evaluation × × × × -- 
Examination of peripheral nerves × × × × x 
Classification of disabilities  × -- × × -- 
Bacilloscopy 1 × -- × × -- 
Biopsy 2 × -- -- -- -- 
ML FLOW 3 × -- -- -- -- 
Complete blood exam 4  × x x -- -- 
Biochemistry x x x  -- 
C reactive protein  × × × × x 
SGOT, SGPT 4 x x x  -- 
Registration of the supervised dose during the 
study × × × × 
-- 
Side effects × × × × x 
Use of concurrent medications × × × × x 
Sulfonuria 5 -- × -- -- -- 
 
 
(1) Bacilloscopy will be performed in all patients during the initial phase of the study, 
and at the end of the treatment and during the annual follow-up in the patients 
with multibacillary disease 
 
(2) The biopsy will be performed in all patients during the initial phase of the study 
and in case of suspected relapse  
 
(3) The ML-Flow test will be performed in all patients during the initial phase of the 
study and in case of suspected relapse. 
 
(4) Complete blood exam and SGOT/SGPT will be performed in all patients at all the 
monthly visits while the patient is taking MDT.  
 
(5) Every month there will be a random selection of 10% of all patients to determine 
which will have the sulfonuria test performed, as proof of the regular intake of the 
self-administered medications. The patients will not be informed beforehand about 
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                            General Instructions Form 
 
 
1.   This patient research file contains one copy of the forms to be utilised for each visit during 
the study: forms for the commencement of the study, clinical visits (Months 2 to 12), annual 
follow-up visits (Years 1 to 6), and final study visit. Forms are also provided to record: 
bacilloscopy, the C reactive protein (beginning of the study, months 2 to 12, years 1 to 6), 
the supervised research dose, concurrent medications, side effects, comments about 




2. In the case that additional forms are needed (e.g. for multiple side effects, etc) please 
include the appropriate alphabetical letter after the page number. For example, the first form 
for Side Effects should come as Page 17 A; the second form as Page 17 B, etc.  
 
 
3. Utilize black ink pen and write legibly. 
 
 
4. All items should be filled out. The following abbreviations must be used when values or 
answers are not obtained: 
 
ND  Not done 
NA  Not applicable 
 
 
5. The forms should be signed and dated by the researcher in the appropriate spaces. 
 
 
6. In case a mistake occurs, draw a horizontal line across the item to be corrected in a way 
that it is still possible to read. Do not tear the form, use correction fluid or erase it. After each 
correction, number the alteration, date it and sign your initials. 















FORMS FOR PATIENT 
DATA COLLECTION AT 
ENTRY INTO THE STUDY  
 1st DOSE 
 
 
                                                                             16 
INSTRUCTIONS FOR PATIENT DATA COLLECTION AT ENTRY 
INTO THE STUDY  1st DOSE 
 
! 1. Review the inclusion and exclusion criteria to verify the eligibility of the patient 
! a. Obtain demographic information. 
 
! b. Verify the diagnosis of leprosy and the date treatment commenced. 
 
! c. Evaluate the cutaneous lesions and/or systemic symptoms. 
 
! d. Review the patient history of previous treatments, and confirm enrolment in study. 
 
       ! e. Verify history of intolerance to any of the medications. 
 
! 2. Inform the patient about the risks and benefits of the study. Complete the informed consent 
form, signed by the patient and by a witness in case the patient is illiterate. Give a copy to the 
patient and keep one copy in the study files. 
 
! 3. If the patient is qualified to enter the study and has signed the Consent Form, begin filling the 
CRF in the sequence of the study. 
 
! 4. Classify the disease as paucibacillary (PB) or multibacillary (MB), according to the WHO 
 norms, using ONLY the number of skin lesions. 
 
! 5. The tests and procedures listed below must be conducted at the beginning of the study. 
(Treatment can be initiated before obtaining the results) If the tests have already been done, 
enter the results in the CRF; otherwise, begin examinations.  
 
! a. Do the Clinical-dermatological evaluation. 
 
! b. Do the neurological examination; nerves must be palpated and evaluated for sensitivity and 
thickness.  
  
! c. Classify the disability grade according to the norms of WHO/Brazilian Ministry of Health. 
 
! d. Obtain blood for laboratory tests (full haemogram including differentials, biochemical tests 
(taken while fasting), C reactive protein) and undertake lymph bacilloscopy. File the results 
in the patients chart and enter them in the form for Laboratory Exam Results. 
 
! e. Obtain the biopsy and request the histopathology exam. 
 
! f. Proceed with the ML Flow test and attach test results at the appropriate place. 
 
! 6. Verify the treatment group for this patient on the randomisation table. 
 
! 7. Give the medication under study to the patient. Register the number of pills given, using the 
Form for Registration of the Experimental Dosage, and record the lot number and the expiration 
date.   
 
! 8. The researcher should check all the data registered on the Visit Form - Study Commencement 
and sign it at the bottom of the page.  
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1. CRITERIA FOR INCLUSION/ EXCLUSION FROM THE STUDY 
INCLUSION CRITERIA 
 1. Five (05) to sixty-five (65) years of age             1.Yes    2. No     3. NA 
                 
 2. Leprosy with characteristic skin lesions, with or 
without systemic symptoms or confirmed by 
histopathological study  
            1.Yes    2. No     3. NA 
                 
3.  Never treated or patient treated more than five 
years ago 
1.Yes     2. No     3. NA 
                 
4. Signed consent form.             1.Yes    2. No     3. NA 
                 
NA  Not applicable 
 
 
_____/_____/____     __________________________________________________ 
          Date                                                    Signature 
 
EXCLUSION CRITERIA 
1. Absence of leprosy skin lesions  1. Yes   2. No     3. NA 
                 
2. Pure neural leprosy (PNL) 1. Yes   2. No     3. NA 
 
3. Patient at risk of death 1. Yes   2. No     3. NA 
                 
4. Patient previously treated for leprosy less than 5 
years ago  
1. Yes   2. No     3. NA 
                 
5. History of intolerance to one of the medications 1. Yes   2. No     3. NA 
                 
6. Discharged as a result of the histopathological 
findings.  
1. Yes   2. No     3. NA 
                 
7. Association with other serious diseases such as 
HIV/AIDS, Tuberculosis, Malaria, LTA, Visceral 
Leishmaniasis, Lymphoma, Leukaemia, 
Immunosuppression, etc. 
1.   Yes    2. No    3. NA 
8. Patient with difficulty following the procedures of 
the study 
1. Yes   2. No     3. NA 
                 




_____/_____/_____    ____________________________________________ 







     
PATIENT NUMBER: 
     
DATE OF VISIT: 
 
 
      
  





2- PATIENT CLINICAL AND HISTOPATHOLOGICAL DATA 
 
        Age 
       Race/Colour 
       1. White   2. Black       3. Yellow 
       4. Red    5. Indigenous  9. Not known 
 
Beginning of Symptoms 
 
Nº Months  _________  
 
 
Type of lesion 
1. Maculae           
2. Plaques  
3. Papules 
4. Diffuse infiltration  
5. Nodules 
6. Anaesthetic area               
Colour  of lesion     
1. Hypo-pigmented   
2. Erythematous 
3. Hyper-pigmented 





Dermatological-neurological exam and complimentary exams  
Bacilloscopy  
1. Negative 
2. Positive  
 
Number of lesions:   
(from one to ten lesions, put 
the exact number)   
 
11. eleven or more lesions 
99. diffuse infiltration 
Number of involved nerves 
 
 
IB Result  















OPERATIONAL CLASSIFICATION  
1. Paucibacillary ( < 5 cutaneous lesions) 
2. Multibacillary ( > 6 cutaneous lesions) 
CLINICAL CLASSIFICATION 
1. Indeterminate leprosy                     2. Tuberculoid leprosy                   3. Lepromatous leprosy  
4. Borderline Tuberculoid leprosy       5. Borderline Borderline leprosy 
6. Borderline Lepromatous leprosy 
HISTOPATHOLOGY 
 
Slide  n.º  
  
Date _____/____/_____
[1] CONFIRMED LEPROSY 
[2] COMPATIBLE WITH LEPROSY  
[3] NON-SPECIFIC 
[4] INDICATIVE OF ANOTHER DISEASE 
HISTOPATHOLOGY  Beginning of the study -  Main findings 
Epidermis: 1 (  )   2 (  )   3 (  )   4 (  )   5 (  )  
Dermis: Inflammatory Infiltration: 6 (  )   7 (  )    8 (  )    9 ( )   10 ( )   11 (  )  12 (  )   13 (  ) 14 ( )  15 (  )   16 (  ) 
Neural  Involvement:  17 (  ) 18 (   )  19 (  )    20 (  )  
Vasculitis: 21 (  )     22 (  )    
Panniculitis: 23 (   )       24 (  )       25 (  ) 
BAAR:  26 (  )    27 (  )       28 (  )     29 (   )      30 (   )   31(  ) others________________________ 
Clinical Form: 32- I [   ] 33- TT [   ]  34-  BT [  ]   35- BB [   ]  36- BL [   ]   37- LL  [   ]   38- [   ] Unclassified 
FINAL CLASSIFICATION   
1. Indeterminate leprosy                     2. Tuberculoid leprosy                   3. Lepromatous leprosy  
4. Borderline Tuberculoid leprosy       5. Borderline Borderline leprosy 
6. Borderline Lepromatous leprosy 
 
______________________________________________       




     
PATIENT NUMBER: 
     
DATE OF VISIT: 
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3 -  CLINICAL- DERMATOLOGICAL EVALUATION 
 Beginning of the study  1st dose  
 1 Remission 2  Improvement 3 Unchanged 4 Worsening
1. Colour   
2. Sensibility   
3. Infiltration   
 Skin Lesions 
4. Other   
 
Sign/symptom Absent mild  moderate severe 
1. Itching     
2. Dry skin     
3.  Skin pigmentation     
4. Rash      
5. Erythrodermia     
6. Photosensitivity     
7. Abdominal pain     
8. Constipation      
9. Nausea     
10. Vomiting     
11. Diarrhoea     
12. Anorexia     
13. Jaundice     
14. Pallor     
15. Cyanosis     
16. Bleeding     
17. Weight loss     
18. Dyspnoea     
19. Asthenia     
20. Fever     
21. Myalgia     
22. Headache     
 Baseline  of symptoms and signs to be studied  
23. Depression     
 
 Have any 
signs/symptoms of 
leprosy reactions? 
1  Yes     If yes, fill out the form for reactions in block V, for each new episode 
2  No                    
 
 Other (specify)  
 
______________________________________________ 






     
PATIENT NUMBER: 
     
DATE OF VISIT: 
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4 -  EXAMINATION OF PERIPHERAL NERVES  






0- Normal  
1- Thickened 
2- Nerve abscess 
KEY 
SCALE OF NEURAL PAIN INDICATED 
0. No pain 
1. Weak pain 
2. Strong pain 
NERVES RIGHT LEFT RIGHT LEFT 
Ulnar     
Median     
Radial     
Fibular     
Posterior Tibial      
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5. SIMPLIFIED EVALUATION OF NEURAL FUNCTION AND COMPLICATIONS  
Beginning of the study  1st dose  
Face   
Nose R L 
Main complaint   
dryness (S/N)   
abrasions (S/N)   
Perforation of the septum (S/N)   
Eyes R L 
Main complaint   
Closes eyes w/o force (mm)   
Closes eyes w/ force (mm)   
Cornea diminished sensibility (S/N)   
Cornea opacity (S/N)   
Cataract (S/N)   
Visual acuity   
   
Upper limbs   
Main complaint   
Nerve palpation R L 
Ulnar   
Median   
Radius   
key: N = normal; T = thickened; P = pain; S = Tinels sign (+) 
Strength evaluation R L 
Opens little finger 
Abduction of the 5th finger (ulnar nerve)        
  
Elevates thumb 
Abduction of the thumb (median nerve)  
  
Elevates wrist 
Wrist extension (radial nerve)  
  
key: S = strong; D = diminished; P = paralysed   or   5 = strong; 4 = partial resistance;  3 = 
complete movement; 2 = partial movement; 1 = contraction; 0 = paralysed 
SENSITIVITY EVALUATION AND STATUS INSPECTION  
R L 
  
key: lilac pen / monofilament (2g): feels#;  does not feel X ; or monofilaments: follow colours 
Mobile claw: M;  rigid claw: R;  bone absorption:          wound:        
 
______________________________________________ 






     
PATIENT NUMBER: 
     
DATE OF VISIT: 
 
 
      
  






Classification of disability grade 
Evaluation date eyes hands feet Highest grade signature 
 R L R L R L   
Evaluation ____/____/____         
Monofilaments 
Monofilament strength in grams interpretation 
1  green 0.05 Normal sensitivity in hand and foot 
2  blue 0.20 Diminished sensitivity in hand and normal in foot / Difficulty in distinguishing texture (light touch) 
3  Lilac 2.00 
Diminished protective sensitivity in hand / Incapable of 
distinguishing texture / Difficulty in distinguishing forms and 
temperatures 
4  dark red 4.00 
Loss of protective sensitivity in hand and sometimes in foot 
/ loss of texture discrimination / Incapable of distinguishing 
forms and temperatures 
5 - orange or red (mark with an  X) 10.00 
Loss of protective sensitivity in foot / loss of texture 
discrimination / Incapable of distinguishing forms and 
temperatures 
6  red circle 300.00 Only has sensation when deep pressure is applied to hand and foot 
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Lower limbs   
Main complaint   
Nerve Palpation R L 
Fibular    
Posterior tibial   
key: N = normal; T = thickened; P = pain; S = Tinels sign (+) 
Strength evaluation R L 
Elevates hallux 
Hallux extension (fibular nerve)  
  
Elevate foot 
Foot dorsiflexion (fibular nerve)  
  
key: S = strong; D = diminished; P = paralysed   or   5 = strong; 4 = partial resistance;  3 = 
complete movement; 2 = partial movement; 1 = contracture; 0 = paralysed 
 SENSITIVITY EVALUATION AND STATUS INSPECTION 
R L 
  
key: lilac pen / monofilament (2g): feels#;  does not feel X ; or monofilaments: follow colours 
Mobile claw: M;  rigid claw: R;  bone absorption:          wound:            






7. REQUEST FOR LABORATORY EXAMS  




BIOCHEMISTRY (urea, creatinine, SGOT, SGPT, alkaline phosphatise, bilirubin,
Fasting plasma glucose ) 
 FULL HAEMOGRAM AND SEDATION RATE 
 BACILLOSCOPY 
 C- REACTIVE PROTEIN 
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8. LABORATORY RESULTS  
Beginning of the study  1st dose 
BIOCHEMISTRY 

















































  A  13  43 















Less than 8 mg/L 
Results to be recorded in block V, page 120 
FULL BLOOD EXAM 










  4,0 - 5,5 
 
tera/l   
HB  11 - 16 
 
g/dl   
HCT  36 - 52 
 




82 - 92 
 




27 - 31 
 




32 - 36 
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FULL BLOOD EXAM  (continuation) 









12 - 15 
 




 150000 - 450000 
 
µL   




54 - 65 
 
%   
% BAST   3-5 
 
%   




23 - 35 
 




3 - 8 
 










0 - 1 
 




2750 - 6500 
 
µL   
#BAST  150-500 µL   




1150 - 3500 
 




200 - 800 
 




50 - 400 
 




0 - 100 
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                                                                             27 
INSTRUCTIONS FOR MONTHLY VISITS (MONTHS 2 to 12) 
 
 
1.  The following tests and procedures should be done during the monthly visits: 
 
! a. Do the Clinical-dermatological evaluation - months 2 through 6 for groups 1 and 2 of PB 
and months 2 through 12 for groups 3 and 4 of MB. 
  
! b. Perform the neurological exam that focuses on the detection of neuropathies. Nerves 
should be palpated and evaluated according to thickness and sensitivity. Record on the patient 
chart: examination of peripheral nerves.  
 
! c. Ask the patient about symptoms of leprosy reactions and evaluate the degree for each one 
of them. Register on the patient chart in the Diagnosis and Follow-up of Reactions Form. 
 
! d. Ask the patient about side effects and register them in the Clinical-Dermatological 
Evaluation Form 
 
! e. Enter the results for the C-reactive protein test. 
 
! f. Register the results of the sulfonuria test.  
 
! g. In case of the onset of a leprosy reaction, classify the disability level according to the norms 
of the Brazilian Ministry of Health and the World Health Organisation. Register this on the 
Diagnosis and Follow-up of Reactions Form. 
 
 
! 2. Register the other medications being used concomitantly in the Use of Concurrent 
 Medications Form, located in Block V.  
 
! 3.  Give the medication under study to the patient: doses 2 to 6 for groups 1 and 2 of PB and group 3 
of MB; and doses 2 to 12 for group 4 of MB. Register the number of capsules given on the Form 
for Registration of Dose under Study, as well as the lot number and the expiration date of the 
medication.   
 
! 4.  The principal researcher should review all the recorded data in the Visit Forms during the study 
and sign them at the bottom of the page 
 




CLINICAL-DERMATOLOGICAL EVALUATION - 2nd DOSE  
 1 Remission 2  Improvement 3 Unchanged 4 Worsening
1. Colour   
2. Sensibility   
3. Infiltration   
 Skin Lesions 
4. Other   
 
Sign/symptom Absent mild  moderate severe 
1. Itching     
2. Dry skin     
3.  Skin pigmentation     
4. Rash      
5. Erythrodermia     
6. Photosensitivity     
7. Abdominal pain     
8. Constipation      
9. Nausea     
10. Vomiting     
11. Diarrhoea     
12. Anorexia     
13. Jaundice     
14. Pallor     
15. Cyanosis     
16. Bleeding     
17. Weight loss     
18. Dyspnoea     
19. Asthenia     
20. Fever     
21. Myalgia     
22. Headache     
 Symptoms and signs  of side effects from MDT 
23. Depression     
 
 Have any signs/symptoms 
of leprosy reaction? 
1  Yes     In this case, fill out the form for reactions in block V, for each new episode*  
2  No 




Signature and stamp of medical examiner 
*In this study, a new episode of leprosy reaction is defined as when the patient develops new signs and symptoms of a reaction after a period 
of regression of the initial symptoms.  It can happen during gradual reduction of the anti-reaction steroid therapy and requires a new 
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0 - Normal  
1- Thickened 
2- Nerve abscess 
KEY 
SCALE OF INDICATED NEURAL PAIN  
0 -  No pain 
1 -  Weak pain 
2  Strong pain 
NERVES RIGHT LEFT RIGHT LEFT 
Ulnar     
Median     
Radial     
Fibular     
Posterior Tibial      




Signature and stamp of medical examiner  
 
 
LABORATORY TEST REQUEST  2nd dose 
  
 C-REACTIVE PROTEIN (Register result in Block V, page 120) 
  FULL BLOOD EXAM 
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CLINICAL-DERMATOLOGICAL EVALUATION  3rd DOSE  
 1 Remission 2  Improvement 3 Unchanged 4 Worsening
1. Colour   
2. Sensibility   
3. Infiltration   
 Skin Lesions 
4. Other   
 
Sign/symptom Absent mild  moderate severe 
1. Itching     
2. Dry skin     
3.  Skin pigmentation     
4. Rash      
5. Erythrodermia     
6. Photosensitivity     
7. Abdominal pain     
8. Constipation      
9. Nausea     
10. Vomiting     
11. Diarrhoea     
12. Anorexia     
13. Jaundice     
14. Pallor     
15. Cyanosis     
16. Bleeding     
17. Weight loss     
18. Dyspnoea     
19. Asthenia     
20. Fever     
21. Myalgia     
22. Headache     
 Symptoms and signs  of side effects from MDT 
23. Depression     
 
 Have any signs/symptoms 
of leprosy reaction? 
1  Yes     In this case, fill out the form for reactions in block V, for each new episode*  
2  No 




Signature and stamp of medical examiner 
*In this study, a new episode of leprosy reaction is defined as when the patient develops new signs and symptoms of a reaction 
after a period of regression of the initial symptoms.  It can happen during gradual reduction of the anti-reaction steroid therapy 
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0 - Normal  
1- Thickened 
2- Nerve abscess 
KEY 
SCALE OF INDICATED NEURAL PAIN  
0 -  No pain 
1 -  Weak pain 
2  Strong pain 
NERVES RIGHT LEFT RIGHT LEFT 
Ulnar     
Median     
Radial     
Fibular     
Posterior Tibial      




Signature and stamp of medical examiner  
 
 
LABORATORY TEST REQUEST  3rd dose 
  
 C-REACTIVE PROTEIN (Register result in Block V, page 120) 
  FULL BLOOD EXAM 
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CLINICAL-DERMATOLOGICAL EVALUATION  4th DOSE 
 1 Remission 2  Improvement 3 Unchanged 4 Worsening
1. Colour   
2. Sensibility   
3. Infiltration   
 Skin Lesions 
4. Other   
 
Sign/symptom Absent mild  moderate severe 
1. Itching     
2. Dry skin     
3.  Skin pigmentation     
4. Rash      
5. Erythrodermia     
6. Photosensitivity     
7. Abdominal pain     
8. Constipation      
9. Nausea     
10. Vomiting     
11. Diarrhoea     
12. Anorexia     
13. Jaundice     
14. Pallor     
15. Cyanosis     
16. Bleeding     
17. Weight loss     
18. Dyspnoea     
19. Asthenia     
20. Fever     
21. Myalgia     
22. Headache     
 Symptoms and signs  of side effects from MDT 
23. Depression     
 
 Have any signs/symptoms 
of leprosy reaction? 
1  Yes     In this case, fill out the form for reactions in block V, for each new episode*  
2  No 




Signature and stamp of medical examiner 
*In this study, a new episode of leprosy reaction is defined as when the patient develops new signs and symptoms of a reaction 
after a period of regression of the initial symptoms.  It can happen during gradual reduction of the anti-reaction steroid therapy and 
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0 - Normal  
1- Thickened 
2- Nerve abscess 
KEY 
SCALE OF INDICATED NEURAL PAIN  
0 -  No pain 
1 -  Weak pain 
2  Strong pain 
NERVES RIGHT LEFT RIGHT LEFT 
Ulnar     
Median     
Radial     
Fibular     
Posterior Tibial      




Signature and stamp of medical examiner  
 
 
LABORATORY TEST REQUEST  4th dose 
  
 C-REACTIVE PROTEIN (Register result in Block V, page 120) 
  FULL BLOOD EXAM 
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CLINICAL-DERMATOLOGICAL EVALUATION  5th DOSE  
 1 Remission 2  Improvement 3 Unchanged 4 Worsening
1. Colour   
2. Sensibility   
3. Infiltration   
 Skin Lesions 
4. Other   
 
Sign/symptom Absent mild  moderate severe 
1. Itching     
2. Dry skin     
3.  Skin pigmentation     
4. Rash      
5. Erythrodermia     
6. Photosensitivity     
7. Abdominal pain     
8. Constipation      
9. Nausea     
10. Vomiting     
11. Diarrhoea     
12. Anorexia     
13. Jaundice     
14. Pallor     
15. Cyanosis     
16. Bleeding     
17. Weight loss     
18. Dyspnoea     
19. Asthenia     
20. Fever     
21. Myalgia     
22. Headache     
 Symptoms and signs  of side effects from MDT 
23. Depression     
 
 Have any signs/symptoms 
of leprosy reaction? 
1  Yes     In this case, fill out the form for reactions in block V, for each new episode*  
2  No 




Signature and stamp of medical examiner 
*In this study, a new episode of leprosy reaction is defined as when the patient develops new signs and symptoms of a reaction after a period 
of regression of the initial symptoms.  It can happen during gradual reduction of the anti-reaction steroid therapy and requires a new 
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0 - Normal  
1- Thickened 
2- Nerve abscess 
KEY 
SCALE OF INDICATED NEURAL PAIN  
0 -  No pain 
1 -  Weak pain 
2  Strong pain 
NERVES RIGHT LEFT RIGHT LEFT 
Ulnar     
Median     
Radial     
Fibular     
Posterior Tibial      




Signature and stamp of medical examiner  
 
 
LABORATORY TEST REQUEST  5th dose 
  
 C-REACTIVE PROTEIN (Register result in Block V, page 120) 
  FULL BLOOD EXAM 
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CLINICAL-DERMATOLOGICAL EVALUATION  6th DOSE  
 1 Remission 2  Improvement 3 Unchanged 4 Worsening
1. Colour   
2. Sensibility   
3. Infiltration   
 Skin Lesions 
4. Other   
 
Sign/symptom Absent mild  moderate severe 
1. Itching     
2. Dry skin     
3.  Skin pigmentation     
4. Rash      
5. Erythrodermia     
6. Photosensitivity     
7. Abdominal pain     
8. Constipation      
9. Nausea     
10. Vomiting     
11. Diarrhoea     
12. Anorexia     
13. Jaundice     
14. Pallor     
15. Cyanosis     
16. Bleeding     
17. Weight loss     
18. Dyspnoea     
19. Asthenia     
20. Fever     
21. Myalgia     
22. Headache     
 Symptoms and signs  of side effects from MDT 
23. Depression     
 
 Have any signs/symptoms 
of leprosy reaction? 
1  Yes     In this case, fill out the form for reactions in block V, for each new episode*  
2  No 




Signature and stamp of medical examiner 
*In this study, a new episode of leprosy reaction is defined as when the patient develops new signs and symptoms of a reaction after a period 
of regression of the initial symptoms.  It can happen during gradual reduction of the anti-reaction steroid therapy and requires a new 




     
PATIENT NUMBER: 
     
DATE OF VISIT: 
 
 
      
  








0 - Normal  
1- Thickened 
2- Nerve abscess 
KEY 
SCALE OF INDICATED NEURAL PAIN  
0 -  No pain 
1 -  Weak pain 
2  Strong pain 
NERVES RIGHT LEFT RIGHT LEFT 
Ulnar     
Median     
Radial     
Fibular     
Posterior Tibial      




Signature and stamp of medical examiner  
 
 
LABORATORY TEST REQUEST  5th dose 
  
 C-REACTIVE PROTEIN (Register result in Block V, page 120) 
  FULL BLOOD EXAM 
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SIMPLIFIED EVALUATION OF NEURAL FUNCTION AND COMPLICATIONS 
7th DOSE (MB - group 4) and 1st month after U-MDT (MB  group 3) 
Face   
Nose R L 
Main complaint   
dryness (S/N)   
abrasions (S/N)   
Perforation of the septum (S/N)   
Eyes R L 
Main complaint   
Closes eyes w/o force (mm)   
Closes eyes w/ force (mm)   
Cornea diminished sensibility (S/N)   
Cornea opacity (S/N)   
Cataract (S/N)   
Visual acuity   
   
Upper limbs   
Main complaint   
Nerve palpation R L 
Ulnar   
Median   
Radius   
key: N = normal; T = thickened; P = pain; S = Tinels sign (+) 
Strength evaluation R L 
Opens little finger 
Abduction of the 5th finger (ulnar nerve)        
  
Elevates thumb 
Abduction of the thumb (median nerve)  
  
Elevates wrist 
Wrist extension (radial nerve)  
  
key: S = strong; D = diminished; P = paralysed   or   5 = strong; 4 = partial resistance;  3 = 
complete movement; 2 = partial movement; 1 = contraction; 0 = paralysed 
SENSITIVITY EVALUATION AND STATUS INSPECTION  
R L 
  
key: lilac pen / monofilament (2g): feels#;  does not feel X ; or monofilaments: follow colours 
Mobile claw: M;  rigid claw: R;  bone absorption:          wound:        
 
______________________________________________ 
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Classification of disability grade 
Evaluation date eyes hands feet Highest grade signature 
 R L R L R L   
Evaluation ____/____/____         
Monofilaments 
Monofilament strength in grams interpretation 
1  green 0.05 Normal sensitivity in hand and foot 
2  blue 0.20 Diminished sensitivity in hand and normal in foot / Difficulty in distinguishing texture (light touch) 
3  Lilac 2.00 
Diminished protective sensitivity in hand / Incapable of 
distinguishing texture / Difficulty in distinguishing forms and 
temperatures 
4  dark red 4.00 
Loss of protective sensitivity in hand and sometimes in foot 
/ loss of texture discrimination / Incapable of distinguishing 
forms and temperatures 
5 - orange or red (mark with an  X) 10.00 
Loss of protective sensitivity in foot / loss of texture 
discrimination / Incapable of distinguishing forms and 
temperatures 
6  red circle 300.00 Only has sensation when deep pressure is applied to hand and foot 
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Lower limbs   
Main complaint   
Nerve Palpation R L 
Fibular    
Posterior tibial   
key: N = normal; T = thickened; P = pain; S = Tinels sign (+) 
Strength evaluation R L 
Elevates hallux 
Hallux extension (fibular nerve)  
  
Elevate foot 
Foot dorsiflexion (fibular nerve)  
  
key: S = strong; D = diminished; P = paralysed   or   5 = strong; 4 = partial resistance;  3 = 
complete movement; 2 = partial movement; 1 = contracture; 0 = paralysed 
 SENSITIVITY EVALUATION AND STATUS INSPECTION 
R L 
  
key: lilac pen / monofilament (2g): feels#;  does not feel X ; or monofilaments: follow colours 
Mobile claw: M;  rigid claw: R;  bone absorption:          wound:            
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CLINICAL DERMATOLOGICAL EVALUATION 
 7th DOSE (MB - group 4) and 1st month after U-MDT (MB  group 3)  
 1 Remission 2  Improvement 3 Unchanged 4 Worsening
1. Colour   
2. Sensibility   
3. Infiltration   
 Skin Lesions 
4. Other   
 
Sign/symptom Absent mild  moderate severe 
1. Itching     
2. Dry skin     
3.  Skin pigmentation     
4. Rash      
5. Erythrodermia     
6. Photosensitivity     
7. Abdominal pain     
8. Constipation      
9. Nausea     
10. Vomiting     
11. Diarrhoea     
12. Anorexia     
13. Jaundice     
14. Pallor     
15. Cyanosis     
16. Bleeding     
17. Weight loss     
18. Dyspnoea     
19. Asthenia     
20. Fever     
21. Myalgia     
22. Headache     
 Symptoms and signs  of side effects from MDT 
23. Depression     
 
 Have any signs/symptoms 
of leprosy reaction? 
1  Yes     In this case, fill out the form for reactions in block V, for each new episode*  
2  No 
3Continued symptoms of previous reaction                    
 
_____________________________________________ 
Signature and stamp of medical examiner 
*In this study, a new episode of leprosy reaction is defined as when the patient develops new signs and symptoms of a reaction after a period of 
regression of the initial symptoms.  It can happen during gradual reduction of the anti-reaction steroid therapy and requires a new intervention 
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 EXAMINATION OF PERIPHERAL NERVES -  




0 - Normal  
1- Thickened 
2- Nerve abscess 
KEY 
SCALE OF INDICATED NEURAL PAIN  
0 -  No pain 
1 -  Weak pain 
2  Strong pain 
NERVES RIGHT LEFT RIGHT LEFT 
Ulnar     
Median     
Radial     
Fibular     
Posterior Tibial      




Signature and stamp of medical examiner  
 
LABORATORY TEST REQUEST 
7th DOSE (MB - group 4) and 1st month after U-MDT (MB  group 3) 
  
 C-REACTIVE PROTEIN (Register result in Block V, page 120) 
  FULL BLOOD EXAM 
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CLINICAL DERMATOLOGICAL EVALUATION 
8th DOSE (MB - group 4) and 2nd month after U-MDT (MB  group 3) 
 1 Remission 2  Improvement 3 Unchanged 4 Worsening
1. Colour   
2. Sensibility   
3. Infiltration   
 Skin Lesions 
4. Other   
 
Sign/symptom Absent mild  moderate severe 
1. Itching     
2. Dry skin     
3.  Skin pigmentation     
4. Rash      
5. Erythrodermia     
6. Photosensitivity     
7. Abdominal pain     
8. Constipation      
9. Nausea     
10. Vomiting     
11. Diarrhoea     
12. Anorexia     
13. Jaundice     
14. Pallor     
15. Cyanosis     
16. Bleeding     
17. Weight loss     
18. Dyspnoea     
19. Asthenia     
20. Fever     
21. Myalgia     
22. Headache     
 Symptoms and signs  of side effects from MDT 
23. Depression     
 
 Have any signs/symptoms 
of leprosy reaction? 
1  Yes     In this case, fill out the form for reactions in block V, for each new episode*  
2  No 
3Continued symptoms of previous reaction                    
 
_____________________________________________ 
Signature and stamp of medical examiner 
*In this study, a new episode of leprosy reaction is defined as when the patient develops new signs and symptoms of a reaction after a period of 
regression of the initial symptoms.  It can happen during gradual reduction of the anti-reaction steroid therapy and requires a new intervention 
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 EXAMINATION OF PERIPHERAL NERVES  




0 - Normal  
1- Thickened 
2- Nerve abscess 
KEY 
SCALE OF INDICATED NEURAL PAIN  
0 -  No pain 
1 -  Weak pain 
2  Strong pain 
NERVES RIGHT LEFT RIGHT LEFT 
Ulnar     
Median     
Radial     
Fibular     
Posterior Tibial      
Others     
 
__________________________________________________________ 
Signature and stamp of medical examiner 
 
REQUEST OF LABORATORY EXAMS  
8th DOSE (MB - group 4) and 2nd month after U-MDT (MB  group 3) 
  
 C-REACTIVE PROTEIN (Register result in Block V, page 120) 
  FULL BLOOD EXAM 













     
PATIENT NUMBER: 
     
DATE OF VISIT: 
 
 
      
  
                                                                             44 
 
CLINICAL DERMATOLOGICAL EXAMINATION 
9th DOSE (MB - group 4) and 3rd month after U-MDT (MB  group 3) 
 1 Remission 2  Improvement 3 Unchanged 4 Worsening
1. Colour   
2. Sensibility   
3. Infiltration   
 Skin Lesions 
4. Other   
 
Sign/symptom Absent mild  moderate severe 
1. Itching     
2. Dry skin     
3.  Skin pigmentation     
4. Rash      
5. Erythrodermia     
6. Photosensitivity     
7. Abdominal pain     
8. Constipation      
9. Nausea     
10. Vomiting     
11. Diarrhoea     
12. Anorexia     
13. Jaundice     
14. Pallor     
15. Cyanosis     
16. Bleeding     
17. Weight loss     
18. Dyspnoea     
19. Asthenia     
20. Fever     
21. Myalgia     
22. Headache     
 Symptoms and signs  of side effects from MDT 
23. Depression     
 
 Have any signs/symptoms 
of leprosy reaction? 
1  Yes     In this case, fill out the form for reactions in block V, for each new episode*  
2  No 
3Continued symptoms of previous reaction                    
 
_____________________________________________ 
Signature and stamp of medical examiner 
*In this study, a new episode of leprosy reaction is defined as when the patient develops new signs and symptoms of a reaction after a period of 
regression of the initial symptoms.  It can happen during gradual reduction of the anti-reaction steroid therapy and requires a new intervention 
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 EXAMINATION OF PERIPHERAL NERVES   




0 - Normal  
1- Thickened 
2- Nerve abscess 
KEY 
SCALE OF INDICATED NEURAL PAIN  
0 -  No pain 
1 -  Weak pain 
2  Strong pain 
NERVES RIGHT LEFT RIGHT LEFT 
Ulnar     
Median     
Radial     
Fibular     
Posterior Tibial      




Signature and stamp of medical examiner 
 
 
REQUEST OF LABORATORY EXAMS 
  9th DOSE (MB - group 4) and 3rd month after U-MDT (MB  group 3) 
 C-REACTIVE PROTEIN (Register result in Block V, page 120) 
  FULL BLOOD EXAM 
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CLINICAL DERMATOLOGICAL EXAMINATION  
 10th DOSE (MB - group 4) and 4th month after U-MDT (MB  group 3) 
 1 Remission 2  Improvement 3 Unchanged 4 Worsening
1. Colour   
2. Sensibility   
3. Infiltration   
 Skin Lesions 
4. Other   
 
Sign/symptom Absent mild  moderate severe 
1. Itching     
2. Dry skin     
3.  Skin pigmentation     
4. Rash      
5. Erythrodermia     
6. Photosensitivity     
7. Abdominal pain     
8. Constipation      
9. Nausea     
10. Vomiting     
11. Diarrhoea     
12. Anorexia     
13. Jaundice     
14. Pallor     
15. Cyanosis     
16. Bleeding     
17. Weight loss     
18. Dyspnoea     
19. Asthenia     
20. Fever     
21. Myalgia     
22. Headache     
 Symptoms and signs  of side effects from MDT 
23. Depression     
 
 Have any signs/symptoms 
of leprosy reaction? 
1  Yes     In this case, fill out the form for reactions in block V, for each new episode*  
2  No 
3Continued symptoms of previous reaction                    
 
_____________________________________________ 
Signature and stamp of medical examiner 
*In this study, a new episode of leprosy reaction is defined as when the patient develops new signs and symptoms of a reaction after a period 
of regression of the initial symptoms.  It can happen during gradual reduction of the anti-reaction steroid therapy and requires a new 
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EXAMINATION OF PERIPHERAL NERVES 




0 - Normal  
1- Thickened 
2- Nerve abscess 
KEY 
SCALE OF INDICATED NEURAL PAIN  
0 -  No pain 
1 -  Weak pain 
2  Strong pain 
NERVES RIGHT LEFT RIGHT LEFT 
Ulnar     
Median     
Radial     
Fibular     
Posterior Tibial      




Signature and stamp of medical examiner 
 
REQUEST OF LABORATORY EXAMS 
10th DOSE (MB - group 4) and 4th month after U-MDT (MB  group 3) 
  
 C-REACTIVE PROTEIN (Register result in Block V, page 120) 
  FULL BLOOD EXAM 
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CLINICAL DERMATOLOGICAL EXAMINATION 
11th DOSE (MB - group 4) and 5th month after U-MDT (MB  group 3) 
 1 Remission 2  Improvement 3 Unchanged 4 Worsening
1. Colour   
2. Sensibility   
3. Infiltration   
 Skin Lesions 
4. Other   
 
Sign/symptom Absent mild  moderate severe 
1. Itching     
2. Dry skin     
3.  Skin pigmentation     
4. Rash      
5. Erythrodermia     
6. Photosensitivity     
7. Abdominal pain     
8. Constipation      
9. Nausea     
10. Vomiting     
11. Diarrhoea     
12. Anorexia     
13. Jaundice     
14. Pallor     
15. Cyanosis     
16. Bleeding     
17. Weight loss     
18. Dyspnoea     
19. Asthenia     
20. Fever     
21. Myalgia     
22. Headache     
 Symptoms and signs  of side effects from MDT 
23. Depression     
 
 Have any signs/symptoms 
of leprosy reaction? 
1  Yes     In this case, fill out the form for reactions in block V, for each new episode*  
2  No 
3Continued symptoms of previous reaction                    
 
_____________________________________________ 
Signature and stamp of medical examiner 
*In this study, a new episode of leprosy reaction is defined as when the patient develops new signs and symptoms of a reaction 
after a period of regression of the initial symptoms.  It can happen during gradual reduction of the anti-reaction steroid therapy and 
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 EXAMINATION OF PERIPHERAL NERVES  




0 - Normal  
1- Thickened 
2- Nerve abscess 
KEY 
SCALE OF INDICATED NEURAL PAIN  
0 -  No pain 
1 -  Weak pain 
2  Strong pain 
NERVES RIGHT LEFT RIGHT LEFT 
Ulnar     
Median     
Radial     
Fibular     
Posterior Tibial      




Signature and stamp of medical examiner 
 
REQUEST OF LABORATORY EXAMS 
 11th DOSE (MB - group 4) and 5th month after U-MDT (MB  group 3) 
 C-REACTIVE PROTEIN (Register result in Block V, page 120) 
  FULL BLOOD EXAM 
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CLINICAL DERMATOLOGICAL EVALUATION 
 12nd DOSE (MB - group 4) and 6th month after U-MDT (MB  group 3) 
 1 Remission 2  Improvement 3 Unchanged 4 Worsening
1. Colour   
2. Sensibility   
3. Infiltration   
 Skin Lesions 
4. Other   
 
Sign/symptom Absent mild  moderate severe 
1. Itching     
2. Dry skin     
3.  Skin pigmentation     
4. Rash      
5. Erythrodermia     
6. Photosensitivity     
7. Abdominal pain     
8. Constipation      
9. Nausea     
10. Vomiting     
11. Diarrhoea     
12. Anorexia     
13. Jaundice     
14. Pallor     
15. Cyanosis     
16. Bleeding     
17. Weight loss     
18. Dyspnoea     
19. Asthenia     
20. Fever     
21. Myalgia     
22. Headache     
 Symptoms and signs  of side effects from MDT 
23. Depression     
 
 Have any signs/symptoms 
of leprosy reaction? 
1  Yes     In this case, fill out the form for reactions in block V, for each new episode*  
2  No 
3Continued symptoms of previous reaction                    
 
_____________________________________________ 
Signature and stamp of medical examiner 
*In this study, a new episode of leprosy reaction is defined as when the patient develops new signs and symptoms of a reaction after a period 
of regression of the initial symptoms.  It can happen during gradual reduction of the anti-reaction steroid therapy and requires a new 
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 EXAMINATION OF PERIPHERAL NERVES  




0 - Normal  
1- Thickened 
2- Nerve abscess 
KEY 
SCALE OF INDICATED NEURAL PAIN  
0 -  No pain 
1 -  Weak pain 
2  Strong pain 
NERVES RIGHT LEFT RIGHT LEFT 
Ulnar     
Median     
Radial     
Fibular     
Posterior Tibial      




Signature and stamp of medical examiner 
 
 
REQUEST OF LABORATORY EXAMS 
 12th DOSE (MB - group 4) and 6th month after U-MDT (MB  group 3) 
 C-REACTIVE PROTEIN (Register result in Block V, page 120) 
  FULL BLOOD EXAM 






















INSTRUCTIONS FOR COMPLETION OF TREATMENT  
(MONTH 7  GROUPS 1 AND 2 [PB]; MONTH 13  GROUP 3 AND 4 [MB]) 
 
1.  The following tests and procedures should be done during the monthly visits: 
 
 ! a. Complete the clinical-dermatological examination. 
  
! b. Perform the neurological examination; nerves must be palpated and evaluated for 
sensitivity and thickness. Register information on the Examination of Peripheral Nerves Form.  
 
! c. Ask the patient about symptoms of leprosy reactions and evaluate the severity for each of 
them. Enter data on the Reaction Follow-up Form.  
 
! d. Record the C - Reactive Protein results. 
  
! f. Enter bacilloscopy results. 
 
! g. Classify the disability grade according to the guidelines of the Brazilian Ministry of Health 
and the WHO 
 
2.  Register other medications in use by the patient in the Concurrent Medications Form. 
  
3. The principal researcher should review all the data recorded on the Visit Forms during the study and 
































Evaluation forms used at 
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CLINICAL DERMATOLOGICAL EVALUATION - End of treatment 
 1 Remission 2  Improvement 3 Unchanged 4 Worsening
1. Colour   
2. Sensibility   
3. Infiltration   
 Skin Lesions 
4. Other   
 
Sign/symptom Absent mild  moderate severe 
1. Itching     
2. Dry skin     
3.  Skin pigmentation     
4. Rash      
5. Erythrodermia     
6. Photosensitivity     
7. Abdominal pain     
8. Constipation      
9. Nausea     
10. Vomiting     
11. Diarrhoea     
12. Anorexia     
13. Jaundice     
14. Pallor     
15. Cyanosis     
16. Bleeding     
17. Weight loss     
18. Dyspnoea     
19. Asthenia     
20. Fever     
21. Myalgia     
22. Headache     
 Symptoms and signs  of side effects from MDT 
23. Depression     
 
 Have any signs/symptoms 
of leprosy reaction? 
1  Yes     In this case, fill out the form for reactions in block V, for each new episode*  
2  No 
3Continued symptoms of previous reaction                    
 
_____________________________________________ 
Signature and stamp of medical examiner 
*In this study, a new episode of leprosy reaction is defined as when the patient develops new signs and symptoms of a reaction after a period 
of regression of the initial symptoms.  It can happen during gradual reduction of the anti-reaction steroid therapy and requires a new 
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EXAMINATION OF PERIPHERAL NERVES 




0 - Normal  
1- Thickened 
2- Nerve abscess 
KEY 
SCALE OF INDICATED NEURAL PAIN  
0 -  No pain 
1 -  Weak pain 
2  Strong pain 
NERVES RIGHT LEFT RIGHT LEFT 
Ulnar     
Median     
Radial     
Fibular     
Posterior Tibial      
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 SIMPLIFIED EVALUATION OF NEURAL FUNCTION AND COMPLICATIONS 
End of Treatment 
Face   
Nose R L 
Main complaint   
dryness (S/N)   
abrasions (S/N)   
Perforation of the septum (S/N)   
Eyes R L 
Main complaint   
Closes eyes w/o force (mm)   
Closes eyes w/ force (mm)   
Cornea diminished sensibility (S/N)   
Cornea opacity (S/N)   
Cataract (S/N)   
Visual acuity   
   
Upper limbs   
Main complaint   
Nerve palpation R L 
Ulnar   
Median   
Radius   
key: N = normal; T = thickened; P = pain; S = Tinels sign (+) 
Strength evaluation R L 
Opens little finger 
Abduction of the 5th finger (ulnar nerve)        
  
Elevates thumb 
Abduction of the thumb (median nerve)  
  
Elevates wrist 
Wrist extension (radial nerve)  
  
key: S = strong; D = diminished; P = paralysed   or   5 = strong; 4 = partial resistance;  3 = 
complete movement; 2 = partial movement; 1 = contraction; 0 = paralysed 
SENSITIVITY EVALUATION AND STATUS INSPECTION  
R L 
  
key: lilac pen / monofilament (2g): feels#;  does not feel X ; or monofilaments: follow colours 
Mobile claw: M;  rigid claw: R;  bone absorption:          wound:        
 
______________________________________________ 
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Classification of disability grade 
Evaluation date eyes hands feet Highest grade signature 
 R L R L R L   
Evaluation ____/____/____         
Monofilaments 
Monofilament strength in grams interpretation 
1  green 0.05 Normal sensitivity in hand and foot 
2  blue 0.20 Diminished sensitivity in hand and normal in foot / Difficulty in distinguishing texture (light touch) 
3  Lilac 2.00 
Diminished protective sensitivity in hand / Incapable of 
distinguishing texture / Difficulty in distinguishing forms and 
temperatures 
4  dark red 4.00 
Loss of protective sensitivity in hand and sometimes in foot 
/ loss of texture discrimination / Incapable of distinguishing 
forms and temperatures 
5 - orange or red (mark with an  X) 10.00 
Loss of protective sensitivity in foot / loss of texture 
discrimination / Incapable of distinguishing forms and 
temperatures 
6  red circle 300.00 Only has sensation when deep pressure is applied to hand and foot 
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Lower limbs   
Main complaint   
Nerve Palpation R L 
Fibular    
Posterior tibial   
key: N = normal; T = thickened; P = pain; S = Tinels sign (+) 
Strength evaluation R L 
Elevates hallux 
Hallux extension (fibular nerve)  
  
Elevate foot 
Foot dorsiflexion (fibular nerve)  
  
key: S = strong; D = diminished; P = paralysed   or   5 = strong; 4 = partial resistance;  3 = 
complete movement; 2 = partial movement; 1 = contracture; 0 = paralysed 
 SENSITIVITY EVALUATION AND STATUS INSPECTION 
R L 
  
key: lilac pen / monofilament (2g): feels#;  does not feel X ; or monofilaments: follow colours 
Mobile claw: M;  rigid claw: R;  bone absorption:          wound:            






REQUEST FOR LABORATORY EXAMS 
 End of Treatment 
  
 BACILLOSCOPY (for all MB patients and those PB patients with positive bacilloscopy 
at the beginning of the study (Record results in Block V, page 119) 
  C-REACTIVE PROTEIN (Register result in Block V, page 121) 
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INTRUCTIONS FOR ANNUAL VISITS (YEARS 1 to 6) 
 
1.  The following tests and procedures should be done at the time of the annual visits: 
 
 ! a. Complete the clinical-dermatological examination. 
  
! b. Do the neurological examination; nerves must be palpated and evaluated for sensitivity and 
thickness. Register information on the Examination of Peripheral Nerves Form. 
 
! c. Ask the patient about symptoms of leprosy reactions and evaluate the severity for each of 
them. Enter data on the Reaction Follow-up Form. 
 
! d. Histopathological exam to evaluate leprosy evolution of the paucibacillary patients.   
 
! e. Record the C - Reactive Protein results. 
 
! f.   Enter bacilloscopy results. 
 
! g. Classify the disability grade according to the guidelines of the Brazilian Ministry of Health 
and the WHO. 
 
 
! 2.  Register other medications in use by the patient in the Concurrent Medications Form.  This form is 
supplied in a separate section under Concurrent Medication Registry. 
 
! 3. The principal researcher should review all the data recorded on the Visit Forms during the study 
and sign them at the bottom of the page.  
 
. 
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SUMMARY OF THE ANNUAL VISITS 
 
 
 ! 1st year follow-up visit performed on ....../....../......  
  
 ! 2nd year follow-up visit performed on....../....../......  
  
 ! 3rd year follow-up visit performed on....../....../......  
  
 ! 4th year follow-up visit performed on....../....../...... 
   
 ! 5th year follow-up visit performed on....../....../......  
  
 ! 6th year follow-up visit performed on....../....../......   
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CLINICAL DERMATOLOGICAL EVALUATION  
 1st year follow-up 
 1 Remission 2  Improvement 3 Unchanged 4 Worsening
1. Colour   
2. Sensibility   
3. Infiltration   
 Skin Lesions 
4. Other   
 
Sign/symptom Absent mild  moderate severe 
1. Itching     
2. Dry skin     
3.  Skin pigmentation     
4. Rash      
5. Erythrodermia     
6. Photosensitivity     
7. Abdominal pain     
8. Constipation      
9. Nausea     
10. Vomiting     
11. Diarrhoea     
12. Anorexia     
13. Jaundice     
14. Pallor     
15. Cyanosis     
16. Bleeding     
17. Weight loss     
18. Dyspnoea     
19. Asthenia     
20. Fever     
21. Myalgia     
22. Headache     
 Symptoms and signs  of side effects from MDT 
23. Depression     
 
 Any signs/symptoms of 
leprosy reaction? 
1  Yes     In this case, fill out the form for reactions in block V, for each new episode*  
2  No 
3Continued symptoms of previous reaction                    
 Any signs/symptoms of 
relapse? 
1  Yes     In this case, fill out the relapse form in block V, page 137*  
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EXAMINATION OF PERIPHERAL NERVES 




0 - Normal  
1- Thickened 
2- Nerve abscess 
KEY 
SCALE OF INDICATED NEURAL PAIN  
0 -  No pain 
1 -  Weak pain 
2  Strong pain 
NERVES RIGHT LEFT RIGHT LEFT 
Ulnar     
Median     
Radial     
Fibular     
Posterior Tibial      
Others     
 
REQUEST FOR LABORATORY EXAMS 
 1st year follow-up 
 
 BACILLOSCOPY    (Register results in Block V, page 119) 
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 SIMPLIFIED EVALUATION OF NEURAL FUNCTION AND COMPLICATIONS 
1st year follow-up 
 
Face   
Nose R L 
Main complaint   
dryness (S/N)   
abrasions (S/N)   
Perforation of the septum (S/N)   
Eyes R L 
Main complaint   
Closes eyes w/o force (mm)   
Closes eyes w/ force (mm)   
Cornea diminished sensibility (S/N)   
Cornea opacity (S/N)   
Cataract (S/N)   
Visual acuity   
   
Upper limbs   
Main complaint   
Nerve palpation R L 
Ulnar   
Median   
Radius   
key: N = normal; T = thickened; P = pain; S = Tinels sign (+) 
Strength evaluation R L 
Opens little finger 
Abduction of the 5th finger (ulnar nerve)        
  
Elevates thumb 
Abduction of the thumb (median nerve)  
  
Elevates wrist 
Wrist extension (radial nerve)  
  
key: S = strong; D = diminished; P = paralysed   or   5 = strong; 4 = partial resistance;  3 = 
complete movement; 2 = partial movement; 1 = contraction; 0 = paralysed 
SENSITIVITY EVALUATION AND STATUS INSPECTION  
R L 
  
key: lilac pen / monofilament (2g): feels#;  does not feel X ; or monofilaments: follow colours 
Mobile claw: M;  rigid claw: R;  bone absorption:          wound:        
 
______________________________________________ 
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Classification of disability grade 
Evaluation date eyes hands feet Highest grade signature 
 R L R L R L   
Evaluation ____/____/____         
Monofilaments 
Monofilament strength in grams interpretation 
1  green 0.05 Normal sensitivity in hand and foot 
2  blue 0.20 Diminished sensitivity in hand and normal in foot / Difficulty in distinguishing texture (light touch) 
3  Lilac 2.00 
Diminished protective sensitivity in hand / Incapable of 
distinguishing texture / Difficulty in distinguishing forms and 
temperatures 
4  dark red 4.00 
Loss of protective sensitivity in hand and sometimes in foot 
/ loss of texture discrimination / Incapable of distinguishing 
forms and temperatures 
5 - orange or red (mark with an  X) 10.00 
Loss of protective sensitivity in foot / loss of texture 
discrimination / Incapable of distinguishing forms and 
temperatures 
6  red circle 300.00 Only has sensation when deep pressure is applied to hand and foot 
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Lower limbs   
Main complaint   
Nerve Palpation R L 
Fibular    
Posterior tibial   
key: N = normal; T = thickened; P = pain; S = Tinels sign (+) 
Strength evaluation R L 
Elevates hallux 
Hallux extension (fibular nerve)  
  
Elevate foot 
Foot dorsiflexion (fibular nerve)  
  
key: S = strong; D = diminished; P = paralysed   or   5 = strong; 4 = partial resistance;  3 = 
complete movement; 2 = partial movement; 1 = contracture; 0 = paralysed 
 SENSITIVITY EVALUATION AND STATUS INSPECTION 
R L 
  
key: lilac pen / monofilament (2g): feels#;  does not feel X ; or monofilaments: follow colours 
Mobile claw: M;  rigid claw: R;  bone absorption:          wound:            
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CLINICAL DERMATOLOGICAL EVALUATION 
 2nd year follow-up 
 1 Remission 2  Improvement 3 Unchanged 4 Worsening
1. Colour   
2. Sensibility   
3. Infiltration   
 Skin Lesions 
4. Other   
 
Sign/symptom Absent mild  moderate severe 
1. Itching     
2. Dry skin     
3.  Skin pigmentation     
4. Rash      
5. Erythrodermia     
6. Photosensitivity     
7. Abdominal pain     
8. Constipation      
9. Nausea     
10. Vomiting     
11. Diarrhoea     
12. Anorexia     
13. Jaundice     
14. Pallor     
15. Cyanosis     
16. Bleeding     
17. Weight loss     
18. Dyspnoea     
19. Asthenia     
20. Fever     
21. Myalgia     
22. Headache     
 Symptoms and signs  of side effects from MDT 
23. Depression     
 
 Any signs/symptoms of 
leprosy reaction? 
1  Yes     In this case, fill out the form for reactions in block V, for each new episode*  
2  No 
3Continued symptoms of previous reaction                    
 Any signs/symptoms of 
relapse? 
1  Yes     In this case, fill out the relapse form in block V, page 137*  
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EXAMINATION OF PERIPHERAL NERVES 




0 - Normal  
1- Thickened 
2- Nerve abscess 
KEY 
SCALE OF INDICATED NEURAL PAIN  
0 -  No pain 
1 -  Weak pain 
2  Strong pain 
NERVES RIGHT LEFT RIGHT LEFT 
Ulnar     
Median     
Radial     
Fibular     
Posterior Tibial      
Others     
 
REQUEST FOR LABORATORY EXAMS 
 2nd year follow-up 
 
 BACILLOSCOPY    (Register results in Block V, page 119) 
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SIMPLIFIED EVALUATION OF NEURAL FUNCTION AND COMPLICATIONS 
2nd year follow-up 
Face   
Nose R L 
Main complaint   
dryness (S/N)   
abrasions (S/N)   
Perforation of the septum (S/N)   
Eyes R L 
Main complaint   
Closes eyes w/o force (mm)   
Closes eyes w/ force (mm)   
Cornea diminished sensibility (S/N)   
Cornea opacity (S/N)   
Cataract (S/N)   
Visual acuity   
   
Upper limbs   
Main complaint   
Nerve palpation R L 
Ulnar   
Median   
Radius   
key: N = normal; T = thickened; P = pain; S = Tinels sign (+) 
Strength evaluation R L 
Opens little finger 
Abduction of the 5th finger (ulnar nerve)        
  
Elevates thumb 
Abduction of the thumb (median nerve)  
  
Elevates wrist 
Wrist extension (radial nerve)  
  
key: S = strong; D = diminished; P = paralysed   or   5 = strong; 4 = partial resistance;  3 = 
complete movement; 2 = partial movement; 1 = contraction; 0 = paralysed 
SENSITIVITY EVALUATION AND STATUS INSPECTION  
R L 
  
key: lilac pen / monofilament (2g): feels#;  does not feel X ; or monofilaments: follow colours 
Mobile claw: M;  rigid claw: R;  bone absorption:          wound:        
 
______________________________________________ 
Signature and stamp of medical examiner 
 
                                                                             69 
 
Classification of disability grade 
Evaluation date eyes hands feet Highest grade signature 
 R L R L R L   
Evaluation ____/____/____         
Monofilaments 
Monofilament strength in grams interpretation 
1  green 0.05 Normal sensitivity in hand and foot 
2  blue 0.20 Diminished sensitivity in hand and normal in foot / Difficulty in distinguishing texture (light touch) 
3  Lilac 2.00 
Diminished protective sensitivity in hand / Incapable of 
distinguishing texture / Difficulty in distinguishing forms and 
temperatures 
4  dark red 4.00 
Loss of protective sensitivity in hand and sometimes in foot 
/ loss of texture discrimination / Incapable of distinguishing 
forms and temperatures 
5 - orange or red (mark with an  X) 10.00 
Loss of protective sensitivity in foot / loss of texture 
discrimination / Incapable of distinguishing forms and 
temperatures 
6  red circle 300.00 Only has sensation when deep pressure is applied to hand and foot 




Signature and stamp of medical examiner 
 
Lower limbs   
Main complaint   
Nerve Palpation R L 
Fibular    
Posterior tibial   
key: N = normal; T = thickened; P = pain; S = Tinels sign (+) 
Strength evaluation R L 
Elevates hallux 
Hallux extension (fibular nerve)  
  
Elevate foot 
Foot dorsiflexion (fibular nerve)  
  
key: S = strong; D = diminished; P = paralysed   or   5 = strong; 4 = partial resistance;  3 = 
complete movement; 2 = partial movement; 1 = contracture; 0 = paralysed 
 SENSITIVITY EVALUATION AND STATUS INSPECTION 
R L 
  
key: lilac pen / monofilament (2g): feels#;  does not feel X ; or monofilaments: follow colours 
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CLINICAL DERMATOLOGICAL EVALUATION 
 3rd year follow-up 
 1 Remission 2  Improvement 3 Unchanged 4 Worsening
1. Colour   
2. Sensibility   
3. Infiltration   
 Skin Lesions 
4. Other   
 
Sign/symptom Absent mild  moderate severe 
1. Itching     
2. Dry skin     
3.  Skin pigmentation     
4. Rash      
5. Erythrodermia     
6. Photosensitivity     
7. Abdominal pain     
8. Constipation      
9. Nausea     
10. Vomiting     
11. Diarrhoea     
12. Anorexia     
13. Jaundice     
14. Pallor     
15. Cyanosis     
16. Bleeding     
17. Weight loss     
18. Dyspnoea     
19. Asthenia     
20. Fever     
21. Myalgia     
22. Headache     
 Symptoms and signs  of side effects from MDT 
23. Depression     
 
 Any signs/symptoms of 
leprosy reaction? 
1  Yes     In this case, fill out the form for reactions in block V, for each new episode*  
2  No 
3Continued symptoms of previous reaction                    
 Any signs/symptoms of 
relapse? 
1  Yes     In this case, fill out the relapse form in block V, page 137*  
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EXAMINATION OF PERIPHERAL NERVES 




0 - Normal  
1- Thickened 
2- Nerve abscess 
KEY 
SCALE OF INDICATED NEURAL PAIN  
0 -  No pain 
1 -  Weak pain 
2  Strong pain 
NERVES RIGHT LEFT RIGHT LEFT 
Ulnar     
Median     
Radial     
Fibular     
Posterior Tibial      
Others     
 
REQUEST FOR LABORATORY EXAMS 
 3rd year follow-up 
 
 BACILLOSCOPY    (Register results in Block V, page 119) 
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SIMPLIFIED EVALUATION OF NEURAL FUNCTION AND COMPLICATIONS 
3rd year follow-up 
 
Face   
Nose R L 
Main complaint   
dryness (S/N)   
abrasions (S/N)   
Perforation of the septum (S/N)   
Eyes R L 
Main complaint   
Closes eyes w/o force (mm)   
Closes eyes w/ force (mm)   
Cornea diminished sensibility (S/N)   
Cornea opacity (S/N)   
Cataract (S/N)   
Visual acuity   
   
Upper limbs   
Main complaint   
Nerve palpation R L 
Ulnar   
Median   
Radius   
key: N = normal; T = thickened; P = pain; S = Tinels sign (+) 
Strength evaluation R L 
Opens little finger 
Abduction of the 5th finger (ulnar nerve)        
  
Elevates thumb 
Abduction of the thumb (median nerve)  
  
Elevates wrist 
Wrist extension (radial nerve)  
  
key: S = strong; D = diminished; P = paralysed   or   5 = strong; 4 = partial resistance;  3 = 
complete movement; 2 = partial movement; 1 = contraction; 0 = paralysed 
SENSITIVITY EVALUATION AND STATUS INSPECTION  
R L 
  
key: lilac pen / monofilament (2g): feels#;  does not feel X ; or monofilaments: follow colours 
Mobile claw: M;  rigid claw: R;  bone absorption:          wound:        
 
______________________________________________ 
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Classification of disability grade 
Evaluation date eyes hands feet Highest grade signature 
 R L R L R L   
Evaluation ____/____/____         
Monofilaments 
Monofilament strength in grams interpretation 
1  green 0.05 Normal sensitivity in hand and foot 
2  blue 0.20 Diminished sensitivity in hand and normal in foot / Difficulty in distinguishing texture (light touch) 
3  Lilac 2.00 
Diminished protective sensitivity in hand / Incapable of 
distinguishing texture / Difficulty in distinguishing forms and 
temperatures 
4  dark red 4.00 
Loss of protective sensitivity in hand and sometimes in foot 
/ loss of texture discrimination / Incapable of distinguishing 
forms and temperatures 
5 - orange or red (mark with an  X) 10.00 
Loss of protective sensitivity in foot / loss of texture 
discrimination / Incapable of distinguishing forms and 
temperatures 
6  red circle 300.00 Only has sensation when deep pressure is applied to hand and foot 
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Lower limbs   
Main complaint   
Nerve Palpation R L 
Fibular    
Posterior tibial   
key: N = normal; T = thickened; P = pain; S = Tinels sign (+) 
Strength evaluation R L 
Elevates hallux 
Hallux extension (fibular nerve)  
  
Elevate foot 
Foot dorsiflexion (fibular nerve)  
  
key: S = strong; D = diminished; P = paralysed   or   5 = strong; 4 = partial resistance;  3 = 
complete movement; 2 = partial movement; 1 = contracture; 0 = paralysed 
 SENSITIVITY EVALUATION AND STATUS INSPECTION 
R L 
  
key: lilac pen / monofilament (2g): feels#;  does not feel X ; or monofilaments: follow colours 
Mobile claw: M;  rigid claw: R;  bone absorption:          wound:            
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CLINICAL DERMATOLOGICAL EVALUATION - 4th year follow-up 
 
 1 Remission 2  Improvement 3 Unchanged 4 Worsening
1. Colour   
2. Sensibility   
3. Infiltration   
 Skin Lesions 
4. Other   
 
Sign/symptom Absent mild  moderate severe 
1. Itching     
2. Dry skin     
3.  Skin pigmentation     
4. Rash      
5. Erythrodermia     
6. Photosensitivity     
7. Abdominal pain     
8. Constipation      
9. Nausea     
10. Vomiting     
11. Diarrhoea     
12. Anorexia     
13. Jaundice     
14. Pallor     
15. Cyanosis     
16. Bleeding     
17. Weight loss     
18. Dyspnoea     
19. Asthenia     
20. Fever     
21. Myalgia     
22. Headache     
 Symptoms and signs  of side effects from MDT 
23. Depression     
 
 Any signs/symptoms of 
leprosy reaction? 
1  Yes     In this case, fill out the form for reactions in block V, for each new episode*  
2  No 
3Continued symptoms of previous reaction                    
 Any signs/symptoms of 
relapse? 
1  Yes     In this case, fill out the relapse form in block V, page 137*  








     
PATIENT NUMBER: 
     
DATE OF VISIT: 
 
 
      
  




EXAMINATION OF PERIPHERAL NERVES 




0 - Normal  
1- Thickened 
2- Nerve abscess 
KEY 
SCALE OF INDICATED NEURAL PAIN  
0 -  No pain 
1 -  Weak pain 
2  Strong pain 
NERVES RIGHT LEFT RIGHT LEFT 
Ulnar     
Median     
Radial     
Fibular     
Posterior Tibial     
Others     
 
 
REQUEST FOR LABORATORY TESTS 
 4th year follow-up 
 
 BACILLOSCOPY   (Register result in Block V, page 119) 
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SIMPLIFIED EVALUATION OF NEURAL FUNCTIONS AND COMPLICATIONS 
4th year follow-up 
 
Face   
Nose R L 
Main complaint   
dryness (S/N)   
abrasions (S/N)   
Perforation of the septum (S/N)   
Eyes R L 
Main complaint   
Closes eyes w/o force (mm)   
Closes eyes w/ force (mm)   
Cornea diminished sensibility (S/N)   
Cornea opacity (S/N)   
Cataract (S/N)   
Visual acuity   
   
Upper limbs   
Main complaint   
Nerve palpation R L 
Ulnar   
Median   
Radius   
key: N = normal; T = thickened; P = pain; S = Tinels sign (+) 
Strength evaluation R L 
Opens little finger 
Abduction of the 5th finger (ulnar nerve)        
  
Elevates thumb 
Abduction of the thumb (median nerve)  
  
Elevates wrist 
Wrist extension (radial nerve)  
  
key: S = strong; D = diminished; P = paralysed   or   5 = strong; 4 = partial resistance;  3 = 
complete movement; 2 = partial movement; 1 = contraction; 0 = paralysed 
SENSITIVITY EVALUATION AND STATUS INSPECTION  
R L 
  
key: lilac pen / monofilament (2g): feels#;  does not feel X ; or monofilaments: follow colours 
Mobile claw: M;  rigid claw: R;  bone absorption:          wound:        
 
______________________________________________ 
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Classification of disability grade 
Evaluation date eyes hands feet Highest grade signature 
 R L R L R L   
Evaluation ____/____/____         
Monofilaments 
Monofilament strength in grams interpretation 
1  green 0.05 Normal sensitivity in hand and foot 
2  blue 0.20 Diminished sensitivity in hand and normal in foot / Difficulty in distinguishing texture (light touch) 
3  Lilac 2.00 
Diminished protective sensitivity in hand / Incapable of 
distinguishing texture / Difficulty in distinguishing forms and 
temperatures 
4  dark red 4.00 
Loss of protective sensitivity in hand and sometimes in foot 
/ loss of texture discrimination / Incapable of distinguishing 
forms and temperatures 
5 - orange or red (mark with an  X) 10.00 
Loss of protective sensitivity in foot / loss of texture 
discrimination / Incapable of distinguishing forms and 
temperatures 
6  red circle 300.00 Only has sensation when deep pressure is applied to hand and foot 
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Lower limbs   
Main complaint   
Nerve Palpation R L 
Fibular    
Posterior tibial   
key: N = normal; T = thickened; P = pain; S = Tinels sign (+) 
Strength evaluation R L 
Elevates hallux 
Hallux extension (fibular nerve)  
  
Elevate foot 
Foot dorsiflexion (fibular nerve)  
  
key: S = strong; D = diminished; P = paralysed   or   5 = strong; 4 = partial resistance;  3 = 
complete movement; 2 = partial movement; 1 = contracture; 0 = paralysed 
 SENSITIVITY EVALUATION AND STATUS INSPECTION 
R L 
  
key: lilac pen / monofilament (2g): feels#;  does not feel X ; or monofilaments: follow colours 




     
PATIENT NUMBER: 
     
DATE OF VISIT: 
 
 
      
  
                                                                             78 
 
CLINICAL DERMATOLOGICAL EVALUATION - 5th year follow-up 
 1 Remission 2  Improvement 3 Unchanged 4 Worsening
1. Colour   
2. Sensibility   
3. Infiltration   
 Skin Lesions 
4. Other   
 
Sign/symptom Absent mild  moderate severe 
1. Itching     
2. Dry skin     
3.  Skin pigmentation     
4. Rash      
5. Erythrodermia     
6. Photosensitivity     
7. Abdominal pain     
8. Constipation      
9. Nausea     
10. Vomiting     
11. Diarrhoea     
12. Anorexia     
13. Jaundice     
14. Pallor     
15. Cyanosis     
16. Bleeding     
17. Weight loss     
18. Dyspnoea     
19. Asthenia     
20. Fever     
21. Myalgia     
22. Headache     
 Symptoms and signs  of side effects from MDT 
23. Depression     
 
 Any signs/symptoms of 
leprosy reaction? 
1  Yes     In this case, fill out the form for reactions in block V, for each new episode*  
2  No 
3Continued symptoms of previous reaction                    
 Any signs/symptoms of 
relapse? 
1  Yes     In this case, fill out the relapse form in block V, page 137*  
2  No 
 
___________________________________________ 
Signature and stamp of medical examiner 
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EXAMINATION OF PERIPHERAL NERVES 




0 - Normal  
1- Thickened 
2- Nerve abscess 
KEY 
SCALE OF INDICATED NEURAL PAIN  
0 -  No pain 
1 -  Weak pain 
2  Strong pain 
NERVES RIGHT LEFT RIGHT LEFT 
Ulnar     
Median     
Radial     
Fibular     
Posterior Tibial     
Others     
 
 
REQUEST FOR LABORATORY TESTS 
 5th year follow-up 
 
 BACILLOSCOPY   (Register results in Block  V, page 119) 
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SIMPLIFIED EVALUATION OF NEURAL FUNCTION AND COMPLICATIONS 
5th year follow-up 
Face   
Nose R L 
Main complaint   
dryness (S/N)   
abrasions (S/N)   
Perforation of the septum (S/N)   
Eyes R L 
Main complaint   
Closes eyes w/o force (mm)   
Closes eyes w/ force (mm)   
Cornea diminished sensibility (S/N)   
Cornea opacity (S/N)   
Cataract (S/N)   
Visual acuity   
   
Upper limbs   
Main complaint   
Nerve palpation R L 
Ulnar   
Median   
Radius   
key: N = normal; T = thickened; P = pain; S = Tinels sign (+) 
Strength evaluation R L 
Opens little finger 
Abduction of the 5th finger (ulnar nerve)        
  
Elevates thumb 
Abduction of the thumb (median nerve)  
  
Elevates wrist 
Wrist extension (radial nerve)  
  
key: S = strong; D = diminished; P = paralysed   or   5 = strong; 4 = partial resistance;  3 = 
complete movement; 2 = partial movement; 1 = contraction; 0 = paralysed 
SENSITIVITY EVALUATION AND STATUS INSPECTION  
R L 
  
key: lilac pen / monofilament (2g): feels#;  does not feel X ; or monofilaments: follow colours 
Mobile claw: M;  rigid claw: R;  bone absorption:          wound:        
 
______________________________________________ 
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DATE OF VISIT: 
 
 
      
  




Classification of disability grade 
Evaluation date eyes hands feet Highest grade signature 
 R L R L R L   
Evaluation ____/____/____         
Monofilaments 
Monofilament strength in grams interpretation 
1  green 0.05 Normal sensitivity in hand and foot 
2  blue 0.20 Diminished sensitivity in hand and normal in foot / Difficulty in distinguishing texture (light touch) 
3  Lilac 2.00 
Diminished protective sensitivity in hand / Incapable of 
distinguishing texture / Difficulty in distinguishing forms and 
temperatures 
4  dark red 4.00 
Loss of protective sensitivity in hand and sometimes in foot 
/ loss of texture discrimination / Incapable of distinguishing 
forms and temperatures 
5 - orange or red (mark with an  X) 10.00 
Loss of protective sensitivity in foot / loss of texture 
discrimination / Incapable of distinguishing forms and 
temperatures 
6  red circle 300.00 Only has sensation when deep pressure is applied to hand and foot 
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Lower limbs   
Main complaint   
Nerve Palpation R L 
Fibular    
Posterior tibial   
key: N = normal; T = thickened; P = pain; S = Tinels sign (+) 
Strength evaluation R L 
Elevates hallux 
Hallux extension (fibular nerve)  
  
Elevate foot 
Foot dorsiflexion (fibular nerve)  
  
key: S = strong; D = diminished; P = paralysed   or   5 = strong; 4 = partial resistance;  3 = 
complete movement; 2 = partial movement; 1 = contracture; 0 = paralysed 
 SENSITIVITY EVALUATION AND STATUS INSPECTION 
R L 
  
key: lilac pen / monofilament (2g): feels#;  does not feel X ; or monofilaments: follow colours 
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CLINICAL DERMATOLOGICAL EVALUATION - 6th year follow-up 
 
 1 Remission 2  Improvement 3 Unchanged 4 Worsening
1. Colour   
2. Sensibility   
3. Infiltration   
 Skin Lesions 
4. Other   
 
Sign/symptom Absent mild  moderate severe 
1. Itching     
2. Dry skin     
3.  Skin pigmentation     
4. Rash      
5. Erythrodermia     
6. Photosensitivity     
7. Abdominal pain     
8. Constipation      
9. Nausea     
10. Vomiting     
11. Diarrhoea     
12. Anorexia     
13. Jaundice     
14. Pallor     
15. Cyanosis     
16. Bleeding     
17. Weight loss     
18. Dyspnoea     
19. Asthenia     
20. Fever     
21. Myalgia     
22. Headache     
 Symptoms and signs  of side effects from MDT 
23. Depression     
 
 Any signs/symptoms of 
leprosy reaction? 
1  Yes     In this case, fill out the form for reactions in block V, for each new episode*  
2  No 
3Continued symptoms of previous reaction                    
 Any signs/symptoms of 
relapse? 
1  Yes     In this case, fill out the relapse form in block V, page 137*  
2  No 
 
___________________________________________ 
Signature and stamp of medical examiner 




EXAMINATION OF PERIPHERAL NERVES 




0 - Normal  
1- Thickened 
2- Nerve abscess 
KEY 
SCALE OF INDICATED NEURAL PAIN  
0 -  No pain 
1 -  Weak pain 
2  Strong pain 
NERVES RIGHT LEFT RIGHT LEFT 
Ulnar     
Median     
Radial     
Fibular     
Posterior Tibial     
Others     
 
REQUEST FOR LABORATORY TESTS 
 6th year follow-up 
 
 BACILLOSCOPY    (Register results in Block V, page119) 
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SIMPLIFIED EVALUATION OF NEURAL FUNCTION AND COMPLICATIONS 
6th year follow-up 
Face   
Nose R L 
Main complaint   
dryness (S/N)   
abrasions (S/N)   
Perforation of the septum (S/N)   
Eyes R L 
Main complaint   
Closes eyes w/o force (mm)   
Closes eyes w/ force (mm)   
Cornea diminished sensibility (S/N)   
Cornea opacity (S/N)   
Cataract (S/N)   
Visual acuity   
   
Upper limbs   
Main complaint   
Nerve palpation R L 
Ulnar   
Median   
Radius   
key: N = normal; T = thickened; P = pain; S = Tinels sign (+) 
Strength evaluation R L 
Opens little finger 
Abduction of the 5th finger (ulnar nerve)        
  
Elevates thumb 
Abduction of the thumb (median nerve)  
  
Elevates wrist 
Wrist extension (radial nerve)  
  
key: S = strong; D = diminished; P = paralysed   or   5 = strong; 4 = partial resistance;  3 = 
complete movement; 2 = partial movement; 1 = contraction; 0 = paralysed 
SENSITIVITY EVALUATION AND STATUS INSPECTION  
R L 
  
key: lilac pen / monofilament (2g): feels#;  does not feel X ; or monofilaments: follow colours 
Mobile claw: M;  rigid claw: R;  bone absorption:          wound:        
 
______________________________________________ 
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Classification of disability grade 
Evaluation date eyes hands feet Highest grade signature 
 R L R L R L   
Evaluation ____/____/____         
Monofilaments 
Monofilament strength in grams interpretation 
1  green 0.05 Normal sensitivity in hand and foot 
2  blue 0.20 Diminished sensitivity in hand and normal in foot / Difficulty in distinguishing texture (light touch) 
3  Lilac 2.00 
Diminished protective sensitivity in hand / Incapable of 
distinguishing texture / Difficulty in distinguishing forms and 
temperatures 
4  dark red 4.00 
Loss of protective sensitivity in hand and sometimes in foot 
/ loss of texture discrimination / Incapable of distinguishing 
forms and temperatures 
5 - orange or red (mark with an  X) 10.00 
Loss of protective sensitivity in foot / loss of texture 
discrimination / Incapable of distinguishing forms and 
temperatures 
6  red circle 300.00 Only has sensation when deep pressure is applied to hand and foot 
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Lower limbs   
Main complaint   
Nerve Palpation R L 
Fibular    
Posterior tibial   
key: N = normal; T = thickened; P = pain; S = Tinels sign (+) 
Strength evaluation R L 
Elevates hallux 
Hallux extension (fibular nerve)  
  
Elevate foot 
Foot dorsiflexion (fibular nerve)  
  
key: S = strong; D = diminished; P = paralysed   or   5 = strong; 4 = partial resistance;  3 = 
complete movement; 2 = partial movement; 1 = contracture; 0 = paralysed 
 SENSITIVITY EVALUATION AND STATUS INSPECTION 
R L 
  
key: lilac pen / monofilament (2g): feels#;  does not feel X ; or monofilaments: follow colours 
Mobile claw: M;  rigid claw: R;  bone absorption:          wound:            
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 DIAGNOSIS AND FOLLOW-UP OF REACTION FORM 







Possible triggering factors: 
1 Concomitant infections 5 Medication 
2 Pregnancy 6 Vaccination 
3 Surgery 7 Not identified 
4 Emotional distress 8    Others 
 
Treatment: 
 1 Corticosteroids 8 Thalidomide+ Clofazimine 
2 Thalidomide 9 Thalidomide + Pentoxifylline 
3 Clofazimine 10 Corticosteroids + Thalidomide + Clofazimine 
4 Pentoxifylline 11 Corticosteroids + Pentoxifylline + Thalidomide 
5 Corticosteroids + Thalidomide 12 Corticosteroids + Pentoxifylline + Clofazimine 
6 Corticosteroids + Clofazimine 13 Corticosteroids + Pentoxifylline + Clofazimine + 
Thalidomide 
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1  Adverse reaction 18 Neuritis 
2 ENL   19 Neuritis + Adverse reaction 
3 Necrotizing ENL 20 Neuritis + ENL 
4 Polymorphous erythema 21 Neuritis + Mixed reaction 
5 Arthritis 22 Neuritis +  Necrotizing ENL 
6 Lymphadenopathy 23 Neuritis +  Polymorphous erythema 
7 Orchitis 24 Neuritis +  Arthritis 
8 Iritis/Iridocyclitis 25 Neuritis +  Lymphadenopathy 
9 Reaction hand and foot 26 Neuritis +  Orchitis 
10 ENL+ Necrotizing ENL 27 Neuritis +  Iritis/ Iridocyclitis 
11 ENL+ polymorphous erythema 28 Neuritis +   Reaction hand/foot 
12 ENL+ orchitis 29 Neuritis +   ENL+ Necrotizing ENL 
13 ENL+ arthritis 30 Neuritis +   ENL+  Polymorphous erythema 
14 ENL+ Lymphadenopathy 31 Neuritis +   ENL+ orchitis 
15 ENL+ Iritis/ Iridocyclitis 32 Neuritis +   ENL+ arthritis 
16 ENL+ Reaction hand/foot 33 Neuritis +   ENL+ Lymphadenopathy 
17 Mixed reaction/ Type 1 + Type 2 34 Neuritis +   ENL+ Iritis/Iridocyclitis 
  35 Neuritis +   ENL+ Reaction hand/foot 
1 Cutaneous 4 Cutaneous  + Systemic 
2 Neural 5 Neural + Systemic 
3 Cutaneous  + Neural 6 Cutaneous  + Neural + Systemic 
 





EXAMINATION OF PERIPHERAL NERVES 




0 - Normal  
1- Thickened 
2- Nerve abscess 
KEY 
SCALE OF INDICATED NEURAL PAIN  
0 -  No pain 
1 -  Weak pain 
2  Strong pain 
NERVES RIGHT LEFT RIGHT LEFT 
Ulnar     
Median     
Radial     
Fibular     
Posterior Tibial     




Signature and stamp of medical examiner 
 
REQUEST FOR LABORATORY TESTS  reaction episodes 
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SIMPLIFIED EVALUATION OF NEURAL FUNCTION AND COMPLICATIONS 
Diagnosis and follow-up of reactions  
Face   
Nose R L 
Main complaint   
dryness (S/N)   
abrasions (S/N)   
Perforation of the septum (S/N)   
Eyes R L 
Main complaint   
Closes eyes w/o force (mm)   
Closes eyes w/ force (mm)   
Cornea diminished sensibility (S/N)   
Cornea opacity (S/N)   
Cataract (S/N)   
Visual acuity   
   
Upper limbs   
Main complaint   
Nerve palpation R L 
Ulnar   
Median   
Radius   
key: N = normal; T = thickened; P = pain; S = Tinels sign (+) 
Strength evaluation R L 
Opens little finger 
Abduction of the 5th finger (ulnar nerve)        
  
Elevates thumb 
Abduction of the thumb (median nerve)  
  
Elevates wrist 
Wrist extension (radial nerve)  
  
key: S = strong; D = diminished; P = paralysed   or   5 = strong; 4 = partial resistance;  3 = 
complete movement; 2 = partial movement; 1 = contraction; 0 = paralysed 
SENSITIVITY EVALUATION AND STATUS INSPECTION  
R L 
  
key: lilac pen / monofilament (2g): feels#;  does not feel X ; or monofilaments: follow colours 
Mobile claw: M;  rigid claw: R;  bone absorption:          wound:        
 
______________________________________________ 
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Classification of disability grade 
Evaluation date eyes hands feet Highest grade signature 
 R L R L R L   
Evaluation ____/____/____         
Monofilaments 
Monofilament strength in grams interpretation 
1  green 0.05 Normal sensitivity in hand and foot 
2  blue 0.20 Diminished sensitivity in hand and normal in foot / Difficulty in distinguishing texture (light touch) 
3  Lilac 2.00 
Diminished protective sensitivity in hand / Incapable of 
distinguishing texture / Difficulty in distinguishing forms and 
temperatures 
4  dark red 4.00 
Loss of protective sensitivity in hand and sometimes in foot 
/ loss of texture discrimination / Incapable of distinguishing 
forms and temperatures 
5 - orange or red (mark with an  X) 10.00 
Loss of protective sensitivity in foot / loss of texture 
discrimination / Incapable of distinguishing forms and 
temperatures 
6  red circle 300.00 Only has sensation when deep pressure is applied to hand and foot 
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Lower limbs   
Main complaint   
Nerve Palpation R L 
Fibular    
Posterior tibial   
key: N = normal; T = thickened; P = pain; S = Tinels sign (+) 
Strength evaluation R L 
Elevates hallux 
Hallux extension (fibular nerve)  
  
Elevate foot 
Foot dorsiflexion (fibular nerve)  
  
key: S = strong; D = diminished; P = paralysed   or   5 = strong; 4 = partial resistance;  3 = 
complete movement; 2 = partial movement; 1 = contracture; 0 = paralysed 
 SENSITIVITY EVALUATION AND STATUS INSPECTION 
R L 
  
key: lilac pen / monofilament (2g): feels#;  does not feel X ; or monofilaments: follow colours 
Mobile claw: M;  rigid claw: R;  bone absorption:          wound:            
                                                                             91 
 
 
DIAGNOSIS AND FOLLOW-UP OF REACTION FORM 







Possible triggering factors: 
1 Concomitant infections 5 Medication 
2 Pregnancy 6 Vaccination 
3 Surgery 7 Not identified 
4 Emotional distress 8    Others 
 
Treatment: 
 1 Corticosteroids 8 Thalidomide+ Clofazimine 
2 Thalidomide 9 Thalidomide + Pentoxifylline 
3 Clofazimine 10 Corticosteroids + Thalidomide + Clofazimine 
4 Pentoxifylline 11 Corticosteroids + Pentoxifylline + Thalidomide 
5 Corticosteroids + Thalidomide 12 Corticosteroids + Pentoxifylline + Clofazimine 
6 Corticosteroids + Clofazimine 13 Corticosteroids + Pentoxifylline + Clofazimine + 
Thalidomide 
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1  Adverse reaction 18 Neuritis 
2 ENL   19 Neuritis + Adverse reaction 
3 Necrotizing ENL 20 Neuritis + ENL 
4 Polymorphous erythema 21 Neuritis + Mixed reaction 
5 Arthritis 22 Neuritis +  Necrotizing ENL 
6 Lymphadenopathy 23 Neuritis +  Polymorphous erythema 
7 Orchitis 24 Neuritis +  Arthritis 
8 Iritis/Iridocyclitis 25 Neuritis +  Lymphadenopathy 
9 Reaction hand and foot 26 Neuritis +  Orchitis 
10 ENL+ Necrotizing ENL 27 Neuritis +  Iritis/ Iridocyclitis 
11 ENL+ polymorphous erythema 28 Neuritis +   Reaction hand/foot 
12 ENL+ orchitis 29 Neuritis +   ENL+ Necrotizing ENL 
13 ENL+ arthritis 30 Neuritis +   ENL+  Polymorphous erythema 
14 ENL+ Lymphadenopathy 31 Neuritis +   ENL+ orchitis 
15 ENL+ Iritis/ Iridocyclitis 32 Neuritis +   ENL+ arthritis 
16 ENL+ Reaction hand/foot 33 Neuritis +   ENL+ Lymphadenopathy 
17 Mixed reaction/ Type 1 + Type 2 34 Neuritis +   ENL+ Iritis/Iridocyclitis 
  35 Neuritis +   ENL+ Reaction hand/foot 
1 Cutaneous 4 Cutaneous  + Systemic 
2 Neural 5 Neural + Systemic 
3 Cutaneous  + Neural 6 Cutaneous  + Neural + Systemic 
 




EXAMINATION OF PERIPHERAL NERVES 




0 - Normal  
1- Thickened 
2- Nerve abscess 
KEY 
SCALE OF INDICATED NEURAL PAIN  
0 -  No pain 
1 -  Weak pain 
2  Strong pain 
NERVES RIGHT LEFT RIGHT LEFT 
Ulnar     
Median     
Radial     
Fibular     
Posterior Tibial     




Signature and stamp of medical examiner 
 
 
REQUEST FOR LABORATORY TESTS  reaction episodes 
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SIMPLIFIED EVALUATION OF NEURAL FUNCTION AND COMPLICATIONS 
Diagnosis and follow-up of reaction episodes  
Face   
Nose R L 
Main complaint   
dryness (S/N)   
abrasions (S/N)   
Perforation of the septum (S/N)   
Eyes R L 
Main complaint   
Closes eyes w/o force (mm)   
Closes eyes w/ force (mm)   
Cornea diminished sensibility (S/N)   
Cornea opacity (S/N)   
Cataract (S/N)   
Visual acuity   
   
Upper limbs   
Main complaint   
Nerve palpation R L 
Ulnar   
Median   
Radius   
key: N = normal; T = thickened; P = pain; S = Tinels sign (+) 
Strength evaluation R L 
Opens little finger 
Abduction of the 5th finger (ulnar nerve)        
  
Elevates thumb 
Abduction of the thumb (median nerve)  
  
Elevates wrist 
Wrist extension (radial nerve)  
  
key: S = strong; D = diminished; P = paralysed   or   5 = strong; 4 = partial resistance;  3 = 
complete movement; 2 = partial movement; 1 = contraction; 0 = paralysed 
SENSITIVITY EVALUATION AND STATUS INSPECTION  
R L 
  
key: lilac pen / monofilament (2g): feels#;  does not feel X ; or monofilaments: follow colours 
Mobile claw: M;  rigid claw: R;  bone absorption:          wound:        
 
______________________________________________ 
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Classification of disability grade 
Evaluation date eyes hands feet Highest grade signature 
 R L R L R L   
Evaluation ____/____/____         
Monofilaments 
Monofilament strength in grams interpretation 
1  green 0.05 Normal sensitivity in hand and foot 
2  blue 0.20 Diminished sensitivity in hand and normal in foot / Difficulty in distinguishing texture (light touch) 
3  Lilac 2.00 
Diminished protective sensitivity in hand / Incapable of 
distinguishing texture / Difficulty in distinguishing forms and 
temperatures 
4  dark red 4.00 
Loss of protective sensitivity in hand and sometimes in foot 
/ loss of texture discrimination / Incapable of distinguishing 
forms and temperatures 
5 - orange or red (mark with an  X) 10.00 
Loss of protective sensitivity in foot / loss of texture 
discrimination / Incapable of distinguishing forms and 
temperatures 
6  red circle 300.00 Only has sensation when deep pressure is applied to hand and foot 
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Lower limbs   
Main complaint   
Nerve Palpation R L 
Fibular    
Posterior tibial   
key: N = normal; T = thickened; P = pain; S = Tinels sign (+) 
Strength evaluation R L 
Elevates hallux 
Hallux extension (fibular nerve)  
  
Elevate foot 
Foot dorsiflexion (fibular nerve)  
  
key: S = strong; D = diminished; P = paralysed   or   5 = strong; 4 = partial resistance;  3 = 
complete movement; 2 = partial movement; 1 = contracture; 0 = paralysed 
 SENSITIVITY EVALUATION AND STATUS INSPECTION 
R L 
  
key: lilac pen / monofilament (2g): feels#;  does not feel X ; or monofilaments: follow colours 
Mobile claw: M;  rigid claw: R;  bone absorption:          wound:            




DIAGNOSIS AND FOLLOW-UP OF REACTION FORM 







Possible triggering factors: 
1 Concomitant infections 5 Medication 
2 Pregnancy 6 Vaccination 
3 Surgery 7 Not identified 
4 Emotional distress 8    Others 
 
Treatment: 
 1 Corticosteroids 8 Thalidomide+ Clofazimine 
2 Thalidomide 9 Thalidomide + Pentoxifylline 
3 Clofazimine 10 Corticosteroids + Thalidomide + Clofazimine 
4 Pentoxifylline 11 Corticosteroids + Pentoxifylline + Thalidomide 
5 Corticosteroids + Thalidomide 12 Corticosteroids + Pentoxifylline + Clofazimine 
6 Corticosteroids + Clofazimine 13 Corticosteroids + Pentoxifylline + Clofazimine + 
Thalidomide 
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1  Adverse reaction 18 Neuritis 
2 ENL   19 Neuritis + Adverse reaction 
3 Necrotizing ENL 20 Neuritis + ENL 
4 Polymorphous erythema 21 Neuritis + Mixed reaction 
5 Arthritis 22 Neuritis +  Necrotizing ENL 
6 Lymphadenopathy 23 Neuritis +  Polymorphous erythema 
7 Orchitis 24 Neuritis +  Arthritis 
8 Iritis/Iridocyclitis 25 Neuritis +  Lymphadenopathy 
9 Reaction hand and foot 26 Neuritis +  Orchitis 
10 ENL+ Necrotizing ENL 27 Neuritis +  Iritis/ Iridocyclitis 
11 ENL+ polymorphous erythema 28 Neuritis +   Reaction hand/foot 
12 ENL+ orchitis 29 Neuritis +   ENL+ Necrotizing ENL 
13 ENL+ arthritis 30 Neuritis +   ENL+  Polymorphous erythema 
14 ENL+ Lymphadenopathy 31 Neuritis +   ENL+ orchitis 
15 ENL+ Iritis/ Iridocyclitis 32 Neuritis +   ENL+ arthritis 
16 ENL+ Reaction hand/foot 33 Neuritis +   ENL+ Lymphadenopathy 
17 Mixed reaction/ Type 1 + Type 2 34 Neuritis +   ENL+ Iritis/Iridocyclitis 
  35 Neuritis +   ENL+ Reaction hand/foot 
1 Cutaneous 4 Cutaneous  + Systemic 
2 Neural 5 Neural + Systemic 
3 Cutaneous  + Neural 6 Cutaneous  + Neural + Systemic 
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EXAMINATION OF PERIPHERAL NERVES 




0 - Normal  
1- Thickened 
2- Nerve abscess 
KEY 
SCALE OF INDICATED NEURAL PAIN  
0 -  No pain 
1 -  Weak pain 
2  Strong pain 
NERVES RIGHT LEFT RIGHT LEFT 
Ulnar     
Median     
Radial     
Fibular     
Posterior Tibial     




Signature and stamp of medical examiner 
 
 
REQUEST OF LABORATORY TESTS  Reaction episodes 
  
















     
PATIENT NUMBER: 
     
DATE OF VISIT: 
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SIMPLIFIED EVALUATION OF NEURAL FUNCTION AND COMPLICATIONS 
Diagnosis and follow-up of reaction episodes 
Face   
Nose R L 
Main complaint   
dryness (S/N)   
abrasions (S/N)   
Perforation of the septum (S/N)   
Eyes R L 
Main complaint   
Closes eyes w/o force (mm)   
Closes eyes w/ force (mm)   
Cornea diminished sensibility (S/N)   
Cornea opacity (S/N)   
Cataract (S/N)   
Visual acuity   
   
Upper limbs   
Main complaint   
Nerve palpation R L 
Ulnar   
Median   
Radius   
key: N = normal; T = thickened; P = pain; S = Tinels sign (+) 
Strength evaluation R L 
Opens little finger 
Abduction of the 5th finger (ulnar nerve)        
  
Elevates thumb 
Abduction of the thumb (median nerve)  
  
Elevates wrist 
Wrist extension (radial nerve)  
  
key: S = strong; D = diminished; P = paralysed   or   5 = strong; 4 = partial resistance;  3 = 
complete movement; 2 = partial movement; 1 = contraction; 0 = paralysed 
SENSITIVITY EVALUATION AND STATUS INSPECTION  
R L 
  
key: lilac pen / monofilament (2g): feels#;  does not feel X ; or monofilaments: follow colours 
Mobile claw: M;  rigid claw: R;  bone absorption:          wound:        
 
______________________________________________ 









     
PATIENT NUMBER: 
     
DATE OF VISIT: 
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Classification of disability grade 
Evaluation date eyes hands feet Highest grade signature 
 R L R L R L   
Evaluation ____/____/____         
Monofilaments 
Monofilament strength in grams interpretation 
1  green 0.05 Normal sensitivity in hand and foot 
2  blue 0.20 Diminished sensitivity in hand and normal in foot / Difficulty in distinguishing texture (light touch) 
3  Lilac 2.00 
Diminished protective sensitivity in hand / Incapable of 
distinguishing texture / Difficulty in distinguishing forms and 
temperatures 
4  dark red 4.00 
Loss of protective sensitivity in hand and sometimes in foot 
/ loss of texture discrimination / Incapable of distinguishing 
forms and temperatures 
5 - orange or red (mark with an  X) 10.00 
Loss of protective sensitivity in foot / loss of texture 
discrimination / Incapable of distinguishing forms and 
temperatures 
6  red circle 300.00 Only has sensation when deep pressure is applied to hand and foot 






     
PATIENT NUMBER: 
     
DATE OF VISIT: 
 
 





     
PATIENT NUMBER: 
     
DATE OF VISIT: 
 
 
      
  
Lower limbs   
Main complaint   
Nerve Palpation R L 
Fibular    
Posterior tibial   
key: N = normal; T = thickened; P = pain; S = Tinels sign (+) 
Strength evaluation R L 
Elevates hallux 
Hallux extension (fibular nerve)  
  
Elevate foot 
Foot dorsiflexion (fibular nerve)  
  
key: S = strong; D = diminished; P = paralysed   or   5 = strong; 4 = partial resistance;  3 = 
complete movement; 2 = partial movement; 1 = contracture; 0 = paralysed 
 SENSITIVITY EVALUATION AND STATUS INSPECTION 
R L 
  
key: lilac pen / monofilament (2g): feels#;  does not feel X ; or monofilaments: follow colours 
Mobile claw: M;  rigid claw: R;  bone absorption:          wound:            




DIAGNOSIS AND FOLLOW-UP OF REACTION FORM 







Possible triggering factors: 
1 Concomitant infections 5 Medication 
2 Pregnancy 6 Vaccination 
3 Surgery 7 Not identified 
4 Emotional distress 8    Others 
 
Treatment: 
 1 Corticosteroids 8 Thalidomide+ Clofazimine 
2 Thalidomide 9 Thalidomide + Pentoxifylline 
3 Clofazimine 10 Corticosteroids + Thalidomide + Clofazimine 
4 Pentoxifylline 11 Corticosteroids + Pentoxifylline + Thalidomide 
5 Corticosteroids + Thalidomide 12 Corticosteroids + Pentoxifylline + Clofazimine 
6 Corticosteroids + Clofazimine 13 Corticosteroids + Pentoxifylline + Clofazimine + 
Thalidomide 










     
PATIENT NUMBER: 
     
DATE OF VISIT: 
 
 
      
  
1  Adverse reaction 18 Neuritis 
2 ENL   19 Neuritis + Adverse reaction 
3 Necrotizing ENL 20 Neuritis + ENL 
4 Polymorphous erythema 21 Neuritis + Mixed reaction 
5 Arthritis 22 Neuritis +  Necrotizing ENL 
6 Lymphadenopathy 23 Neuritis +  Polymorphous erythema 
7 Orchitis 24 Neuritis +  Arthritis 
8 Iritis/Iridocyclitis 25 Neuritis +  Lymphadenopathy 
9 Reaction hand and foot 26 Neuritis +  Orchitis 
10 ENL+ Necrotizing ENL 27 Neuritis +  Iritis/ Iridocyclitis 
11 ENL+ polymorphous erythema 28 Neuritis +   Reaction hand/foot 
12 ENL+ orchitis 29 Neuritis +   ENL+ Necrotizing ENL 
13 ENL+ arthritis 30 Neuritis +   ENL+  Polymorphous erythema 
14 ENL+ Lymphadenopathy 31 Neuritis +   ENL+ orchitis 
15 ENL+ Iritis/ Iridocyclitis 32 Neuritis +   ENL+ arthritis 
16 ENL+ Reaction hand/foot 33 Neuritis +   ENL+ Lymphadenopathy 
17 Mixed reaction/ Type 1 + Type 2 34 Neuritis +   ENL+ Iritis/Iridocyclitis 
  35 Neuritis +   ENL+ Reaction hand/foot 
1 Cutaneous 4 Cutaneous  + Systemic 
2 Neural 5 Neural + Systemic 
3 Cutaneous  + Neural 6 Cutaneous  + Neural + Systemic 
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EXAMINATION OF PERIPHERAL NERVES 





0 - Normal  
1- Thickened 
2- Nerve abscess 
KEY 
SCALE OF INDICATED NEURAL PAIN  
0 -  No pain 
1 -  Weak pain 
2  Strong pain 
NERVES RIGHT LEFT RIGHT LEFT 
Ulnar     
Median     
Radial     
Fibular     
Posterior Tibial     




Signature and stamp of medical examiner 
 
 
REQUEST OF LABORATORY TESTS  reaction episodes 
 
  















     
PATIENT NUMBER: 
     
DATE OF VISIT: 
 
 





     
PATIENT NUMBER: 
     
DATE OF VISIT: 
 
 
      
  




SIMPLIFIED EVALUATION OF NEURAL FUNCTION AND COMPLICATIONS 
Diagnosis and follow-up of reaction episodes 
Face   
Nose R L 
Main complaint   
dryness (S/N)   
abrasions (S/N)   
Perforation of the septum (S/N)   
Eyes R L 
Main complaint   
Closes eyes w/o force (mm)   
Closes eyes w/ force (mm)   
Cornea diminished sensibility (S/N)   
Cornea opacity (S/N)   
Cataract (S/N)   
Visual acuity   
   
Upper limbs   
Main complaint   
Nerve palpation R L 
Ulnar   
Median   
Radius   
key: N = normal; T = thickened; P = pain; S = Tinels sign (+) 
Strength evaluation R L 
Opens little finger 
Abduction of the 5th finger (ulnar nerve)         
  
Elevates thumb 
Abduction of the thumb (median nerve)  
  
Elevates wrist 
Wrist extension (radial nerve)  
  
key: S = strong; D = diminished; P = paralysed   or   5 = strong; 4 = partial resistance;  3 = 
complete movement; 2 = partial movement; 1 = contraction; 0 = paralysed 
SENSITIVITY EVALUATION AND STATUS INSPECTION  
R L 
  
key: lilac pen / monofilament (2g): feels#;  does not feel X ; or monofilaments: follow colours 
Mobile claw: M;  rigid claw: R;  bone absorption:          wound:        
 
______________________________________________ 









     
PATIENT NUMBER: 
     
DATE OF VISIT: 
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Classification of disability grade 
Evaluation date eyes hands feet Highest grade signature 
 R L R L R L   
Evaluation ____/____/____         
Monofilaments 
Monofilament strength in grams interpretation 
1  green 0.05 Normal sensitivity in hand and foot 
2  blue 0.20 Diminished sensitivity in hand and normal in foot / Difficulty in distinguishing texture (light touch) 
3  Lilac 2.00 
Diminished protective sensitivity in hand / Incapable of 
distinguishing texture / Difficulty in distinguishing forms and 
temperatures 
4  dark red 4.00 
Loss of protective sensitivity in hand and sometimes in foot 
/ loss of texture discrimination / Incapable of distinguishing 
forms and temperatures 
5 - orange or red (mark with an  X) 10.00 
Loss of protective sensitivity in foot / loss of texture 
discrimination / Incapable of distinguishing forms and 
temperatures 
6  red circle 300.00 Only has sensation when deep pressure is applied to hand and foot 




REACTION DIAGNOSIS AND FOLLOW-UP FORM 
EPISODE NUMBER: ___                                                              REACTION 
Lower limbs   
Main complaint   
Nerve Palpation R L 
Fibular    
Posterior tibial   
key: N = normal; T = thickened; P = pain; S = Tinels sign (+) 
Strength evaluation R L 
Elevates hallux 
Hallux extension (fibular nerve)  
  
Elevate foot 
Foot dorsiflexion (fibular nerve)  
  
key: S = strong; D = diminished; P = paralysed   or   5 = strong; 4 = partial resistance;  3 = 
complete movement; 2 = partial movement; 1 = contracture; 0 = paralysed 
 SENSITIVITY EVALUATION AND STATUS INSPECTION 
R L 
  
key: lilac pen / monofilament (2g): feels#;  does not feel X ; or monofilaments: follow colours 




     
PATIENT NUMBER: 
     
DATE OF VISIT: 
 
 





     
PATIENT NUMBER: 
     
DATE OF VISIT: 
 
 
      
  







Possible triggering factors: 
1 Concomitant infections 5 Medication 
2 Pregnancy 6 Vaccination 
3 Surgery 7 Not identified 
4 Emotional distress 8    Others 
 
Treatment: 
 1 Corticosteroids 8 Thalidomide+ Clofazimine 
2 Thalidomide 9 Thalidomide + Pentoxifylline 
3 Clofazimine 10 Corticosteroids + Thalidomide + Clofazimine 
4 Pentoxifylline 11 Corticosteroids + Pentoxifylline + Thalidomide 
5 Corticosteroids + Thalidomide 12 Corticosteroids + Pentoxifylline + Clofazimine 
6 Corticosteroids + Clofazimine 13 Corticosteroids + Pentoxifylline + Clofazimine + 
Thalidomide 




Signature and stamp of investigator  
1  Adverse reaction 18 Neuritis 
2 ENL   19 Neuritis + Adverse reaction 
3 Necrotizing ENL 20 Neuritis + ENL 
4 Polymorphous erythema 21 Neuritis + Mixed reaction 
5 Arthritis 22 Neuritis +  Necrotizing ENL 
6 Lymphadenopathy 23 Neuritis +  Polymorphous erythema 
7 Orchitis 24 Neuritis +  Arthritis 
8 Iritis/Iridocyclitis 25 Neuritis +  Lymphadenopathy 
9 Reaction hand and foot 26 Neuritis +  Orchitis 
10 ENL+ Necrotizing ENL 27 Neuritis +  Iritis/ Iridocyclitis 
11 ENL+ polymorphous erythema 28 Neuritis +   Reaction hand/foot 
12 ENL+ orchitis 29 Neuritis +   ENL+ Necrotizing ENL 
13 ENL+ arthritis 30 Neuritis +   ENL+  Polymorphous erythema 
14 ENL+ Lymphadenopathy 31 Neuritis +   ENL+ orchitis 
15 ENL+ Iritis/ Iridocyclitis 32 Neuritis +   ENL+ arthritis 
16 ENL+ Reaction hand/foot 33 Neuritis +   ENL+ Lymphadenopathy 
17 Mixed reaction/ Type 1 + Type 2 34 Neuritis +   ENL+ Iritis/Iridocyclitis 
  35 Neuritis +   ENL+ Reaction hand/foot 
1 Cutaneous 4 Cutaneous  + Systemic 
2 Neural 5 Neural + Systemic 
3 Cutaneous  + Neural 6 Cutaneous  + Neural + Systemic 
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EXAMINATION OF PERIPHERAL NERVES 





0 - Normal  
1- Thickened 
2- Nerve abscess 
KEY 
SCALE OF INDICATED NEURAL PAIN  
0 -  No pain 
1 -  Weak pain 
2  Strong pain 
NERVES RIGHT LEFT RIGHT LEFT 
Ulnar     
Median     
Radial     
Fibular     
Posterior Tibial     




Signature and stamp of medical examiner 
 
REQUEST OF LABORATORY EXAMS  reaction episodes 
  















     
PATIENT NUMBER: 
     
DATE OF VISIT: 
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SIMPLIFIED EVALUATION OF NEURAL FUNCTION AND COMPLICATIONS 
Diagnosis and follow-up of reaction episodes 
Face   
Nose R L 
Main complaint   
dryness (S/N)   
abrasions (S/N)   
Perforation of the septum (S/N)   
Eyes R L 
Main complaint   
Closes eyes w/o force (mm)   
Closes eyes w/ force (mm)   
Cornea diminished sensibility (S/N)   
Cornea opacity (S/N)   
Cataract (S/N)   
Visual acuity   
   
Upper limbs   
Main complaint   
Nerve palpation R L 
Ulnar   
Median   
Radius   
key: N = normal; T = thickened; P = pain; S = Tinels sign (+) 
Strength evaluation R L 
Opens little finger 
Abduction of the 5th finger (ulnar nerve)        
  
Elevates thumb 
Abduction of the thumb (median nerve)  
  
Elevates wrist 
Wrist extension (radial nerve)  
  
key: S = strong; D = diminished; P = paralysed   or   5 = strong; 4 = partial resistance;  3 = 
complete movement; 2 = partial movement; 1 = contraction; 0 = paralysed 
SENSITIVITY EVALUATION AND STATUS INSPECTION  
R L 
  
key: lilac pen / monofilament (2g): feels#;  does not feel X ; or monofilaments: follow colours 
Mobile claw: M;  rigid claw: R;  bone absorption:          wound:        
 
______________________________________________ 




     
PATIENT NUMBER: 
     
DATE OF VISIT: 
 
 
      
  




Classification of disability grade 
Evaluation date eyes hands feet Highest grade signature 
 R L R L R L   
Evaluation ____/____/____         
Monofilaments 
Monofilament strength in grams interpretation 
1  green 0.05 Normal sensitivity in hand and foot 
2  blue 0.20 Diminished sensitivity in hand and normal in foot / Difficulty in distinguishing texture (light touch) 
3  Lilac 2.00 
Diminished protective sensitivity in hand / Incapable of 
distinguishing texture / Difficulty in distinguishing forms and 
temperatures 
4  dark red 4.00 
Loss of protective sensitivity in hand and sometimes in foot 
/ loss of texture discrimination / Incapable of distinguishing 
forms and temperatures 
5 - orange or red (mark with an  X) 10.00 
Loss of protective sensitivity in foot / loss of texture 
discrimination / Incapable of distinguishing forms and 
temperatures 
6  red circle 300.00 Only has sensation when deep pressure is applied to hand and foot 








     
PATIENT NUMBER: 
     
DATE OF VISIT: 
 
 
      
  
Lower limbs   
Main complaint   
Nerve Palpation R L 
Fibular    
Posterior tibial   
key: N = normal; T = thickened; P = pain; S = Tinels sign (+) 
Strength evaluation R L 
Elevates hallux 
Hallux extension (fibular nerve)  
  
Elevate foot 
Foot dorsiflexion (fibular nerve)  
  
key: S = strong; D = diminished; P = paralysed   or   5 = strong; 4 = partial resistance;  3 = 
complete movement; 2 = partial movement; 1 = contracture; 0 = paralysed 
 SENSITIVITY EVALUATION AND STATUS INSPECTION 
R L 
  
key: lilac pen / monofilament (2g): feels#;  does not feel X ; or monofilaments: follow colours 
Mobile claw: M;  rigid claw: R;  bone absorption:          wound:            





DIAGNOSIS AND FOLLOW-UP OF REACTION FORM 







Possible triggering factors: 
1 Concomitant infections 5 Medication 
2 Pregnancy 6 Vaccination 
3 Surgery 7 Not identified 
4 Emotional distress 8    Others 
 
Treatment: 
 1 Corticosteroids 8 Thalidomide+ Clofazimine 
2 Thalidomide 9 Thalidomide + Pentoxifylline 
3 Clofazimine 10 Corticosteroids + Thalidomide + Clofazimine 
4 Pentoxifylline 11 Corticosteroids + Pentoxifylline + Thalidomide 
5 Corticosteroids + Thalidomide 12 Corticosteroids + Pentoxifylline + Clofazimine 
6 Corticosteroids + Clofazimine 13 Corticosteroids + Pentoxifylline + Clofazimine + 
Thalidomide 









     
PATIENT NUMBER: 
     
DATE OF VISIT: 
 
 
      
  
1  Adverse reaction 18 Neuritis 
2 ENL   19 Neuritis + Adverse reaction 
3 Necrotizing ENL 20 Neuritis + ENL 
4 Polymorphous erythema 21 Neuritis + Mixed reaction 
5 Arthritis 22 Neuritis +  Necrotizing ENL 
6 Lymphadenopathy 23 Neuritis +  Polymorphous erythema 
7 Orchitis 24 Neuritis +  Arthritis 
8 Iritis/Iridocyclitis 25 Neuritis +  Lymphadenopathy 
9 Reaction hand and foot 26 Neuritis +  Orchitis 
10 ENL+ Necrotizing ENL 27 Neuritis +  Iritis/ Iridocyclitis 
11 ENL+ polymorphous erythema 28 Neuritis +   Reaction hand/foot 
12 ENL+ orchitis 29 Neuritis +   ENL+ Necrotizing ENL 
13 ENL+ arthritis 30 Neuritis +   ENL+  Polymorphous erythema 
14 ENL+ Lymphadenopathy 31 Neuritis +   ENL+ orchitis 
15 ENL+ Iritis/ Iridocyclitis 32 Neuritis +   ENL+ arthritis 
16 ENL+ Reaction hand/foot 33 Neuritis +   ENL+ Lymphadenopathy 
17 Mixed reaction/ Type 1 + Type 2 34 Neuritis +   ENL+ Iritis/Iridocyclitis 
  35 Neuritis +   ENL+ Reaction hand/foot 
1 Cutaneous 4 Cutaneous  + Systemic 
2 Neural 5 Neural + Systemic 
3 Cutaneous  + Neural 6 Cutaneous  + Neural + Systemic 
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EXAMINATION OF PERIPHERAL NERVES 




0 - Normal  
1- Thickened 
2- Nerve abscess 
KEY 
SCALE OF INDICATED NEURAL PAIN  
0 -  No pain 
1 -  Weak pain 
2  Strong pain 
NERVES RIGHT LEFT RIGHT LEFT 
Ulnar     
Median     
Radial     
Fibular     
Posterior Tibial     




Signature and stamp of medical examiner 
 
REQUEST OF LABORATORY EXAMS  reaction episodes 
  















     
PATIENT NUMBER: 
     
DATE OF VISIT: 
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DATE OF VISIT: 
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SIMPLIFIED EVALUATION OF NEURAL FUNCTION AND COMPLICATIONS 
 Diagnosis and follow-up of reaction episodes 
Face   
Nose R L 
Main complaint   
dryness (S/N)   
abrasions (S/N)   
Perforation of the septum (S/N)   
Eyes R L 
Main complaint   
Closes eyes w/o force (mm)   
Closes eyes w/ force (mm)   
Cornea diminished sensibility (S/N)   
Cornea opacity (S/N)   
Cataract (S/N)   
Visual acuity   
   
Upper limbs   
Main complaint   
Nerve palpation R L 
Ulnar   
Median   
Radius   
key: N = normal; T = thickened; P = pain; S = Tinels sign (+) 
Strength evaluation R L 
Opens little finger 
Abduction of the 5th finger (ulnar nerve)        
  
Elevates thumb 
Abduction of the thumb (median nerve)  
  
Elevates wrist 
Wrist extension (radial nerve)  
  
key: S = strong; D = diminished; P = paralysed   or   5 = strong; 4 = partial resistance;  3 = 
complete movement; 2 = partial movement; 1 = contraction; 0 = paralysed 
SENSITIVITY EVALUATION AND STATUS INSPECTION  
R L 
  
key: lilac pen / monofilament (2g): feels#;  does not feel X ; or monofilaments: follow colours 
Mobile claw: M;  rigid claw: R;  bone absorption:          wound:        
 
______________________________________________ 




     
PATIENT NUMBER: 
     
DATE OF VISIT: 
 
 
      
  




Classification of disability grade 
Evaluation date eyes hands feet Highest grade signature 
 R L R L R L   
Evaluation ____/____/____         
Monofilaments 
Monofilament strength in grams interpretation 
1  green 0.05 Normal sensitivity in hand and foot 
2  blue 0.20 Diminished sensitivity in hand and normal in foot / Difficulty in distinguishing texture (light touch) 
3  Lilac 2.00 
Diminished protective sensitivity in hand / Incapable of 
distinguishing texture / Difficulty in distinguishing forms and 
temperatures 
4  dark red 4.00 
Loss of protective sensitivity in hand and sometimes in foot 
/ loss of texture discrimination / Incapable of distinguishing 
forms and temperatures 
5 - orange or red (mark with an  X) 10.00 
Loss of protective sensitivity in foot / loss of texture 
discrimination / Incapable of distinguishing forms and 
temperatures 
6  red circle 300.00 Only has sensation when deep pressure is applied to hand and foot 








     
PATIENT NUMBER: 
     
DATE OF VISIT: 
 
 
      
  
Lower limbs   
Main complaint   
Nerve Palpation R L 
Fibular    
Posterior tibial   
key: N = normal; T = thickened; P = pain; S = Tinels sign (+) 
Strength evaluation R L 
Elevates hallux 
Hallux extension (fibular nerve)  
  
Elevate foot 
Foot dorsiflexion (fibular nerve)  
  
key: S = strong; D = diminished; P = paralysed   or   5 = strong; 4 = partial resistance;  3 = 
complete movement; 2 = partial movement; 1 = contracture; 0 = paralysed 
 SENSITIVITY EVALUATION AND STATUS INSPECTION 
R L 
  
key: lilac pen / monofilament (2g): feels#;  does not feel X ; or monofilaments: follow colours 
Mobile claw: M;  rigid claw: R;  bone absorption:          wound:            




REACTION DIAGNOSIS AND FOLLOW-UP FORM 







Possible triggering factors: 
1 Concomitant infections 5 Medication 
2 Pregnancy 6 Vaccination 
3 Surgery 7 Not identified 
4 Emotional distress 8    Others 
 
Treatment: 
 1 Corticosteroids 8 Thalidomide+ Clofazimine 
2 Thalidomide 9 Thalidomide + Pentoxifylline 
3 Clofazimine 10 Corticosteroids + Thalidomide + Clofazimine 
4 Pentoxifylline 11 Corticosteroids + Pentoxifylline + Thalidomide 
5 Corticosteroids + Thalidomide 12 Corticosteroids + Pentoxifylline + Clofazimine 
6 Corticosteroids + Clofazimine 13 Corticosteroids + Pentoxifylline + Clofazimine + 
Thalidomide 










     
PATIENT NUMBER: 
     
DATE OF VISIT: 
 
 
      
  
1  Adverse reaction 18 Neuritis 
2 ENL   19 Neuritis + Adverse reaction 
3 Necrotizing ENL 20 Neuritis + ENL 
4 Polymorphous erythema 21 Neuritis + Mixed reaction 
5 Arthritis 22 Neuritis +  Necrotizing ENL 
6 Lymphadenopathy 23 Neuritis +  Polymorphous erythema 
7 Orchitis 24 Neuritis +  Arthritis 
8 Iritis/Iridocyclitis 25 Neuritis +  Lymphadenopathy 
9 Reaction hand and foot 26 Neuritis +  Orchitis 
10 ENL+ Necrotizing ENL 27 Neuritis +  Iritis/ Iridocyclitis 
11 ENL+ polymorphous erythema 28 Neuritis +   Reaction hand/foot 
12 ENL+ orchitis 29 Neuritis +   ENL+ Necrotizing ENL 
13 ENL+ arthritis 30 Neuritis +   ENL+  Polymorphous erythema 
14 ENL+ Lymphadenopathy 31 Neuritis +   ENL+ orchitis 
15 ENL+ Iritis/ Iridocyclitis 32 Neuritis +   ENL+ arthritis 
16 ENL+ Reaction hand/foot 33 Neuritis +   ENL+ Lymphadenopathy 
17 Mixed reaction/ Type 1 + Type 2 34 Neuritis +   ENL+ Iritis/Iridocyclitis 
  35 Neuritis +   ENL+ Reaction hand/foot 
1 Cutaneous 4 Cutaneous  + Systemic 
2 Neural 5 Neural + Systemic 
3 Cutaneous  + Neural 6 Cutaneous  + Neural + Systemic 
                                                                             112 
 
 
EXAMINATION OF PERIPHERAL NERVES 




0 - Normal  
1- Thickened 
2- Nerve abscess 
KEY 
SCALE OF INDICATED NEURAL PAIN  
0 -  No pain 
1 -  Weak pain 
2  Strong pain 
NERVES RIGHT LEFT RIGHT LEFT 
Ulnar     
Median     
Radial     
Fibular     
Posterior Tibial     








REQUEST FOR LABORATORY EXAMS  reaction episodes 
  


















     
PATIENT NUMBER: 
     
DATE OF VISIT: 
 
 





     
PATIENT NUMBER: 
     
DATE OF VISIT: 
 
 
      
  




SIMPLIFIED EVALUATION OF NEURAL FUNCTION AND COMPLICATIONS 
 Diagnosis and follow-up of reaction episodes 
Face   
Nose R L 
Main complaint   
dryness (S/N)   
abrasions (S/N)   
Perforation of the septum (S/N)   
Eyes R L 
Main complaint   
Closes eyes w/o force (mm)   
Closes eyes w/ force (mm)   
Cornea diminished sensibility (S/N)   
Cornea opacity (S/N)   
Cataract (S/N)   
Visual acuity   
   
Upper limbs   
Main complaint   
Nerve palpation R L 
Ulnar   
Median   
Radius   
key: N = normal; T = thickened; P = pain; S = Tinels sign (+) 
Strength evaluation R L 
Opens little finger 
Abduction of the 5th finger (ulnar nerve)        
  
Elevates thumb 
Abduction of the thumb (median nerve)  
  
Elevates wrist 
Wrist extension (radial nerve)  
  
key: S = strong; D = diminished; P = paralysed   or   5 = strong; 4 = partial resistance;  3 = 
complete movement; 2 = partial movement; 1 = contraction; 0 = paralysed 
SENSITIVITY EVALUATION AND STATUS INSPECTION  
R L 
  
key: lilac pen / monofilament (2g): feels#;  does not feel X ; or monofilaments: follow colours 
Mobile claw: M;  rigid claw: R;  bone absorption:          wound:        
 
______________________________________________ 





     
PATIENT NUMBER: 
     
DATE OF VISIT: 
 
 
      
  




Classification of disability grade 
Evaluation date eyes hands feet Highest grade signature 
 R L R L R L   
Evaluation ____/____/____         
Monofilaments 
Monofilament strength in grams interpretation 
1  green 0.05 Normal sensitivity in hand and foot 
2  blue 0.20 Diminished sensitivity in hand and normal in foot / Difficulty in distinguishing texture (light touch) 
3  Lilac 2.00 
Diminished protective sensitivity in hand / Incapable of 
distinguishing texture / Difficulty in distinguishing forms and 
temperatures 
4  dark red 4.00 
Loss of protective sensitivity in hand and sometimes in foot 
/ loss of texture discrimination / Incapable of distinguishing 
forms and temperatures 
5 - orange or red (mark with an  X) 10.00 
Loss of protective sensitivity in foot / loss of texture 
discrimination / Incapable of distinguishing forms and 
temperatures 
6  red circle 300.00 Only has sensation when deep pressure is applied to hand and foot 
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Lower limbs   
Main complaint   
Nerve Palpation R L 
Fibular    
Posterior tibial   
key: N = normal; T = thickened; P = pain; S = Tinels sign (+) 
Strength evaluation R L 
Elevates hallux 
Hallux extension (fibular nerve)  
  
Elevate foot 
Foot dorsiflexion (fibular nerve)  
  
key: S = strong; D = diminished; P = paralysed   or   5 = strong; 4 = partial resistance;  3 = 
complete movement; 2 = partial movement; 1 = contracture; 0 = paralysed 
 SENSITIVITY EVALUATION AND STATUS INSPECTION 
R L 
  
key: lilac pen / monofilament (2g): feels#;  does not feel X ; or monofilaments: follow colours 
Mobile claw: M;  rigid claw: R;  bone absorption:          wound:            





DIAGNOSIS AND FOLLOW-UP OF REACTION FORM 







Possible triggering factors: 
1 Concomitant infections 5 Medication 
2 Pregnancy 6 Vaccination 
3 Surgery 7 Not identified 
4 Emotional distress 8    Others 
 
Treatment: 
 1 Corticosteroids 8 Thalidomide+ Clofazimine 
2 Thalidomide 9 Thalidomide + Pentoxifylline 
3 Clofazimine 10 Corticosteroids + Thalidomide + Clofazimine 
4 Pentoxifylline 11 Corticosteroids + Pentoxifylline + Thalidomide 
5 Corticosteroids + Thalidomide 12 Corticosteroids + Pentoxifylline + Clofazimine 
6 Corticosteroids + Clofazimine 13 Corticosteroids + Pentoxifylline + Clofazimine + 
Thalidomide 
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1  Adverse reaction 18 Neuritis 
2 ENL   19 Neuritis + Adverse reaction 
3 Necrotizing ENL 20 Neuritis + ENL 
4 Polymorphous erythema 21 Neuritis + Mixed reaction 
5 Arthritis 22 Neuritis +  Necrotizing ENL 
6 Lymphadenopathy 23 Neuritis +  Polymorphous erythema 
7 Orchitis 24 Neuritis +  Arthritis 
8 Iritis/Iridocyclitis 25 Neuritis +  Lymphadenopathy 
9 Reaction hand and foot 26 Neuritis +  Orchitis 
10 ENL+ Necrotizing ENL 27 Neuritis +  Iritis/ Iridocyclitis 
11 ENL+ polymorphous erythema 28 Neuritis +   Reaction hand/foot 
12 ENL+ orchitis 29 Neuritis +   ENL+ Necrotizing ENL 
13 ENL+ arthritis 30 Neuritis +   ENL+  Polymorphous erythema 
14 ENL+ Lymphadenopathy 31 Neuritis +   ENL+ orchitis 
15 ENL+ Iritis/ Iridocyclitis 32 Neuritis +   ENL+ arthritis 
16 ENL+ Reaction hand/foot 33 Neuritis +   ENL+ Lymphadenopathy 
17 Mixed reaction/ Type 1 + Type 2 34 Neuritis +   ENL+ Iritis/Iridocyclitis 
  35 Neuritis +   ENL+ Reaction hand/foot 
1 Cutaneous 4 Cutaneous  + Systemic 
2 Neural 5 Neural + Systemic 
3 Cutaneous  + Neural 6 Cutaneous  + Neural + Systemic 
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EXAMINATION OF PERIPHERAL NERVES 




0 - Normal  
1- Thickened 
2- Nerve abscess 
KEY 
SCALE OF INDICATED NEURAL PAIN  
0 -  No pain 
1 -  Weak pain 
2  Strong pain 
NERVES RIGHT LEFT RIGHT LEFT 
Ulnar     
Median     
Radial     
Fibular     
Posterior Tibial     




Signature and stamp of medical examiner 
 
REQUEST FOR LABORATORY TESTS  reactions 
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SIMPLIFIED EVALUATION OF NEURAL FUNCTION AND COMPLICATIONS 
 Diagnosis and follow-up of reaction episodes 
Face   
Nose R L 
Main complaint   
dryness (S/N)   
abrasions (S/N)   
Perforation of the septum (S/N)   
Eyes R L 
Main complaint   
Closes eyes w/o force (mm)   
Closes eyes w/ force (mm)   
Cornea diminished sensibility (S/N)   
Cornea opacity (S/N)   
Cataract (S/N)   
Visual acuity   
   
Upper limbs   
Main complaint   
Nerve palpation R L 
Ulnar   
Median   
Radius   
key: N = normal; T = thickened; P = pain; S = Tinels sign (+) 
Strength evaluation R L 
Opens little finger 
Abduction of the 5th finger (ulnar nerve)        
  
Elevates thumb 
Abduction of the thumb (median nerve)  
  
Elevates wrist 
Wrist extension (radial nerve)  
  
key: S = strong; D = diminished; P = paralysed   or   5 = strong; 4 = partial resistance;  3 = 
complete movement; 2 = partial movement; 1 = contraction; 0 = paralysed 
SENSITIVITY EVALUATION AND STATUS INSPECTION  
R L 
  
key: lilac pen / monofilament (2g): feels#;  does not feel X ; or monofilaments: follow colours 
Mobile claw: M;  rigid claw: R;  bone absorption:          wound:        
 
______________________________________________ 
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Classification of disability grade 
Evaluation date eyes hands feet Highest grade signature 
 R L R L R L   
Evaluation ____/____/____         
Monofilaments 
Monofilament strength in grams interpretation 
1  green 0.05 Normal sensitivity in hand and foot 
2  blue 0.20 Diminished sensitivity in hand and normal in foot / Difficulty in distinguishing texture (light touch) 
3  Lilac 2.00 
Diminished protective sensitivity in hand / Incapable of 
distinguishing texture / Difficulty in distinguishing forms and 
temperatures 
4  dark red 4.00 
Loss of protective sensitivity in hand and sometimes in foot 
/ loss of texture discrimination / Incapable of distinguishing 
forms and temperatures 
5 - orange or red (mark with an  X) 10.00 
Loss of protective sensitivity in foot / loss of texture 
discrimination / Incapable of distinguishing forms and 
temperatures 
6  red circle 300.00 Only has sensation when deep pressure is applied to hand and foot 
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Lower limbs   
Main complaint   
Nerve Palpation R L 
Fibular    
Posterior tibial   
key: N = normal; T = thickened; P = pain; S = Tinels sign (+) 
Strength evaluation R L 
Elevates hallux 
Hallux extension (fibular nerve)  
  
Elevate foot 
Foot dorsiflexion (fibular nerve)  
  
key: S = strong; D = diminished; P = paralysed   or   5 = strong; 4 = partial resistance;  3 = 
complete movement; 2 = partial movement; 1 = contracture; 0 = paralysed 
 SENSITIVITY EVALUATION AND STATUS INSPECTION 
R L 
  
key: lilac pen / monofilament (2g): feels#;  does not feel X ; or monofilaments: follow colours 
Mobile claw: M;  rigid claw: R;  bone absorption:          wound:            




        




        
  BACILLOSCOPY RESULTS 
 Right ear 
lobe Left ear lobe 
Elbow   
R  




indexes  BI  
Beginning of the 
study 
Date __/__/__ 
     
End of treatment* 
Date __/__/__ 
     
1st year visit post-      
discharge 
Date __/__/__ 
     
2nd year visit post-      
discharge 
Date __/__/__ 
     
3rd year visit post-      
discharge 
Date __/__/__ 
     
4th year visit post-      
discharge 
Date __/__/__ 
     
5th year visit post-      
discharge 
Date __/__/__ 
     
6th year visit post-      
discharge 
Date __/__/__ 
     
 








Signature and stamp of medical examiner 
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SULFONURIA  RESULTS ( Positive or negative) 
Test Result Comments 
1st month 

















7th month * 
 date __/__/____ 
  
8th month * 
 date __/__/____ 
  
9th month * 
 date __/__/____ 
  
10th month * 
 date __/__/____ 
  
11th month * 
 date __/__/____ 
  
12th month * 
 date __/__/____ 
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If test was not done, indicate with ND 
BEGINNING OF THE 
STUDY 1st dose/ Date    
2nd DOSE/ Date    
3rd DOSE / Date    
4th DOSE / Date    
5th DOSE / Date    
6th DOSE / Date    
 
7th DOSE / Date    
 
8th DOSE / Date    
 
9th DOSE / Date    
 
10th DOSE / Date    
 
11th DOSE / Date    
 
12th DOSE / Date    
End of treatment / Date 
    
Normal value < 8 units mg/L 
 




Signature and stamp of medical examiner 
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If test was not done, indicate with ND 
1st  Year/ Date    
2nd Year/ Date    
3rd Year/ Date    
4th Year/ Date    
5th Year/ Date    
6th Year/ Date    
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If test was not done, indicate with ND 
DATE __/__/____    
DATE __/__/____    
DATE __/__/____    
DATE __/__/____    
DATE __/__/____    
DATE __/__/____    
DATE __/__/____    
DATE __/__/____    
DATE __/__/____    
DATE __/__/____    
DATE __/__/____    
DATE __/__/____    
DATE __/__/____    




Signature and stamp of medical examiner 
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REGISTRATION OF DOSE UNDER STUDY 
VISIT 
Date of Visit 
(day /month/ 
year) 






_ _ /_ _ _ _ 
 
BEGINNING OF 




2nd DOSE ___/____/____  
  
3rd DOSE  ___/____/____  
  
4th DOSE  ___/____/____  
  
5th DOSE  ___/____/____  
  
6th DOSE ___/____/____  
  
 
7th DOSE* ___/____/____  
  
 
8th DOSE* ___/____/____  
  
 
9th DOSE* ___/____/____  
  
 
10th DOSE* ___/____/____  
  
 
11th DOSE*  ___/____/____  
  
 
12th DOSE*  ___/____/____  
  
 
* For group 4 of multibacillary patients 
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Signature and stamp of medical examiner 
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DESCRIPTION OF CRITICAL SIDE EFFECTS 
DATE RESEARCHER DESCRIPTION 
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CLINICAL DERMATOLOGICAL EVALUATION  RELAPSE  
KEY:  
 1. Altered     2. Normal Alterations observed 
 Cardiovascular  
 Musculoskeletal  
 Respiratory  
 Gastrointestinal  
 Liver  
 Metabolic/Endocrine  
 Genital-Urinary  
 Neurological  




 Musculoskeletal  
 Signs/ symptoms of 
reaction present? 
1  Yes                    
2  No 
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0 - Normal  
1- Thickened 
2- Nerve abscess 
KEY 
SCALE OF INDICATED NEURAL PAIN  
0 -  No pain 
1 -  Weak pain 
2  Strong pain 
NERVES RIGHT LEFT RIGHT LEFT 
Ulnar     
Median     
Radial     
Fibular     
Posterior Tibial     





Signature and stamp of medical examiner 
 
REQUEST FOR LABORATORY EXAMS - RELAPSE FORM 
   
 
BACILLOSCOPY  
 HISTOPATHOLOGICAL    
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SIMPLIFIED EVALUATION OF NEURAL FUNCTION AND COMPLICATIONS 
RELAPSE FORM 
Face   
Nose R L 
Main complaint   
dryness (S/N)   
abrasions (S/N)   
Perforation of the septum (S/N)   
Eyes R L 
Main complaint   
Closes eyes w/o force (mm)   
Closes eyes w/ force (mm)   
Cornea diminished sensibility (S/N)   
Cornea opacity (S/N)   
Cataract (S/N)   
Visual acuity   
   
Upper limbs   
Main complaint   
Nerve palpation R L 
Ulnar   
Median   
Radius   
key: N = normal; T = thickened; P = pain; S = Tinels sign (+) 
Strength evaluation R L 
Opens little finger 
Abduction of the 5th finger (ulnar nerve)        
  
Elevates thumb 
Abduction of the thumb (median nerve)  
  
Elevates wrist 
Wrist extension (radial nerve)  
  
key: S = strong; D = diminished; P = paralysed   or   5 = strong; 4 = partial resistance;  3 = 
complete movement; 2 = partial movement; 1 = contraction; 0 = paralysed 
SENSITIVITY EVALUATION AND STATUS INSPECTION  
R L 
  
key: lilac pen / monofilament (2g): feels#;  does not feel X ; or monofilaments: follow colours 
Mobile claw: M;  rigid claw: R;  bone absorption:          wound:        
 
______________________________________________ 
Signature and stamp of medical examiner 





Classification of disability grade 
Evaluation date eyes hands feet Highest grade signature 
 R L R L R L   
Evaluation ____/____/____         
Monofilaments 
Monofilament strength in grams interpretation 
1  green 0.05 Normal sensitivity in hand and foot 
2  blue 0.20 Diminished sensitivity in hand and normal in foot / Difficulty in distinguishing texture (light touch) 
3  Lilac 2.00 
Diminished protective sensitivity in hand / Incapable of 
distinguishing texture / Difficulty in distinguishing forms and 
temperatures 
4  dark red 4.00 
Loss of protective sensitivity in hand and sometimes in foot 
/ loss of texture discrimination / Incapable of distinguishing 
forms and temperatures 
5 - orange or red (mark with an  X) 10.00 
Loss of protective sensitivity in foot / loss of texture 
discrimination / Incapable of distinguishing forms and 
temperatures 
6  red circle 300.00 Only has sensation when deep pressure is applied to hand and foot 
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Lower limbs   
Main complaint   
Nerve Palpation R L 
Fibular    
Posterior tibial   
key: N = normal; T = thickened; P = pain; S = Tinels sign (+) 
Strength evaluation R L 
Elevates hallux 
Hallux extension (fibular nerve)  
  
Elevate foot 
Foot dorsiflexion (fibular nerve)  
  
key: S = strong; D = diminished; P = paralysed   or   5 = strong; 4 = partial resistance;  3 = 
complete movement; 2 = partial movement; 1 = contracture; 0 = paralysed 
 SENSITIVITY EVALUATION AND STATUS INSPECTION 
R L 
  
key: lilac pen / monofilament (2g): feels#;  does not feel X ; or monofilaments: follow colours 
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RELAPSE REGISTRATION  
DERMATOLOGICAL-NEUROLOGICAL EXAM AND COMPLEMENTARY EXAMINATIONS 
 
Beginning of current symptoms  
 
No. of months _________  
 
 
Type of lesion 
7. Maculae            
8. Plaques 
9. Papules 
10. Diffuse infliltration 
11. Nodules 
12. Anaesthetic area              
Colour of lesion 
5. Hypo-chromatic   
6. Erythematose  
7. Hyper-chromatic 






Bacilloscopy             
3. Negative 
4. Positive  
 
Number of lesions (from 1 to 10 lesions, 
enter the exact number)   
11. Eleven or more lesions 
88. Iinfiltração difusa 
Número de nervos comprometidos 
 
 
Resultado do IB 
 















OPERATIONAL CLASSIFICATION  
1. Paucibacillary ( < 5 skin lesions) 
2. Multibacillary  ( > 6 skin lesions) 
CLINICAL CLASSIFICATION 
1. Indeterminate leprosy                                 2. Tuberculoid leprosy                               3. Lepromatous leprosy                   
4. Borderline Tuberculoid leprosy                   5. Borderline Borderline leprosy      
6. Borderline Lepromatous leprosy 
BIOPSY    LEVEL OF CERTAINTY 
 
Slide  no.  
  
Date _____/____/_____
[39] CONFIRMED LEPROSY 
[40] CONSISTENT WITH LEPROSY  
[41] NON-SPECIFIC 
[42] INDICATIVE OF ANOTHER DISEASE 
BIOPSY  Beginning of study -  Principle findings 
Epidermis: 1 (  )   2 (  )   3 (  )   4 (  )   5 (  )  
Dermis: Infiltrated / Inflamed: 6 (  )   7 (  )    8 (  )    9 ( )   10 ( )   11 (  )  12 (  )   13 (  ) 14 ( )  15 (  )   16 (    )  
Nerve damage:  17 (  ) 18 (   )  19 (  )    20 (  )  
Vasculitis: 21 (  )     22 (  )    
Panniculitis: 23 (   )       24 (  )       25 (  ) 
Bacilloscopy:  26 (  )    27 (  )       28 (  )     29 (   )      30 (   )   31(  ) others________________________ 
Clinical form: 32- I [   ] 33- TT [   ]  34-  BT [  ]   35- BB [   ]  36- BL [   ]   37- LL  [   ]   38- [   ] Not classified 
FINAL CLASSIFICATION   
1. Indeterminate leprosy                               2. Tuberculoid leprosy                            3. Lepromatous leprosy                   
4. Borderline Tuberculoid leprosy                  5. Borderline Borderline leprosy      
6. Borderline Lepromatous leprosy         
 
 
Stamp and Signature of Researcher 
 




FORM FOR WITHDRAWAL FROM THE STUDY 
 1 YES 2 NO DATE 


















REASON FOR WITHDRAWAL (More than 1 option may be 
chosen): COMMENTS 
1. VIOLATION OF THE PROTOCOL, EX. BIOPSY DID NOT 
CONFIRM LEPROSY 
 
2. PATIENT WANTS TO WITHDRAW FROM THE STUDY  
3. PATIENT NOT FOUND DURING FOLLOW-UP  
4. INTERCURRENT DISEASE  
5. SIDE EFFECTS (Fill in the Form for Side Effects}.  
6. CONFIRMED DIAGNOSIS OF RELAPSE (Fill out the Relapse 
Form) 
 
7. DEATH (Fill out the Death Certificate, if necessary)  
8. OTHERS (specify)  
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Independent study to establish the efficacy of the six dose uniform MDT regimen  




APPENDIX I of SOP UMDT 013 
 
Note  To facilitate the keeping of records, this appendix is available in Microsoft Excel 
(Located in file name:  amostras.xls).  
Place here the name of the Centre where the sample is being collected 
  Boxes A    B    C Dates  
 Chart No. No. project 
CRF  
Name of Patient Birth. Sample Professional 
Responsible 
A1       
A2       
A3       
A4       
A5       
A6       
A7       
A8       
A9       
A10       
A11       
A12       
       
B1       
B2       
B3       
B4       
B5       
B6       
B7       
B8       
B9       
B10       
B11       
B12       
The numbering of samples is always preceded by the letter of alphabet so that each letter will be 
followed by numerals from 1 to 12. 
Independent study to establish the efficacy of the six dose uniform MDT regimen  




APPENDIX I of SOP UMDT 015 




Age: _____________                  Date of birth: ___/ ____ / _____               Sex: _______               
 
Date of biopsy: _____/_____/_______       Chart no.:  _____________             CRF:_________ 
RESULTS OF HISTOPATHOLOGICAL EXAM  
Macroscopy:  
• Skin biopsy with punch -   _____ /_____ /_____   cm in the widest section. 




• Epidermis:  
     1 (  ) atrophic    2 (  ) acanthotic    3 (  ) ulcerated    4 (  ) damaged (eroded)      5 (  ) normal 
 
• Dermis:  
Inflammatory infiltrate: 6 (  ) focal  7(  ) diffuse  
     8(  )mononuclear perivascular   9 (  )mononuclear/perivascular/periannexal/erector muscle   
   10(  ) mononuclear with epithelioid cells 11(   ) few and limited granulomas with epithelioid cells 
   12(  ) multiple granulomas with epithelioid cells 13(   ) plasmacytes   14(  ) neutrophiles    
   15(  ) Virchow cells     16(    ) Langerhans cells 
   Nerves affected:   17(   )yes   18(   )no   19(  )doubtful   20(  ) nerve sheath not seen 
   Vasculitis:   21(   ) yes     22(   ) no  
   Panniculitis:  23(   ) yes     24(  )  no     25(   )Subcutaneous layer not present  
   Bacilloscopy:        26 (    +/6+)yes    27(   )intact  28(   )fragmented  29(   ) granulated  30(   ) no   
   31 - Other:  ______________________________________________________________________ 
• Classification:  32 - I(   ) 33 - TT(   )   34 - BT(   )       35 - BB(   )   
                              36- BL (   )    37- LL (   )         38- (   )Non-classifiable  
• Degree of certainty: 
39  Confirmed leprosy                  (   ) 
40  Consistent with leprosy, but diagnosis not confirmed (   ) 
41 - Unspecific       (   ) 
42  Indicative of other disease     (   ) 
43  If other disease confirmed, indicate which: ________________________________________ 
44 - Obs.: _________________________________________________________________________ 
 
        Responding Physician: ___________________________________Date ____/____/____ 
 
 
 
 
